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A vaccine expressing virus-like particles is an attractive candidate for the development of an 
effective vaccine for human immunodeficiency virus type 1 (HIV-1).  A single vaccine plasmid 
was constructed to express HIV-1 Gag, Pol, Env, Tat, Rev and Vpu.  Safety mutations and 
deletions were introduced into the VLP DNA to generate a vaccine insert that was non-
infectious.  The 5’and 3’ long terminal repeats, integrase, vif, vpr and nef were removed to 
further enhance the safety of the vaccine insert.  Moreover, mutations were introduced into 
nucleocapsid and reverse transcriptase to severely restrict viral RNA packaging and to abolish 
RT and RNase H activity.  Virus-like particles were efficiently released from primate cells, but 
particles were not produced in rodent cells.  Therefore, purified particles were used as the 
inoculum to test the immunogenicity of the VLP vaccines in a rodent system.  Systemic and 
mucosal immune responses to HIV-1 were enhanced by intranasal immunization of purified 
VLPs expressed from the virally-regulated multi-gene DNA vaccine.  VLPs were co-immunized 
with cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODNs) to enhance the immune 
response to HIV-1 gene products.  VLPs elicited specific immunity to HIV-1 antigens in both the 
systemic and mucosal immune compartments.  Anti-Env antibodies were detected in the sera, as 
well as in the washes from harvested lungs, intestines and vagina from immunized mice.  In 
addition, Env- and Gag-specific IFN-γ-secreting splenocytes were elicited in the mice vaccinated 
with VLPs.  Co-inoculation of CpG ODNs with VLPs significantly enhanced both arms of the 
immune response.  In addition, these particulate immunogens were compared to soluble proteins 
(Gag and Env).  Mice immunized with soluble protein alone or co-vaccinated with CpG ODNs 
elicited much lower immune responses compared to VLP-vaccinated mice.  Specifically, CTLs 
were induced by vaccination with VLPs, whereas the immune response elicited by soluble 
proteins (+/- CpG ODNs) was almost exclusively antibody-mediated.  Overall, a vaccine 
expressing virus-like particles is one of the most promising alternatives to replication-competent 
virus in eliciting high levels of cross-reactive neutralizing antibodies in combination with a 
robust cell-mediated response against multiple viral antigens to protect an HIV-infected host 
from life-long infection or disease.        
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I.A. Global Impact of the AIDS Epidemic 
 
 At the end of 2004, approximately 39.4 million people were infected worldwide 
with human immunodeficiency virus type 1 (HIV-1), the causative agent of Acquired 
Immune Deficiency Syndrome (AIDS).  Greater than 95% of HIV infections occur in 
developing countries (25.4 million infected people living in Sub-Saharan Africa and 8.2 
million infected individuals reside in Asia) 286.  It is estimated that one-fourth of the one 
million United States (U.S.) residents living with HIV are unaware that they are infected 
474.  In addition, half of the 400,000 newly infected individuals are younger than 25 years 
of age each year in the U.S. (70% men, 30% women) 91.  HIV/AIDS will continue to 
threaten human life and health, especially in developing countries, until an effective 
vaccine is developed. 
 
I.B. Taxonomy  
 
 Viruses in the retrovirus family, Retroviridae, generally contain an RNA genome 
that is converted to a DNA form and integrates into the host chromosomal DNA.  There 
are simple (alpharetroviruses, betaretroviruses, gammaretroviruses) and complex 
(deltaretroviruses, epsilonretroviruses, lentiviruses, spumaviruses) retroviruses.  The 
simple viruses only contain the gag, RT, PR and env genes, whereas the complex 
retroviruses contain these 4 genes plus an assortment of regulatory and accessory genes.   
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 HIV-1 is a complex virus member of the Lentivirus genus along with HIV type 2 
(HIV-2), simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), 
feline immunodeficiency virus (FIV), caprine arthritis encephalitis virus (CAEV) and 
visna/maedi virus.  Lentiviruses are characteristically identified by cylindrical or cone-
like cores.  The genome of all lentiviruses contains the gag, PR, RT and env genes along 
with small regulatory proteins that assist in transcription, RNA processing, virion 
assembly, host gene expression and many other functions in the replication cycle 161.   
 HIV-1 was isolated and determined to be the causative agent of AIDS in 1983 31, 
520.  As a result, each laboratory gave each isolate a different name for this virus:  
lymphadenopathy-associated virus (LAV), human T-cell lymphotropic virus type III 
(HTLV-III), and AIDS-associated retrovirus (ARV).  In 1986, the International 
Committee on Taxonomy of Viruses named this virus, HIV-1.   
 HIV-1, HIV-2 and SIV are examples of primate lentiviruses of the Retroviradae 
family 121, 530, 668.  Each virus is able to induce an acquired immunodeficiency disease in 
the respective host 198, 488.  HIV-1 is genotypically divided into three distinct groups:  
major (M), outlier (O), and non-M/non-O (N).  The strains of HIV-1 that infect most 
humans worldwide are found within the M group.  Since its introduction into the human 
population, the M group has evolved into at least 10 distinct clades (A, B, C, D, F, G, H 
and J) and 13 different circulating recombinant forms (CRF) 394, 470.  Interestingly, HIV-2 
is more closely related to virus strains isolated from sooty mangabey monkeys, SIVsm, 
than HIV-1 267.   The genetic diversity of HIV has been studied using group M 
viruses of different geographic origins 393, 394, 622.  The genetic diversity of the HIV-1 
population can vary from 6-10% within an infected individual.  Moreover, intraclade 
 18
nucleotide diversity can vary 15% (Gag) or up to 30% (Envgp120), whereas interclade 
variability may range between 30-40% depending on the gene examined.   
 
I.C. HIV-1 Virus and Genome 
 
 HIV-1 is an enveloped RNA virus (100-120 nm) (Figure 1).  The envelope is 
composed of a lipid bilayer derived from the host cell membrane during the budding 
process and is embedded with multimeric glycoproteins.  Each envelope (Env; 7-15 Env 
trimers per virion) glycoprotein, is composed of a surface, globular domain (gp120, SU) 
and a transmembrane domain (gp41, TM).  The matrix (MA, p17) protein lines the inner 
surface of the viral envelope and surrounds the capsid.  The capsid (CA, p24) layer 
contains approximately 2,000 molecules and encases the nucleocapsid (NC, p9), which 
surrounds the viral genome and associated viral proteins.   
 The HIV-1 proviral genome consists of double-stranded DNA (dsDNA) that 
contains 9 open reading frames that encode for 15 viral proteins 642 (Figure 1 and Table 
1).  Similar to all retroviruses, HIV contains three major genes (gag, pol and env), which 
encode polyprotein precursors that are cleaved to yield the core structural (CA, MA, NC), 
enzymatic (PR, RT, IN) and envelope (gp120, gp41) proteins, respectively.  The HIV-1 
genome contains two regulatory genes (tat and rev) and 4 accessory genes (nef, vif, vpu, 
and vpr) that are required for efficient virion replication and maturation (Table 1).  There 
are two long terminal repeat (LTRs) which flank both the 5' and 3' ends of the proviral 
DNA genome.  The 5’ LTR contains the HIV-1 promoter and enhancer sequences that 
regulate gene expression. 
 19
 
 
Figure 1.  Schematic representation of HIV-1 virion and proviral genome.  
(A) The mature HIV-1 virion contains multiple viral gene products. Gag and Env are the 
main structural proteins that form the spherical shape with spiked glycoproteins 
protruding from the outer surface.  The gag gene products include the capsid (Gagp24), 
matrix (Gag17), and nucleocapsid (Gagp6/7) proteins.  The env gene products include 
surface (SU, Envgp120) and transmembrane (TM, Envgp41) glycoproteins.  The Env 
glycoproteins are inserted in the lipid bilayer, which is derived from the host cell 
membrane during the budding process.  In addition, there are 2 enzymatic (RT and IN) 
and 3 accessory (Vif, Vpr, Nef) proteins found in the mature virion.  HIV-1, like all 
lentiviruses, contains 2 copies of its single stranded RNA genome (ssRNA).  (B) The 
proviral genome is flanked by 2 long terminal repeats (LTRs) (black).  Transcription of 
viral genes is initiated from the promoter found in the 5’LTR.  In the HIV-1 genome, 
there are 9 open reading frames, which generate 15 different gene products.  The Gag-Pol 
precursor polypeptide is cleaved into gag (red) and pol (blue) gene products.  The 
Env/Vpu mRNA is singly spliced to produce Vpu (yellow) or the env gene precursor 
(Envgp160) that is processed to Envgp120 and Envgp41 (purple).  Regulatory (Tat and Rev) 
(orange) and accessory (Vif, Vpr, Nef) (green) proteins are generated by multiply 
splicing of the Gag-Pol precursor mRNA. 
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Table 1.  Summary of HIV-1 proteins and potential use in VLP vaccines. 
 
PROTEIN MAIN FUNCTION VLP ADVANTAGE VLP  DISADVANTAGE REFS 
Gag 
(CA, MA,  
NC, p6) 
Structural protein  
Forms sphere of virion, 
encapsidation of vRNA 
Required for particle 
formation and strong 
cell mediated 
immune response 
None  
192, 310, 
447, 459 
Env 
(SU, TM) 
 
Structural protein 
Virus binding and entry 
into susceptible cells 
Binding and entry of 
VLPs into 
susceptible cells, 
target of neutralizing 
antibodies 
May induce apoptosis of 
bystander cells 
 
101, 102, 
268, 567 
Pol-IN 
 
Enzymatic activity  
Directs proviral 
integration into host 
chromosome 
Persistent expression 
of viral proteins, no 
boosting required 
(must have LTRs) 
Lifelong infection with 
vaccine strain, may induce 
reversion or recombination 
 
115, 180, 
472 
Pol-RT 
 
Enzymatic activity 
Converts  genomic viral 
RNA to proviral DNA  
Additional vaccine 
target 
May induce reversion or 
recombination, replication is 
error-prone, escape mutants 
 
257, 276 
Pol-PR 
 
Enzymatic activity 
Cleaves Gag-Pol pr55 
into 7 gene products 
Cleavage of Gag-Pol 
and Gag polypeptide 
into 7 gene products 
May induce reversion or 
recombination, resistance to 
drug therapy 
 
32, 163 
Tat 
 
Regulatory protein 
Promoting and 
enhancing viral 
transcription 
Strong cell-mediated 
response seen early 
in infection, viral 
transcription   
Strong induction of 
apoptosis, modulation of 
expression of many cellular 
genes   
 
179, 387, 
522 
Rev Regulatory protein 
Nuclear export of 
unspliced and singly 
spliced vRNAs 
Required for nuclear 
export of Gag-Pol 
and Env mRNAs to 
be translated into 
proteins 
None  
273, 522 
Nef 
 
Accessory protein 
Downregulation of CD4 
and MHC I, increases 
infectivity 
 
Very strong cell 
mediated response 
early in infection 
 
Downregulates CD4/MHC I, 
perturbs T-cell activation 
infectivity of virus 
 
20, 214, 
302 
Vpu 
 
Accessory protein 
Downregulation of CD4 
and enhances virus 
release 
Inhibits CD4-Env 
binding in ER and 
Env degradation, 
enhances virus 
budding  
Downregulates CD4, lowers 
expression of Env 
 
5, 175 
Vpr 
 
Accessory protein 
Nuclear localization of 
PIC, cell cycle arrest 
(G2) 
Additional vaccine 
target 
Induces cell cycle arrest at 
G2 phase, prevents 
incorporation of deleterious 
dUTPs into virion  
 
172, 588, 
589 
Vif 
 
Accessory protein 
Required for replication 
in vivo, enhances 
infectivity  
Additional vaccine 
target 
Restores infectivity in Vif, 
inhibits cellular antiviral 
factors 
 
5, 58 
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I.C.1. Structural and Enzymatic Genes 
 
I.C.1.a.  gag 
      
 The group associated antigen (gag) gene encodes a 55 kDa precursor protein 
(p55), which is expressed from the unspliced viral messenger RNA (mRNA).  The 
precursor protein is proteolytically cleaved into three main structural gene products that 
are incorporated into mature virions: matrix, capsid and nucleocapsid.  Assembly and 
maturation of HIV particles is dependent on the Gag gene products.  
 
Matrix 
 The MA (p17) protein undergoes post-translational myristylation at the N-
terminus, promotes attachment of Gagp55 to the cell membrane and forms the 
submembrane layer of the virion.  Two distinct features of MA are involved in membrane 
targeting: N-terminal myristate group and basic residues found within the first 50 amino 
acids (together known as the “membrane-binding” or “M” domain).  Trimeric MA 
associates with the cell membrane by insertion of the 3 myristate groups into the lipid 
bilayer located directly above the trimer, and the interaction occurs between the basic 
residues on MA and bilayer phospholipid head groups.  In addition to Gag/Gag-Pol 
membrane targeting,  MA  assists  in  Env  incorporation  into  the  virions  by  
association  with  the cytoplasmic tail of Env 266, 422.  Although controversial, MA has 
been implicated in facilitating infection of nondividing cells types (particularly 
macrophages).  MA also contains a nuclear localization signal (NLS) and has been 
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associated with the pre-integration complex (PIC) and HIV-1 IN 79, 80, 201, 202.   However, 
additional studies will need to clarify the role of MA in the infection of nondividing cells.          
 
Capsid 
 The CA (p24) protein is the most abundant viral protein found in the virus and is 
required for Gag-Gag multimerization.  CA is composed of two domains: 1) N-terminal 
region or core domain (virion maturation and incorporation of cyclophilin A (CypA)) and 
2) C-terminal “dimerization” domain (Gag-Gag interactions). CypA is a peptidyl-prolyl 
cis-trans isomerase, and viruses deficient in CypA exhibit defects early post-infection 64, 
617, 631.  Mutation of the C-terminal third (known as the “interacting” or “I” domain) of 
CA greatly impairs virus production 97, 156, 272, 305, 315, 413, 536, 656, 726.  More specifically, 
mutations in the major homology region (MHR) result in defects in assembly, maturation 
and infectivity 413.  The MHR forms a network of hydrogen bonds that stabilize the 
conformation of the entire domain and assists in interactions between Gag molecules170, 
171, 204, 657.  CA is also required for the incorporation of Gag-Pol polyprotein into virions, 
which is essential for the recruitment of PR, RT and IN into the virus particle281, 602, 612. 
 
Nucleocapsid 
 NC is located within the capsid layer and is responsible for packaging of the viral 
RNA genome 442.  Highly conserved among all retroviruses (except spumaviruses), NC 
contains 2 zinc-finger motifs (Cys-X2-Cys-X4-His-X4-Cys, CCHC) found in many 
cellular DNA binding proteins 427.  NC is tightly associated with the viral RNA in virions 
by binding to the packaging signal, psi (ψ), located near the major splice donor site 
 23
(immediately 5’ of gag) 107, 366.  The interaction between NC and ψ requires intact zinc 
fingers and the flanking basic residues 519, 572.  In addition to RNA binding and 
encapsidation, NC plays a role in: 1) RNA dimerization 124,129,558, 2) Gag-Gag 
interactions, 3) virus assembly 155, 272, 4) tRNA incorporation and annealing to the primer 
binding site (pbs)/strand transfer during RT 85, 281, and 3) stability of the PIC90.     
 
p6 
 In contrast to the other Gag gene products, HIV-1 p6 has not been intensely 
investigated.  This proline-rich protein is located at the C-terminus of Gag and is 
important in the incorporation of Vpr into the virion 340, 401, 507.  p6 binds to Vpr at 
residues 32-39 and three hydrophobic residues in a highly conserved sequence motif 
(Leu41-X42-Ser43-Leu44-Phe45-Gly46) 98, 340.  Similar to other retroviruses, HIV-1 p6 
contains a “late” or “L” domain, which plays a role in the final release of virions from the 
cell surface.  Mutations in this region (Pro7-Thr8-Ala9-Pro10-Pro11, PTAP) result in the 
accumulation of virus particles at the plasma membrane 228.  In addition, many of these 
particles have been observed tethered to the membrane, which is suggestive of a block in 
a very late stage of budding 282.  However, the role of p6 during assembly/release is still 
under investigation.  
 
I.C.1.b. pol 
 
 Three viral enzymes are encoded by the polymerase (pol) gene (PR, RT, IN) 
(Figure 1 and Table 1).  The pol gene products are derived from the Gag-Polp160 
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precursor.  This polypeptide is generated by ribosomal frameshifting during translation of 
Gagp55.  The frameshift only occurs 5-10% of the time, thereby ensuring that pol gene 
products are expressed at low levels compared to Gag gene products.  All three enzymes 
are associated with the viral genome.   
 
Protease 
 PR is responsible for the proteolytic processing of the Gag-Polp160 and Gagp55 
precursor polyproteins and thus plays a critical role in the maturation of the virion.  HIV-
1 PR is similar to cellular aspartic proteases such as rennin and pepsin, which contain a 
conserved sequence (Asp, Thr, Gly; protease amino acid positions 25-27) in the active 
site 125.  Similar to cellular aspartic proteases, HIV-1 PR uses two apposed Asp residues 
at the active site to direct a water molecule that catalyzes the hydrolysis of a peptide bond 
in the target protein.  Mutation of the Asp, found at amino acid 25, abrogates the activity 
of PR and prevents the cleavage of Gag and Gag-Pol precursors 25.  The binding cleft in 
HIV-1 PR can hold a 7-amino acid peptide 50.  Unlike cellular aspartic proteases, HIV-1 
PR functions as a true dimer 365, 477, 691.  The substrate binding site is located within a cleft 
formed between the two monomers.  The first cleavage event in all retroviral Gag-Pol 
polyproteins is the autolytic processing of PR.  PR is flanked by p6 at the N-terminus and 
RT at the C-terminus (Figure 1).  Autoprocessing of PR appears to occur via 2 steps: 1) 
intramolecular cleavage at the N-terminus of PR concomitant with the enzymatic activity 
391, 392 and 2) intermolecular cleavage at the C-terminus 694.   
 Following its release, PR forms a dimer and cleaves a number of sites in the Gag 
and Gag-Pol precursors.  Gag processing by PR occurs at junctions between MA/CA, 
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CA/p2, p2/NC, NC/p1 and p1/p6, but each site is cleaved at different rates.  Based on 
Gag proteins translated in vitro, the processing occurs at primary, secondary and tertiary 
sites that are cleaved sequentially in Gag: 1) p2/NC (NC condensation), 2) NC/p6 
(formation of submembrane shell), 3) MA/CA (formation of core shell initiation) and 4) 
CA/p2 (formation of core shell completion) 511, 639.  Consistent with these results, 
mutation of the cleavage sites results in particles with aberrant morphologies that is 
suggestive of a similar order of Gag processing (p2/NC, MA/CA, CA/p2) 2, 348, 683.  PR 
appears to be most active just before particle release from the cells 311.  Proteolytic 
cleavage of Gag/Gag-Pol precursors results in a dramatic change in the morphology of 
the particle, which is known as maturation.  Without a functional PR, particles appear 
doughnut-shaped (immature) by electron microscopy (EM).  Premature cleavage of 
Gag/Gag-Pol polyproteins is detrimental for virion assembly; therefore, it is imperative 
that PR is not activated until after assembly/budding is initiated.   
 
Reverse transcriptase  
 RT converts the viral ssRNA genome into the double-stranded (ds) DNA form 
known as the provirus 27, 629.  Although each virus contains two strands of RNA, only one 
provirus is made 278.  The mature RT holoenzyme is a heterodimer (p51/p66; 250 
molecules per virion) and has three enzymatic functions: 1) RNA-directed DNA 
polymerization (minus-strand DNA synthesis), 2) RNaseH activity (degradation of the 
tRNA primer and genomic RNA in the DNA/RNA hybrid intermediates) and 3) DNA-
directed DNA polymerization (plus-strand DNA synthesis).  The polymerase domain is 
linked to RNase H by a connection domain.  The active site contains three critical Asp 
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residues (110, 185, 186) with two coordinated Mg2+ ions.  Mutation of these Asp residues 
abolishes RT polymerizing activity 95. 
 Reverse transcription of the HIV-1 ss RNA genome to a ds DNA copy occurs via 
a series of controlled steps 227.  First, minus-strand DNA synthesis is initiated from the 
3’OH of the tRNA bound to the pbs, and DNA synthesis continues to the 5’ end of the 
genome.  RNaseH digests the RNA portion of the RNA/DNA hybrid leaving the short, ss 
DNA fragment (minus-strand, strong-stop RNA).  The minus-strand, strong stop DNA is 
transferred to the 3’ end of the genome where it binds to the repeated (R) region present 
at the 5’ and 3’ ends of the RNA genome.  Minus-strand synthesis continues to the pbs at 
the 5’ end of the genome.  Meanwhile, RNaseH partially degrades the RNA in the 
resulting RNA/DNA hybrid.  Fragments not removed by RNaseH serve as primers for 
plus-strand synthesis (major priming site: polypurine tract, PPT).  RNaseH removes the 
tRNA that initially served as the primer for minus-strand synthesis.  This exposes the pbs 
at the 3’ end of the plus-strand DNA, allowing the plus-strand DNA to transfer and bind 
to the homologous region at the 3’ end of the minus strand DNA.  Plus- and minus-strand 
syntheses continue to completion.  Plus-strand synthesis terminates at the end of the 
minus-strand at a sequence known as the central termination signal (CTS) 96.  The final 
product of reverse transcription is a ds DNA molecule that can integrate into the host 
chromosomal DNA.  The high mutation rate of HIV-1 is largely due to the error-prone 
nature of RT, which lacks proofreading activity and frequently switches templates 628.  In 
vivo, the total HIV-1 mutation rate (substitutions, simple deletions, frameshifts and 
deletions with insertions) was measured at 3 X 10-5 per cycle of replication 414.  The 
mutation rate for HIV-1 was 2-10 fold higher compared to other retroviruses.  
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Integrase 
 IN (p32) mediates the integration of the viral DNA into host cell chromosomes 
during the replication cycle.  Retroviral INs are comprised of 3 structural/functional 
domains: 1) N-terminal zinc-finger-containing domain, 2) core domain and 3) the 
relatively conserved C-terminal domain.  Although the integration of murine leukemia 
virus (MuLV) was the first described, integration of all retroviruses follow the same 
series of events 72, 196.  IN removes 2-3 nucleotides from the blunt 3’ terminus of both 
strands of full-length, ds DNA forming the pre-integration substrate.  Randomly, IN 
catalyzes a staggered cleavage of the cellular target sequence once inside the nuclease.  
The 3’ recessive ends of viral DNA are joined to the 5’ ends of the cleaved cellular DNA 
(strand transfer).  Host cell repair machinery fills in the gaps thus completing the 
integration process 72, 196, 549.  The integrated viral DNA (provirus) is flanked by a 5 bp 
direct repeat (5’-TG, CA-3’).  The direct repeat is from the duplication of cellular target 
sequences.  Mutation of highly conserved residues, found in HIV-1 IN and other 
polynucleotydl transferases (Asp-64, Asp-116, Glu-152 and D,D-35-E motif), block IN 
function in vivo and in vitro.  Mutating these conserved residues or deleting the gene 
sequence prevents integration of viral DNA and subsequently replication of the HIV-1.               
 
I.C.1.c. env 
 
 The env gene encodes for glycoproteins that are important in receptor binding and 
entry (Table 1) 11, 168, 541, 652.  The env gene is expressed as a polyprotein precursor, 
Envgp160.  Envgp160 is then cleaved by a cellular protease, furin, into the two Env 
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glycoproteins, gp120 and gp41.  Envgp120 and Envgp41 associate through noncovalent 
interaction.  These molecules form a multimeric structure (most likely a trimer) on the 
surface of the virion 94, 626, 679, 710.  Envgp41 forms the transmembrane domain of the Env 
complex, while Envgp120 is presented on the surface of infected cells or virions.  Envgp120 
has five hypervariable (V) and five constant (C) regions, designated V1-V5 and C1-C5, 
respectively.  The amino acid sequence in the variable loops can vary greatly among 
HIV-1 isolates 63, 561, 577, 592, 623, 681, 702, 703.  One such region is V3, which is an important 
determinant in cell tropism for HIV-1 and contains the chemokine receptor binding 
domain 88, 89, 108, 285, 326, 361, 362.  
 Both Envgp120 and Envgp41 are responsible for mediating entry of the virus into 
host cells.  Initially, Envgp120 binds to human CD4 (hCD4) on the surface of target cells 95, 
144, 153, 162.  This interaction results in a conformational change in Envgp120, which exposes 
the chemokine receptor-binding domain.  Binding of the virus to the chemokine receptor 
leads to another conformational change in Envgp120 that exposes the fusogenic domain in 
Envgp41.  The fusogenic domain instigates entry of the viral core by fusing the viral and 
host cell membranes 95, 191, 263. 
 
I.C.2. Regulatory Genes 
 
 Two viral proteins, Tat and Rev, regulate gene expression of the integrated 
proviral DNA (Table 1).  During the replication cycle, these proteins are expressed very  
early.  Without these proteins, HIV-1 cannot properly undergo viral replication.    
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I.C.2.a.  tat 
 
 The trans-activator of transcription protein (Tat) is a transcriptional trans-
activator that greatly improves elongation of viral mRNAs.  The HIV-1 5’ LTR contains 
enhancer and promoter regions necessary for the binding of cellular and viral 
transcriptional factors for viral transcription.  In the absence of Tat, the transcription of 
the integrated proviral DNA is terminated prematurely due to abortive elongation, thus 
producing short, incomplete transcripts.  However, Tat enhances the processivity of 
elongation and allows for efficient production of full-length HIV-1 mRNAs (Table 1).  
Tat overcomes the poor processivity of the elongating complexes by binding to the trans-
activation response (TAR) RNA sequence (stem and loop structure) and is located near 
the initiation site of the promoter within the 5’ LTR.  Tat binds to the TAR stem loop, in 
conjunction with the cellular protein, Tat-associated kinase (TAK).  The viral-cellular 
protein complex phosphorylates the C-terminal domain of RNA polymerase II and 
converts the transcription complexes into a favorable form suitable for processive 
elongation.  Tat is also secreted from the infected cell.  Even though the extracellular 
activities of Tat are still unclear, Tat inhibits antigen-induced, but not mitogen-induced, 
proliferation of peripheral mononuclear blood cells (PBMCs) 655 and stimulates the 
growth of cultured Koposi sarcoma cells from patients with AIDS 178. 
 
I.C.2.b.  rev 
 
 The regulator of virion protein, Rev,  is a  19 kDa protein (Table 1).  The presence  
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of Rev in cells is an indication of gene expression switching from the early phase 
(multiply spliced mRNAs) to the late phase (singly and unspliced mRNAs) of viral 
transcription.  Using cellular post-transcriptional processing machinery, HIV pre-mRNAs 
undergo a series of modifications (capping, 3’-end cleavage, polyadenylation and 
splicing) prior to leaving the nucleus.  Rev is responsible for the export of viral unspliced 
and singly spliced mRNA from the nucleus into the cytoplasm.  The unspliced mRNA 
serves as the viral genome or for Gag/Pol expression, whereas Env and Vpu are 
expressed from singly spliced mRNAs.  Rev contains a leucine-rich nuclear export signal 
(NES) located at the carboxy terminal domain 187, 409.  The signal is recognized by several 
cellular proteins such as Crm1, eukaryotic initiation factor 5A (eIF-5A), ribosomal 
protein L5, exportin 1, and Ran-GTP.  These cellular proteins are required for Rev-
dependent, nuclear export of viral RNAs.  The mechanism by which Rev functions is 
debatable.  The current model suggests that one copy of Rev binds specifically to a 
sequence in the viral mRNA termed the Rev-responsive element (RRE) 410.  Found in the 
Envgp41 sequence, the RRE is approximately 250 nucleotides in length and contains 
several stem loop structures.  The Rev/RNA complex then recruits eIF-5A and ribosomal 
protein L5.  EIF-5a and L5 provide Rev-bound RNA access to exportin-1 and Ran-GTP 
189, 475, 479.  Once the complex is formed, it is translocated to the cytoplasm.  The complex 
disassembles in the cytoplasm by hydrolysis of Ran-GTP to Ran-GDP 475.  Rev is then 
shuttled back into the nucleus following exposure of its nuclear localization signal. 
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I.C.3. Accessory Genes 
 
 The accessory proteins (Vif, Vpr, Vpu and Nef) have multiple functions within 
the replication cycle.  These accessory proteins are responsible for enhancing viral 
infectivity and replication.  However, they are not always required for replication in vitro.   
  
I.C.3.a.  vpr 
 
 Vpr (viral protein R, 14 kDa) is one of the viral proteins that are incorporated into 
the virion at high levels (100/virion).  There are three major functions proposed for Vpr: 
1) stimulation of gene expression by the HIV-1 promoter, 2) transport of the viral PIC to 
the nucleus following uncoating and reverse transcription and 3) arrest of infected cells in 
the G2 phase of the cell cycle.  The stimulation of gene expression by Vpr is mediated 
through interactions with Sp1 569, 670, TFIIB 329 and TFIID 329. Following HIV-1 entry and 
uncoating, Vpr mediates the transport of the PIC to the nucleus.  Vpr plays an important 
role in the ability of HIV to infect nondividing cells, as well as dividing cells, by 
facilitating nuclear localization of the PIC even in the absence of mitotic nuclear 
envelope breakdown.  In addition to nuclear localization, Vpr also blocks cell division by 
arresting cells in the G2 phase.         
 
I.C.3.b.  vif 
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Vif  (virus infectivity factor,  p23) is  incorporated into the  virion  at  small  levels,  
promotes infectivity of particles and is required for reverse transcription of the ss RNA 
into ds DNA (Table 1).  Vif is highly conserved throughout lentiviruses (except EIAV) 
318 and is also essential for replication of HIV-1 in primary lymphocytes, macrophages 
and some T cell lines.  However, multiple cells lines are permissive to vif-defective virus 
(293T, HeLa, COS, SupT1, CEM-SS and Jurkat) 200.  This discrepancy is most likely due 
to differences in host cell factors.  There are two proposed theories: 1) Vif-permissive 
cells contain a factor that substitutes for Vif or 2) nonpermissive cells contain a factor 
that suppresses virus replication in the absence of Vif.  Earlier reports suggest a role of 
Vif as a suppressor of host factor(s) to enhance viral replication, but specific Vif/host 
protein interactions have not been elucidated 405, 597, 598.  Vif-defective virions, produced 
from nonpermissive cells, do not efficiently reverse-transcribe their RNA genomes 
following infection 609.  The mechanism by which Vif affects reverse transcription is 
currently being tested. 
 
I.C.3.c.  vpu 
 
 Vpu (viral protein U, p16) is a multimeric, integral membrane phosphoprotein 
(Table 1) 408.  Vpu is found at intracellular levels comparable to Gag in infected cells but 
has not been detected in the virion.  The two main functions of Vpu are: 1) enhancement 
of particle release 621, 630  and 2) CD4 degradation 57, 99, 377, 576, 654.  Vpu-defective virus 
remains at the plasma membrane or in intracellular vesicles but does not affect Gag 
processing or transport 333.  The mechanism by which Vpu stimulates virus particle 
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release is still under investigation; however, it is independent of CD4 or Env 212, 716.  Vpu 
directly binds to the cytoplasmic tail of CD4 within the endoplasmic reticulum 57, 99, 377, 
576, 654.  This interaction prevents Env binding to CD4, therefore allowing Env to continue 
to the cell surface 688.  However, the presence of Env is not required for the degradation 
of CD4 by Vpu 99, 688.  One model involves CD4/Vpu/h-βTrCP complexes that are 
targeted for ubiquitin-mediated proteolysis via interactions with the cellular factor, Skp1, 
and h-βTrCP 415.  Inhibition of proteosome activity blocks Vpu-mediated CD4 
degradation and supports this theory 195.   
 
I.C.3.d.  nef 
 
 Negative regulatory factor (Nef, 27 kDa) is the first protein detectable after viral 
infection and is found at low levels in virions (Table 1).  Nef is only found in primate 
lentiviruses and has several functions including: 1) downregulation of CD4 and MHC 
class I molecules 208, 243, 581, 2) enhancement of virus infectivity and 3) modulation of 
cellular activation pathways.  Nef binds to the di-Leu-based motif in the C-terminal 
region of CD4, leading to internalization and degradation of CD4 via the endocytosis 
pathway 8, 208, 243.  In contrast, downregulation of MHC I by Nef requires the presence of 
a Tyr-based motif 367.  This downregulation may occur by increased endocytosis of MHC 
I from the cell surface or reduced trafficking of MHC I from the trans-Golgi network to 
the plasma membrane 72, 236, 367.  The downregulation of CD4 and MHC I may prevent 
hyperinfection of the cell and/or presentation of viral peptides to the immune systems 110.  
Virus infectivity appears to be enhanced by Nef at an early stage in the replication cycle, 
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because nef-deleted virus fail to efficiently reverse transcribe their genomes after 
infection 8, 103, 580.  However, the mechanism by which Nef promotes viral infectivity 
remains to be elucidated.   Several studies have suggested that Nef influences cellular 
transduction pathways and alters the activation state of the cell 418.  This area of research 
has remained highly controversial due to the differences in cell culture systems, inherent 
cross-talk between cellular signaling pathways and potential differences between SIV and 
HIV.  Lastly, Nef is proteolytically cleaved by PR; however, cleavage of Nef does not 
influence its ability to stimulate virus infectivity 444.  Even though Nef is incorporated at 
low levels in the virion, the majority of Nef found in the virus is smaller than the full-
length protein detected in infected cells 78, 500, 680.  It is not clear at this time what function 
is served by proteolytic cleavage or virion incorporation of Nef. 
  
I.D. Replication Cycle of HIV-1 
 
 The HIV replication cycle occurs in an orderly fashion (Figure 2).  HIV-1 entry 
into target cells is mediated through a complex interaction between the viral envelope 
glycoprotein and specific cell surface receptors.  HIV-1 infects susceptible cells by 
binding to CD4 on the CCR5 and CXCR4.  After coreceptor binding, a subsequent 
conformational change exposes the fusion domain in Envgp41 and results in fusion of the 
viral and plasma membranes.  This process culminates in  viral entry and release of  the  
viral core into  the cytoplasm of the cell 95, 144, 153, 160.  The HIV ss RNA genome is 
transcribed into ds DNA by the virally encoded reverse transcriptase upon successful 
entry into the target cell 227, 561, 623 (see Section I.C.1.b).  After translocation of the PIC to  
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Figure 2.  Replication cycle of HIV-1. 
HIV-1 enters permissible cells by Env-specific interaction with human CD4 and a 
coreceptor (CXCR4 or CCR5).  The virus fuses to the cell membrane and undergoes 
uncoating, which results in the loss of the viral membrane.  The viral core is then 
transported to the nucleus.  During this time, the viral protein, reverse transcriptase, 
converts the single-stranded RNA genome to a double-stranded DNA form.  The viral 
genome is transported to the nucleus where it integrates into the host chromosomes via 
the long terminal repeats (LTRs) and the viral integrase (IN).  The integrated, double-
stranded DNA form of the viral genome is known as the provirus.  Transcription of viral 
genes occurs via the HIV-1 promoter found in the 5’ LTR along with viral and cellular 
proteins and host cell machinery.  Rev is responsible for nuclear export of viral mRNAs.  
The viral mRNAs accumulate in the cytoplasm and are translated in proteins using host 
cell proteins and machinery.  The viral proteins are then directed to the cell surface where 
they undergo assembly followed by budding of immature virions.  Post-budding, 
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maturation of the virions causes the particles to become infectious and promotes further 
infection of other permissible cells.    
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the nucleus, the viral DNA is integrated randomly into the host chromosomal DNA via 
the viral integrase and LTRs 386, 582 (see Section I.C1.b).  At this stage, the viral genome 
is called the provirus.  The integrated provirus is flanked by repeat sequences known as 
LTRs, which are important for integration. In addition, the 5’ LTR contains the 
promoter/enhancer elements necessary for viral gene expression 109, 386.  Upon cellular 
activation by environmental and cellular transcription factors as well as the HIV 
transactivator protein, Tat, transcription of the proviral genome is initiated (see Section 
I.C.2.a).  Using host cell proteins and machinery three different viral mRNAs are 
produced:  1) multiply-spliced, 2) singly-spliced and 3) unspliced mRNAs 323, 529, 638.  
Initially, the multiply-spliced mRNAs are transcribed during the early phase of HIV-1 
transcription (Tat, Rev and Nef).  The singly-spliced mRNAs encode for Env, Vpu, Vif 
and Vpr.  Unspliced mRNAs are transcribed in the late phase of HIV-1 transcription 
(Gag, Gag-Pol, and genomic RNA).  Nuclear export of singly and unspliced viral 
mRNAs is provided by the viral protein, Rev along with cellular proteins and machinery 
(see Section I.C.2.b).  Once in the cytoplasm, these mRNAs are then translated into viral 
proteins.  The envelope proteins are synthesized, glycosylated and processed in the 
endoplasmic reticulum and Golgi apparatus.  Following cleavage by furin, the envelope 
proteins form mulitmers (most likely trimers) and migrate to the cell surface 168, 686.  The 
structural gene products accumulate at the cell surface and assemble into an immature 
viral particle, which encapsidates two copies of the viral genome along with the 
associated proteins.  The virus undergoes budding and is released from the infected cell 
192, 310, 459.  In addition to HIV-1 Env, the viral membrane contains host-derived proteins, 
such as MHC class I 181.  The particle undergoes a maturation process that involves the 
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proteolytic processing of the Gag and Gag-Pol polyproteins by the viral protease (see 
Section I.C.1.b).  Gagp55 is processed to yield the MA, CA, NC and p6, while Gag-Polp160 
is cleaved to produce the Gag gene products plus PR, RT and IN 587.  
 
I.E. Disease Course and Immune Response to HIV-1 in Humans 
 
 There are four major modes of HIV-1 transmission:  1) sexual intercourse, 2) 
blood products, 3) contaminated needles from intravenous drug use and 4) mother-to-
child during the prenatal period 121.  Many immunological and viral hallmarks are 
observed during the course of infection of HIV-1 106, 114, 122, 501, 633.  The timeline for 
disease progression from infection with HIV-1 to the development of AIDS varies 
between individuals.  In general, the first symptoms of clinical AIDS become evident 8-
15 years after infection.   
 HIV infection typically follows an established course:  1) primary acute infection 
often with a mononucleosis-like disease, 2) a prolonged period without obvious, visible 
symptoms   and  3)   a  severe immunodeficiency that results in  the  development of 
opportunistic  infections and tumors that lead to the major causes of death in AIDS 
patients (Figure 3) 484.  The rate of progression through these phases varies among 
infected individuals.  In the first days after infection, the acute phase is characterized by 
high levels of viral replication in activated lymphocytes located in the lymph nodes 
(lymphadenopathy).  Individuals generally experience flu-like symptoms during this 
phase of HIV-1 disease (6-12 weeks).  During this time, the viral population is relatively 
macrophage-tropic (M-tropic).  M-tropic HIV-1 isolates, seen during the early stage of 
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Figure 3.  Viral and immunological features during the course of HIV-1 infection.  
 Initially, an individual becomes infected usually through the exchange of bodily 
fluids.  A transient peak in viremia (          ) is noted in the first 2 months post 
infection.  Anti-Gag cellular response is responsible for controlling the initial 
viremia, which decreases viral loads to low or undetectable levels (set point).  The 
next stage of infection, the asymptomatic phase, can last from months to >10 years. 
Viral replication persists during this stage, while neutralizing antibody titers 
gradually increase (           ).  There is a rise in viral titer and concomitantly a 
dramatic decrease in the number of CD4+ T-cells (        ).  Although the total 
number of CD8+ T-cells  (           ) is maintained during this time, the activity of 
HIV-specific CTLs (          ) significantly decrease.  Once the CD4+ T cell count 
drops below 200/mm3, the patient develops disease symptoms of disease, is 
diagnosed with AIDS and usually succumbs to an AIDS-related illness within 2-4 
years. 
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 infection, infect cells expressing the chemokine receptor, CCR5.  The activation of 
cytotoxic T cells (CTL) and induction of anti-HIV antibodies result in containment of the 
initial viremia.  An increase in CD8+ cytotoxic T lymphocytes is seen in the acute phase, 
but neutralizing antibodies are not detected until 6 months after infection.  CD4+ T 
lymphocytes decrease during this phase but return to near normal levels after six months 
(Figure 3). 
 The asymptomatic phase occurs approximately 3-4 months after infection.  
Minimal viral replication occurs during this stage, and the level of HIV detected in the 
blood remains relatively stable for many years (Figure 3).  The amount of virus in the 
blood (viral load) decreases to a setpoint (steady state level of virus) and is prognostic for 
the course of infection and disease; higher setpoints correlate with a more rapid disease 
progression.  Viral load set points of < 103 copies of viral RNA/mm3 of plasma generally 
are associated with a slower progression to AIDS 439, 440, 570.  During the asymptomatic 
phase, patients experience mild symptoms that may include fatigue, weight loss and 
shingles.  Despite the immune response to HIV-1, virus replication continues at a low 
rate.  At the beginning of the asymptomatic phase, the viral population consists mainly of 
M-tropic strains.  However, the viral population becomes more heterogeneous (M-tropic, 
dual tropic and T cell tropic (T-tropic) HIV-1 strains) towards the end of the 
asymptomatic stage.    
 The symptomatic or AIDS phase is the end stage of HIV-1 disease and is 
characterized by a dramatic drop in CD4+ T lymphocyte population (<200 cells/mm3 of 
blood) and is associated with a rise in viremia.  Normal healthy adults usually have 
greater than 1.0 x 103 CD4+ T cells per mm3 of blood 121, 183, 439, 440, 570.  In the lymph 
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nodes, HIV-1 replication increases and lymphoid cells and tissue are destroyed.  In the 
last phase, the virus population becomes more homogenous with the emergence of the 
virulent, T-tropic viruses.  T-tropic HIV-1 isolates appear later in the course of HIV 
infection and infect cells expressing the chemokine receptor, CXCR4.  The mechanism 
by which CD4+ T cells are depleted remains to be identified.  Different mechanisms for 
the destruction of CD4+ and CD8+ T cells have been proposed: 1) direct infection of the 
cell, 2) the induction of apoptosis and 3) syncytium formation of healthy T cells with 
infected T cells.   
 AIDS is characterized by a state of immunodeficiency that allows for the 
development of secondary, opportunistic infections.  During this stage, opportunistic 
infections develop and eventually the patient succumbs to an AIDS-related illness.  Some 
of the most prevalent opportunistic infections of AIDS are Pneumocystis carinii, 
Cryptosporidium, Toxoplasma, Mycobacterium avium/tuberculosis and Salmonella 111, 
148, 199, 436, 484, 562.  Tumors usually associated with HIV infection are Kaposi’s sarcoma 
(skin), non-Hodgkin’s lymphoma (lymphatic tissues) and primary lymphoma of the brain 
56, 265, 396, 494.   
 
I.F. Antiretroviral Therapy  
 
 Currently, highly active anti-retroviral therapy (HAART) is a treatment regimen 
widely used by physicians.  HAART involves using an assortment of antiretroviral drugs 
to reduce or prevent viral replication (usually inhibitors of HIV-1 PR and RT).  A 
combination of two or more antiretroviral medications is generally more effective than 
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using just one of these medications (monotherapy) for treating HIV infection 624. The 
regimen usually consists of one protease inhibitor (e.g. lamivudine) and one or more 
reverse transcriptase inhibitors (e.g. zidovudine or stavudine) and results in reduced 
levels of virus (<50 copies of viral RNA/mm3 blood) after one year of treatment in 
approximately 60-80% of patients 270.  The use of HAART has enhanced both the 
longevity and quality of life for infected individuals by controlling viral replication 270.  
Some of the advantages of combination antiretroviral drug therapy for the treatment of 
HIV are: 1) minimal incidence of HIV-related complications, 2) decrease in viral 
loads/induction of lower viral setpoints, 3) lessened severity and delayed onset of 
symptoms and 4) prolonged survival of infected individuals 269, 498.  Despite the 
effectiveness of HAART, several drawbacks are accompanied with this treatment that 
limit its worldwide use (particularly in developing nations).  First, HAART does not 
protect patients against initial infection nor does HAART clear viral infection.  Other 
disadvantages include: toxicity, non-adherence, lack of efficacy, interactions with other 
drugs and food, unfavorable pharmacokinetics, transportation and storage, high 
production cost and drug resistance 133-135, 251, 619.   
  
I.G. Correlates of Protection 
 
 The correlates of protection for HIV-1 have yet to be fully elucidated.  However, 
a significant amount of information regarding the mechanism of protection has been 
accumulated through vaccination trials and natural infection of HIV-1.  Live-attenuated 
virus and Env subunit (gp120 and gp160) vaccines were the first approaches attempted to 
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generate a vaccine for HIV-1.  Due to safety concerns, second generation vaccines, such 
as inactivated virus, were later developed.  Although these vaccines were safer than live-
attenuated virus, inactivated HIV-1 was not as immunogenic as the replication-competent 
virus.  The third generation of HIV vaccines included purified or synthetic proteins, 
which also did not achieve the level of immunity observed with live-attenuated virus.  
Most recently, a fourth generation of HIV vaccines (DNA and viral vector vaccines) has 
emerged due to modern advances in molecular biology and genetic engineering.  
Although most vaccine approaches to HIV have failed to protect the vaccinee from virus 
challenge, a significant amount of knowledge has been uncovered regarding the 
mechanisms underlying the generation of immune responses and the development of 
advanced technologies to monitor the immune response elicited by a vaccine.  
 As expected, the immune response elicited varies considerably depending on the 
nature of the immunogen.  In general, live-attenuated virus vaccines induce immune 
responses similar to those observed in natural infection.  Killed virus vaccines and 
purified synthetic proteins preferentially elicit neutralizing antibodies and CD4+ T cell 
responses but not CTLs.  Replication defective virus-based vectors, alone or in 
combination with DNA, induce CTLs and CD4+ T cell responses but are less effective in 
generating neutralizing antibodies.  In contrast to HIV-1, a number of live-attenuated 
virus, inactivated virus or soluble protein vaccines have been proven effective against a 
variety of viral pathogens (smallpox, measles, polio, varicella zoster, hepatitis B).  
However, the mechanism of control (antibodies, CD4+ T cells, CTLs or combination) 
varies between pathogens.  There are considerable obstacles that have impeded the 
development of an effective vaccine against HIV-1 including integration of viral 
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genome/life-long infection of host, viral escape from neutralizing antibodies and CTLs, 
sequence variability/error-prone nature of HIV-1 RT and immune evasion.   
 Despite the evasive nature of the virus, both arms of the immune response are 
directed against multiple viral proteins during a natural infection of HIV-1.  Different 
components of the immune system are effective in producing antiviral responses to 
different forms of HIV-1 (virions, latently infected cells and virus-producing infected 
cells).  Neutralizing antibodies are efficient in blocking virus particles from infecting new 
cells but are poorly effective against cell-associated virus.  Some CTLs are effective 
against virus-producing infected cells but not against free virus particles.  Neither 
antibodies nor CTLs are effective against latently infected cells.   
 Cellular responses to HIV-1 have been studied extensively in infected individuals.  
There is an abundance of HIV-specific CD4+ T cell that secrete IFN-γ despite the loss of 
HIV-specific CD4+ T cells with the capacity to proliferate 516.  This suggests that the 
problem is not a lack of HIV-specific CD4+ T cells but a distortion toward one functional 
population of CD4+ T cells.  The cellular response to HIV-1 is ineffective compared to 
other viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) 19, 70, 93, 256.  
There are three distinct functional T cell populations that are associated with different 
conditions of antigen persistence and antigen load during infection with EBV or CMV: 
CD4+ T cells that secrete IL-2 only (antigen clearance), IFN-γ only (antigen persistence 
and high antigen load) and a combination of IL-2 and IFN-γ (prolonged antigen exposure 
and low antigen load).  Interestingly, HIV-1 long term non-progressors (LTNP) 
maintained polyfunctional CD4+ T cell responses similar to CMV and EBV.   
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 Overall, the same generalities can be assessed to CTLs.  Despite a high frequency 
of HIV-specific, IFN-γ-secreting CD8+ T cells that recognize multiple epitopes 
throughout the viral genome, viral replication is not controlled 6, 45.  Distinct differences, 
similar to those seen for CD4+ T cells, have been observed in the antigen-specific, CD8+ 
T cells induced against HIV compared to CMV and EBV.  The presence of virus-specific 
CD8+ T cells that are able to proliferate and secrete IL-2 seems to be associated with low 
levels of viral load and viral control 443.  These effective cells are found in CMV and 
EBV infections in addition to HIV-1 LTNPs.  In general, chronic, progressive HIV-1 
infection is associated with a monofunctional T-cell response (IFN-γ), whereas LTNP 
induce a polyfunctional cellular response from memory CD4+ and CD8+ T cells at 
different stages of differentiation 256.  These results suggest that the effectiveness of the 
cellular immune response is based on the quality, not quantity, of the vaccine-induced T 
cells.   
 Results from several studies have validated this theory.  1) Virus-specific CD8+ T 
cells responses have been detected in individuals exposed to HIV-1 but remaining 
uninfected 316, 317, 553.  2) Following interruption of HAART in HIV-infected patients, 
virus control is associated with the preservation of HIV-specific CD4+ T cell responses 
during primary infection 546.  3) In the SIV/macaque model, depletion of CD8+ T cells 
results in uncontrolled viral replication; SIV replication is quickly controlled following 
the restoration of CD8 + T cell responses 297, 573.  4) There is a small group of individuals 
(LTNP) that does not experience disease progression even in the absence of antiviral 
treatment.  5) LTNPs maintain polyfunctional, memory cellular responses similar to the 
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responses observed in CMV and EBV 443, 557.  In light of these observations, HIV-specific 
cellular responses may contribute to the effective control of replication during infection.     
 In addition to an effective cellular response, a broadly cross-reactive humoral 
response will most likely be required to protect individuals against viral challenge.  
Neutralizing antibodies may play a more influential role in preventing the initial infection 
of HIV rather than in the control of chronic, established HIV infection.  Passive 
immunization with neutralizing antibodies prevented the establishment of chronic 
infection of chimpanzees with HIV-1 176, 420.  Although controversial, there is evidence 
that neutralizing antibodies may influence the level of chronic steady-state viremia 574.  
The limited effect may be due to the rapid escape of virus from neutralizing antibodies 
observed in infected individuals 538, 678.   
 In the presence of pre-existing, vaccine-induced immunity, the correlates of 
protection may not be the same as those involved in preventing disease progression 
during natural infection with HIV-1.  Research will need to further define the mechanism 
of viral control and how pre-existing immunity may affect the outcome of HIV-1 
infection.  Nonetheless, an ideal HIV/AIDS vaccine will most likely need to elicit both 
cross-reactive, neutralizing antibodies and a strong cellular immune response against 
multiple HIV antigens to protect individuals against viral challenge.   
 
I.H. HIV-1 Vaccines 
  
 Over the past two decades, many strategies have been explored in the search for 
an effective vaccine against HIV-1.  Several of these vaccines are effective in inducing 
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strong cellular and humoral response.  Some of the most prominent immunogens include: 
1) live-attenuated virus, 2) subunit protein, 3) DNA, 4) viral vectors and 5) virus-like 
particles.  Particle-based vaccines (live-attenuated virus and VLPs) are described in detail 
in Section I.I.  
 
I.H.1. Subunit Vaccines 
 
 Unlike hepatitis B, subunit vaccines have not proven effective against 
immunogens such as HIV-1.  Subunit vaccines involve inoculation of purified, soluble 
protein that induces mainly a humoral response regardless of the inoculation site.  
Historically, subunit vaccines for HIV focused on the Env protein, although other 
proteins have been tested.  Env is the only realistic target for neutralizing antibodies 
against HIV-1, because it is the only viral protein found on the outer surface of the virion 
and mediates entry of the virus into susceptible cells.  In early Env subunit vaccine 
studies in mice and non-human primates, neutralizing antibodies were enhanced 248, 435 
and some (not all) chimpanzees were protected from infection following challenge with 
HIV 41, 74.  Based on these results, recombinant Envgp120 was evaluated for safety and 
immunogenicity in humans.  Antibodies to Env were detected in almost all vaccinees, 
and neutralizing antibodies were detected in the majority of recipients 150, 579.  It became 
evident later that these neutralizing antibodies were transient and limited to homologous, 
laboratory-adapted HIV strains 421, 696.  HIV Env subunit vaccines do not generally induce 
significant CTL responses against Env 233, 433, nor do they neutralize primary isolates 231, 
421, 426.  Most experts in the field do not support monomeric Envgp120 as a viable vaccine 
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candidate for the future 83, 457.  In spite of the compounding negative results for Envgp120 
subunit vaccines, there is currently an ongoing Phase III trial testing two bivalent Envgp120 
vaccines in humans (Vaxgen) 42, 190, 371.     
 The failure of Envgp120 subunit vaccines prompted researchers to investigate 
strategies that may produce more inmmunologically relevant antibodies to the native 
structure of Env such as oligomeric gp140 and particle based-vaccines.  Various 
approaches to construct soluble, trimeric forms of Env that more closely mimic the native 
Envgp160 on the surface of virions have been employed.  Some of these include stabilized 
Envgp120/gp41 subunits 51, Envgp160 and Envgp140 oligomers 167, 710 and trimeric Env 495, 548.  
Soluble, trimerized Envgp140, unstablized or stabilized with domains (GCN4, T4 
bacteriophage fibritin motifs or by additional disulfide bonding (SOS)), elicited modest 
levels of enhancement of neutralizing antibody compared to antibody elicited by 
monomeric forms of Env 1, 61, 563, 578, 711,.  Future studies in primates should determine 
whether neutralizing antibodies induced by vaccination with these modified Envs are able 
to confer protection against virus challenge.          
 
I.H.2. DNA Vaccines 
 
 DNA (genetic) vaccination delivers the gene encoding for a protein rather the 
proteins or peptides themselves into a host.  These genes are usually expressed from 
eukaryotic expression vectors, which use transcriptional and translational machinery of 
the transfected eukaryotic cell to produce the associated protein.  Plasmids (circular ds 
DNA) usually contain a eukaryotic promoter and poly adenylation signal for efficient 
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transcription of the vaccine gene insert.  In addition, most plasmids include a bacterial 
origin of replication and an antibiotic resistance gene for amplification and selection in 
media.  The gene of interest is molecularly cloned into the expression vector at the 
multiple cloning site (MCS) located between the promoter and poly adenylation signal.   
 Nearly every gene of HIV-1 has been vaccinated in the form of DNA (most 
widely tested: gag and pol gene products, Env, Tat, Nef).  Strong antibody and cellular 
responses were induced with these DNA vaccines.  DNA vaccines are particularly 
suitable for eliciting strong cell-mediated responses, because they may be expressed and 
presented by professional APC and directed to the MHC I presentation pathway.  The 
majority of the preliminary studies of DNA vaccines were performed in rodents, and the 
results appeared promising.  However, the immunogenicity of DNA vaccines observed in 
mice has not transferred into other species.  Currently, there are 11 HIV-1 DNA vaccines 
in human trials 286.  All trials (except a study with tat only) include gag in the vaccine 
cocktail.  Most vaccination regimens consist of multiple genes (gag, pol, env, nef and tat) 
given as individual genes or as epitopes/peptides.         
 DNA vaccines can be inoculated into animals by various routes.  Intramuscular 
(i.m.) (needle injection) and intradermal (i.d.)/gene gun (g.g.) inoculations are the two 
most common routes of DNA immunization.  The primary cell type that expresses the 
DNA vaccine is different in these two systems.  Muscle cells are the primary cell that 
express the DNA following intramuscular inoculation of DNA vaccines 644.  Muscle cells 
are not professional antigen-presenting cells (APCs), so the main function of these cells is 
to produce protein in large quantities.  The proteins are then engulfed by APCs, which 
transport the immunogen to the regional-draining lymph nodes where the immune 
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response is initiated 113, 521.  In contrast, gene gun inoculation results in direct transfection 
of dendritic cells.  Proteins are expressed in these transfected cells and presented on 
MHC I.  In addition, proteins may also be engulfed by other untransfected APCs and 
presented on MHC II molecules.  Both types of inoculation lead to cellular and humoral 
immune responses.       
 Several methods have been implemented to increase the immunogenicity of DNA 
vaccines: the addition of strong transcription and translation enhancers into the vaccine 
vector346, codon optimization of gene sequences 18, 253, 485, and the use of adjuvants 
(interleukin (IL) 12 (IL-12), RANTES, IL-2) 29, 221, 583, 706.  In particular, codon 
optimization of gene sequences has greatly enhanced the immunogenicity of DNA 
vaccines.  The use of codon optimization and adjuvants are further described for particle-
based vaccines in Section I.I.3.g.   
 The most effective means of augmenting the immune response by DNA vaccines 
is the inclusion of DNA as the priming component in a heterologous “prime-boost” 
vaccination regimen.  Prime-boost vaccination strategies consist of 2 different vaccine 
vectors encoding a common immunogen.  This combinatorial approach usually results in 
an enhancement of the immune response compared to either immunogen alone 28, 382.  
Some of the boosting components that have been used in conjunction with DNA vaccines 
are viral vectors, subunit proteins and purified particles 15, 252, 254, 292, 527, 543, 575.           
  
I.H.3. Viral Vector Vaccines 
 
 Vaccination  of  live viral   vectors  expressing   HIV  proteins   has  demonstrated  
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favorable immunogenicity data in rodents and non-human primates.  In general, a viral 
vector is used to deliver the gene of interest into a susceptible cell.  The viral vector is 
either attenuated (replicates but does not cause disease in host) or undergoes only a single 
cycle of replication in the host.  Once the viral vector infects the cell, transcription of the 
HIV gene(s) located within the genome of the viral vector can be initiated.  Therefore, 
proteins expressed from viral vectors may elicit humoral and cellular responses.   
   Several viral vectors have been tested in rodents and primates containing genes 
from many pathogens.  Although vaccinia virus may be an effective vector for HIV 
genes, safety issues preclude its use in humans due to a case where vaccinia virus 
disseminated and caused a fatal encephalitis in an immunosuppressed, HIV-infected 
individual 535.  Therefore, the majority of research using poxviruses as vectors for HIV 
research involves an abortive replication cycle in human cells.  Recombinant modified 
vaccinia Ankara (MVA), canarypox and fowlpox (FPV) produce sufficient HIV proteins 
to induce cellular and humoral responses against multiple genes in non-human primates.  
Currently, there is a human trial in Thailand testing the efficacy of a canarypox vector 
expressing HIV Env, but the results to date do not look promising 182.  In addition, there 
are early-phase human clinical trials with HIV proteins expressed from recombinant 
MVA and FPV that are still ongoing.   
 In contrast, recombinant adenovirus vectors have become a promising  
AIDS vaccine candidate 594.  Adenovirus 5 (Ad5) was made replication-incompetent by 
deletion of the E1 and/or E3 gene(s).  In rodents and non-human primates, this 
recombinant viral vector has proven highly immunogenic as a vector for HIV proteins 595.  
These vaccines are currently entering advanced-phase human clinical trials.  So far, HIV-
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specific T cell responses have been detected in the vaccinees.  However, there are serious 
problems associated with pre-existing immunity to the vector that may limit its success in 
humans 30.  Multiple strategies have been developed to circumvent this problem.  One of 
these approaches involves a prime-boost strategy incorporating DNA expressing the same 
immunogen prior to vaccination with the recombinant Ad5 379.  In addition, research is 
underway to vaccinate volunteers with different serotypes of human or chimpanzee 
adenoviruses expressing HIV gene products, thus avoiding the issue of pre-existing 
immunity to Ad5.  Some other live recombinant viral vectors currently being testing 
include: 1) Venezuelan equine encephalitis (VEE) virus, 2) Semliki forest virus (SFV) 
and 3) parvovirus adeno-associated virus (AAV).    
 The use of a prime-boost vaccination regimen has recently become quite popular 
for lentiviruses.  Viral vectors have become a key component of these strategies due to 
their success in primates.  Although viral vectors and DNA elicit cellular immune 
responses quite efficiently, a protein component will need to be incorporated in the 
vaccination regimen to induce antibodies capable of neutralizing a broad range of viruses. 
 
I.I. Particle-Based HIV-1 Vaccine Therapy 
 
I.I.1. Introduction 
 
The use of live-attenuated viruses as vaccines has been successful for the control of 
viral infections.  However, the development of an effective vaccine against the human 
immunodeficiency virus (HIV) has proven to be a challenge.  HIV infects cells of the 
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immune system and results in a severe immunodeficiency.  In addition, the ability of the 
virus to adapt to immune pressure and the ability to reside in an integrated form in host 
cells present hurdles to vaccinologists to overcome.  A particle-based vaccine strategy 
has promise for eliciting high titer, long-lived, immune responses to a diverse number of 
viral epitopes from different HIV antigens.  Live-attenuated viruses are effective at 
generating both cellular and humoral immunity.  However, a live-attenuated vaccine for 
HIV is problematic.  The possibility of a live-attenuated vaccine to revert to a pathogenic 
form or recombine with a wild-type or defective virus in an infected individual is a 
drawback to this approach.  Therefore, these vaccines are currently only being tested in 
non-human primate models. These vaccines are effective in stimulating immunity, 
however, challenged animals rarely clear viral infection and the degree of attenuation 
directly correlates with the protection of animals from disease.  Another particle-based 
vaccine approach for HIV involves the use of virus-like particles (VLP).  VLPs mimic 
the viral particle without causing an immunodeficiency disease.  HIV-like particles (HIV 
VLP) are defined as self-assembling, non-replicating, nonpathogenic, genomeless 
particles that are similar in size and conformation to intact virions.  A variety of VLPs for 
both HIV and SIV are currently in pre-clinical and clinical trials.   
 
I.I.2. Live-Attenuated Virus Vaccines 
 
 Historically, live-attenuated vaccines have been widely used for the control of 
many viral infections such as measles, smallpox, mumps, and rubella 157, 304.  The use of 
live-attenuated virus therapy has been an attractive vaccine strategy because it:  1) elicits 
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both humoral and cell-mediated immune responses, 2) is capable of eliciting an 
immunological memory response, and 3) often only requires one or two immunizations to 
elicit high titer protective immunity. For more information on live-attenuated vaccines 
see reviews by Ruprecht, Johnson, Geretti, Kuwata and Haga. 213, 247, 299, 358, 556.  
 The effective use of live-attenuated lentiviral vaccines has demonstrated that these 
formulations are effective at eliciting protective immune responses in a non-human 
primate model 299.  Live-attenuated vaccines elicit a robust, broad CTL response in 
conjunction with high levels of cross-reactive neutralizing antibodies 298.  Moreover, live-
attenuated lentiviral vaccines persistently express viral antigens requiring fewer boosts, 
contain multiple viral antigens including the native Env conformation(s), and are capable 
of infecting professional antigen presenting cells (APCs).    However, research using live-
attenuated HIV vaccines have been limited to non-human primates due to: 1) the 
potential of the attenuated virus to revert to a virulent form, 2) the possible recombination 
of the vaccine strain with wild-type, pathogenic virus in an infected individual, 3) the 
ability of the proviral genome to integrate into the host genome, 4) the dysregulation of 
the immune system by viral proteins and 5) disease caused by the vaccine strain.  In 
addition, live-attenuated lentiviral vaccines have an inverse relationship between 
attenuation and efficacy as observed in multiple rhesus macaque studies, therefore as the 
degree of attenuation increases the efficacy of the vaccine decreases  143, 299, 300.  
 
I.I.2.a. Live-attenuated SIV vaccines 
 
 The SIV/rhesus macaque model has been used extensively to study the efficacy  
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and safety of potential HIV-1 vaccines 143, 217, 616.  Some of the early attenuation strategies 
focused on abrogating the function of Nef.  A representative study achieved attenuation 
of SIVmacC8 by deleting 4 amino acids in nef.  The 12 base-pair deletion  (amino acids 
143-146 in nef) is found in the region where nef and the 5’ LTR overlap 682.   
Interestingly, 17 weeks post-vaccination, the vaccine strain had reverted to a pathogenic 
form and the monkeys developed AIDS-like disease.  Virus isolated from the PBMCs of 
these vaccinated monkeys contained a functional Nef protein and upon further analysis, 
the deleted gene sequences were restored.  Similar results were seen with a live-
attenuated SIVmac239 vaccine containing a single base-pair mutation that introduced a 
premature stop at amino acid 93 in Nef 324.  Consequently, attenuated SIV vaccines with 
deletions in nef require additional attenuation to further debilitate the virus and prevent 
reversion of the vaccine strain to a wild-type, pathogenic entity.   
 Multiple mutations were introduced into SIV vaccine strains to further debilitate 
the virus.  Two attenuated SIV strains, SIVmac293∆nef (SIV∆nef) containing a complete 
deletion of the nef gene and SIVmac293∆3 (SIV∆3), containing a combination of three 
deletions including the nef and vpr genes and the negative regulatory element (NRE) of 
the LTR were constructed 218, 453.  Deletion of the nef and vpr genes resulted in an 
attenuated strain of SIV that does not achieve high levels of virus replication and does not 
lead to development of disease in rhesus macaques.  The NRE of the LTR was removed 
to ensure adequate replication of the vaccine strain.  Twenty-four adult rhesus macaques 
were vaccinated (intravenously, i.v.) with SIV∆nef or SIV∆3 (12 monkeys each group).  
Seventeen animals developed persistent infection with the vaccine strain and had long-
lasting anti-Env and anti-Gag antibodies.  In contrast, 7 monkeys were only transiently 
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infected and they did not mount persistent antibody responses.  The macaques were 
divided into 4 groups and challenged at different intervals (weeks 8, 20, 79, or 
unchallenged) with wild-type, pathogenic SIVmac251 (10 animal infectious doses).  After 
challenge, the 17 monkeys (with persistent immune responses) vaccinated with SIV∆nef 
or SIV∆3 showed no signs of simian AIDS compared to naïve monkeys (week 79).  The 
animals receiving SIV∆3 elicited a better immune response compared to macaques 
immunized with SIV∆nef as determined by cell-associated viral loads, CD4+ cell counts, 
and disease symptoms. However, there were no CTL assays performed in this study.  
Initial safety and efficacy studies with SIV∆3 appeared promising in adult macaques 123, 
699.  However, further analysis revealed that this vaccine caused an AIDS-like illness in 
adult macaques and death in neonatal macaques at high doses 23, 24.   Therefore, it is 
conceivable that a live-attenuated HIV-1 vaccine based on similar attenuation strategies 
may result in AIDS in vaccinated patients. 
 In contrast to initial studies with SIV∆3, Wyand et al. showed neonatal rhesus 
macaques to be resistant to SIV∆3 700.  Neonatal macaques did not develop AIDS-like 
symptoms upon exposure to SIV∆3 from pregnant mothers during gestation or delivery.  
Adult female macaques were vaccinated (i.v, 11.3ng of Gagp27 in the second trimester 
between days 80-100), and the offspring were orally vaccinated (5, 50, or 283ng of 
Gagp27) on the day of delivery.  Eighty-nine percent of the neonatal macaques were 
successfully vaccinated with no adverse effects.  However, 10% of the neonatal monkeys 
developed high levels of viremia and subsequent AIDS-like disease.  Interestingly, these 
two animals were born to the unvaccinated mothers and therefore these neonates lacked 
the associated maternal antibodies that the other uninfected neonates possessed.  In 
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addition, there was a lack of in utero transmission of SIV∆3 to the neonates born to 
vaccinated mothers. 
 Another interesting aspect of attenuated lentiviruses is that the degree of 
attenuation inversely correlates with ability to elicit effective immune responses.  
Johnson et al. demonstrated that SIV strains with varying degrees of attenuation differed 
in their ability to elicit high titer immune responses in rhesus macaques 300.  Female 
monkeys were vaccinated intravenously with one of the following attenuated SIVmac239 
strains:  SIV∆3, SIVmac293∆3X (SIV∆3X), or SIVmac293∆4 (SIV∆4).  The SIV∆3X 
vaccine strain contains a complete deletion of the nef and vpx genes that are important in 
achieving high levels of virus replication.  In addition, the negative regulatory element 
(NRE) in the upstream (US) sequences of the LTR was removed to ensure adequate viral 
replication of the vaccine strain.  SIV∆4 has the same three deletions as SIV∆3X plus the 
complete deletion of the vpr gene.  Rhesus macaques were then challenged (61 weeks 
post vaccination, p.v.) with pathogenic SIVmac251 (100ng (i.v.) or 48ng (vaginally) of 
Gagp27).  Monkeys immunized with any of these vaccines and challenged with live virus 
had low levels of viremia and normal CD4+ cell counts. Thirty-three percent of macaques 
vaccinated with SIV∆3X and 50% of macaques vaccinated with SIV∆4 were also 
superinfected with the challenge virus.  After challenge, vaccinated monkeys had lower 
viral loads than challenged naive animals.  The most likely reason for the ability of the 
vaccinated monkeys to survive challenge was the induction of an early CTL response 
directed at epitopes in the Gag protein and not neutralizing antibodies against Env. 
 Live-attenuated SIV vaccines have also been reported to induce cross-clade viral 
protection 354, 483, 698.  Wyand et al. vaccinated rhesus macaques with SIV∆3 and found 
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them to be resistant to a challenge with highly pathogenic SHIV89.6P or pathogenic 
SIVsmE660 698.  Monkeys immunized with SIV∆3 and challenged intravenously with 
SHIV89.6P (37 months p.v.) had normal CD4+ T cell counts and were free of AIDS-like 
disease even though all the monkeys had fluctuating viremia (300-10,000 copies of 
RNA/ml of plasma).  Other monkeys vaccinated with SIV∆3 and challenged with 
SIVsmE660 had lower levels of viremia compared to naïve animals.  However, the levels 
of viremia in SHIV89.6P challenged monkeys were significantly lower than the viremia in 
monkeys using SIVmac239 and significantly less compared to previous studies with 
SIVmac251 123, 299, 698.     
 Overall, the results from these live-attenuated SIV studies revealed that a broadly 
cross-reactive, long-lived immune response can be elicited in non-human primates after 
vaccination.  However, the variability in attenuation (and reversion capability) inversely 
correlated with the efficacy of the vaccine.  Therefore, similar outcomes and 
complications could be expected using live-attenuated HIV strains in humans.    
 
I.I.2.b. Live-attenuated HIV vaccines 
 
 HIV-1 infection results in a severe immunodeficiency in only humans and 
chimpanzees; each syndrome has similar epidemiology and disease outcomes 463, 488.  The 
HIV/chimpanzee model has been used to study HIV pathogenesis and vaccine design 220, 
321.  However, in 1998, the U.S. National Institutes of Health (NIH) implemented a 
chimpanzee-breeding moratorium on NIH-supported AIDS research thereby curtailing 
almost all HIV/AIDS vaccine studies using chimpanzees.  Currently, there are no 
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sponsored studies involving live-attenuated HIV vaccines in human subjects by the NIH 
or the World Health Organization (WHO).  In this section, live-attenuated viruses will be 
summarized using a cohort of individuals unintentionally infected with an attenuated 
strain of HIV. 
 Researchers have been able to explore the efficacy of live-attenuated virus 
vaccination in individuals unintentionally infected with attenuated strain(s) of HIV via 
contaminated blood products (1981-1984) from a common infected donor.  This study is 
known as the Sydney Blood Bank Cohort (SBBC) 369, 537.  Nine individuals were given 
blood products infected with an attenuated strain of HIV-1, which contained a 3’ end 
deletion of the nef gene 130.  This attenuation was similar to the SIV∆nef vaccine 
described previously. One member of the SBBC, who had systemic lupus erythematosus, 
died in 1987 (at 22 years old) of causes possibly related to HIV infection, while two other 
recipients have since died of causes unrelated to HIV.   
 Three members of SBBC are long-term non-progressors (LTNP) and continue to 
maintain near normal CD4+ T lymphocyte counts and have minimal HIV/AIDS 
symptoms 166, 370, 434, 724.  Each LTNP has maintained robust HIV-specific proliferative 
and CTL responses to Gagp24.  In contrast, the original donor, as well as two recipients, 
have dramatically declining CD4+ T cell counts, detectable viral loads, and are now 
termed long-term survivors (LTS).  Two of the LTS members (D36 and C98) were re-
evaluated in 2002 before HAART therapy was initiated 52.  Before therapy, both 
members had low CD4+ T cell counts (160 and 387/mm3 blood) and high viral loads 
(9900 and 11491 copies of vRNA/ml of blood).  After one month of therapy, both 
individuals had a significant drop in the levels of viremia (<400 copies/ml of blood) as 
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well as a concomitant increase in the number of CD4+ T lymphocytes.  Virus samples 
from both members were analyzed.  Interestingly, the deletion in the overlapping region 
between nef/LTR was found to be larger than the original documented deletion.   
 In 1999, the donor developed AIDS, and Jekle et al. compared viral strains 
collected before (1995) and after (1999) the onset of AIDS 296.  Both isolates were less 
effective in depleting CD4+ T cells compared to a reference dual tropic strain containing 
the nef gene.  CD4+ T-cell depletion was assessed by measuring the ratio of CD4+ to 
CD8+ T cells in the infected and uninfected individuals.  In contrast, virus isolated in 
1999 readily induced apoptosis in CD4+ T cells in human lymphoid cell cultures 
compared to the 1995 sample.  While the 1995 viral strain was restricted to CCR5+ cells, 
the 1999 isolate could efficiently and equally infect CCR5+ and CXCR4+ expressing 
cells.  Therefore, conversion from an R5-restricted to an X4-phenotype was correlative 
with enhanced cytopathic capabilities and advancement to AIDS.  Evidence from these 
studies supports the possible use of a live-attenuated HIV vaccine in humans.  However, 
it also identifies the shortcomings and safety issues associated with this type of vaccine. 
 
I.I.2.c. Live-attenuated SIV-HIV (SHIV) chimeric vaccines 
 
 Chimeric SIV-HIV (SHIV) viruses are recombinant SIV containing the HIV-1 
envelope glycoprotein.  SHIVs have been used as vaccines, as well as challenge viruses, 
for many years 177, 355, 675, 687, 718.  The prototypic SHIV, NM-3rN, encodes the env, tat, 
rev, vpu, and vpr gene sequences of HIV-1NL4-3 and the long terminal repeats, gag, pol, 
vif, vpx, and nef genes from SIVmac239 357, 560, 591.  Attenuation of a SHIV strain is usually 
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achieved by deletion of nef, vpr, or both genes and usually results in a nonpathogenic 
strain for macaques 247, 288.  In contrast, live-attenuated SIV or HIV vaccines often cause 
disease in primates 23, 24, 476.  Some advantages of using attenuated SHIV for vaccine 
development include: 1) use of monkey models to evaluate vaccines, 2) induction of 
strong and long-lasting cell-mediated responses and humoral immune responses 288, 289, 
375, 658, 3) the ability to test the efficacy of neutralizing antibodies against HIV-1 Env, 4) 
cross-reactivity of immune responses to SIV proteins with HIV proteins, 5) replication-
competence of SHIVs in human and macaque peripheral blood mononuclear cells 
(PBMCs) 398, 560, and 6) increased safety of SHIV vaccines compared to HIV live-
attenuated vaccines 357, 591.     
 Numerous attenuated SHIV vaccines have been constructed 247, 643, 698 including 
SHIV-dn (deleted nef), SHIV-drn (deleted vpr and nef) and SHIV-dxrn (deleted vpx, vpr, 
and nef).  All three vaccines are derived from the non-pathogenic paternal strain, 
SHIVNM-3rN 288.  Macaques vaccinated with SHIV-dn and SHIV-drn had transient viremia 
of the vaccine strain, whereas no virus replication was detected in monkeys inoculated 
with SHIV-dxrn.  Overall, all three groups of SHIV vaccinated macaques remained 
disease-free before challenge.  Fifty percent of the macaques immunized with SHIV-dn 
possessed neutralizing antibodies and CTLs specific for SIV Gag and HIV-1 Env 
proteins.  In addition, most animals demonstrated elevated natural killer cell activity.  
Following intravenous challenge with SHIVNM-3rN (1 or 2 years p.v.), no signs of 
integrated genome were found in the plasma, PBMCs, or inguinal lymph nodes two years 
after vaccination.  Macaques immunized with SHIV-dn were completely protected from 
homologous challenge, whereas animals vaccinated with SHIV-drn (2 of 4) and SHIV-
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dxrn (4 of 4) were infected with the challenge strain (detected by PCR). Macaques that 
were PCR positive (SHIVNM-3rN) maintained the presence of much lower viral loads that 
were sporadic and delayed compared to naïve animals.  Results from this study also 
support the observation of an inverse relationship between attenuation and efficacy of 
live-attenuated virus vaccines.  
 SHIV-dn was then re-evaluated for the ability to protect non-human primates with 
the highly pathogenic SHIV89.6P 177.  Four SHIV-dn vaccinated macaques were 
challenged with SHIV89.6P.  Levels of SHIV89.6P were three to five-fold lower in 
vaccinated animals compared to naïve macaques.  In addition, there was no decline in the 
number of CD4+ T cells in three of the four vaccinated macaques, whereas the CD4+ 
counts in the naïve macaques decreased dramatically.  Enhanced levels of protection 
were observed in macaques immunized with SHIV-dn and challenged vaginally with 
SHIV89.6P.  The vaccinated animals did not develop an immunodeficiency disease even 
though they were infected with the challenge virus (SHIV89.6P).   
 Overall, the use of nonpathogenic SHIVs for the development a live-attenuated 
HIV vaccine is promising, because they are safer than live-attenuated HIV or SIV 
vaccines.  Live-attenuated SHIV vaccines are able to persistently infect monkeys, and 
most likely humans, in a similar manner to live-attenuated SIV vaccines without causing 
disease. The animals immunized with live-attenuated SHIV vaccines did not develop 
disease or die from the reversion of the vaccine strain to a virulent form.  Rather, they 
died from AIDS-like illness because they failed to elicit a protective immune response to 
the challenge strain.  Consequently, the efficacy of SHIV vaccines must be improved 
before they can be used for human clinical trials. 
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I.I.3. Lentivirus-Like Particle Vaccines 
 
I.I.3.a. Methods of constructing, purifying and administering VLPs 
 
Virus-like particles (VLPs) or “pseudovirions” can be defined as self-assembling, 
nonreplicating, nonpathogenic, genomeless particles that are similar in size and 
conformation to intact virions.  For lentiviruses, this definition permits inclusion of VLPs 
consisting of HIV and/or SIV gene products.  VLPs must contain capsid (Gagp24 (HIV) or 
Gagp27 (SIV)) proteins to effectively undergo particle assembly, budding and release from 
the host cell to form a spherical structure encapsidated by a lipid bilayer derived from the 
host cell.  The capsid protein can be expressed as an individual protein or as one of the 
gene products derived from the proteolytic processing of the Gag precursor polypeptide 
(Gagpr55 (HIV) or Gagpr56 (SIV)).  Proper cleavage of the precursor polypeptide by PR 
results in expression of capsid (Gagp24), matrix (Gagp17), nucleocapsid (Gagp6/p7), 
polymerase (RT), integrase (IN), and protease (PR).  Most VLP vaccine strategies 
involve removing the IN gene along with one or both LTRs to prevent integration of the 
vaccine into the host genome and/or recombination with live or defective virus in an 
infected individual.   
Multiple combinations of viral proteins may be used to generate VLPs.  The Gag-
Pol polypeptide precursor, Gagpr55, encodes for structural proteins (p24, p17, and p6/p7) 
and viral enzymatic proteins (RT, IN, and PR).  Protease must be expressed to properly 
cleave the polypeptide precursor to generate products that will be able to assemble and 
subsequently bud from the cell forming a particle.  Gagp24 VLPs contain only the capsid 
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protein that are capable of self-assembly and budding.  VLPs may consist of only Gag 
proteins (Gagp24 only or Gagp24 and Gagp17) surrounded by a lipid bilayer derived from 
the host cell during budding or these particles can also have Env protruding from the lipid 
bilayer.  Some VLPs contain sequences from env inserted into dispensable regions of the 
gag gene, and therefore they do not contain Env incorporated into the particle.  Most 
VLPs that have been described contain different forms of the Env protein including 
unprocessed Env (Envgp160), processed Env (full length, Envfl), and truncated Env (Envt).   
Lentivirus-like particles can be constructed and purified by a variety of methods, 
but most often use a viral expression system such as baculovirus or vaccinia that 
effectively produce HIV/SIV particles 81, 210, 245, 666, 714.  The vaccinia expression system 
consists of infecting cells (TK-143B, human B cell) with wild-type vaccinia virus that are 
then transfected with plasmids expressing Env and Gag proteins.  The recombinant 
vaccinia virus (rVV), with the gag and env genes incorporated in the viral genome, is 
selected for resistance using BUdR, β-galactosidase expression (selectable markers), and 
plaque purification.  Recombinant vaccinia infects the TK-143B cells, expresses Gag and 
Env proteins that assemble and bud from the cells as VLPs.  The VLPs are then purified 
by ultracentrifugation using standard 20-60% sucrose or Optiprep gradients 145.  These 
purified VLPs can then be resuspended in saline and used for vaccination.  EM, silver 
staining of protein gels, and immunoblots can validate purity of the preparations. 
Baculovirus expression systems are faster and generate a higher yield of virus for VLP 
production compared to vaccinia expression systems 666.  Insect cells (Sf9) are directly 
transfected with recombinant baculovirus (rBV) DNA that contains the genes of interest 
(gag and env).  Negative selection against non-rBV is usually achieved using 
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gancyclovir.  The rBV infects Sf9 cells and results in expression of Gag and Env proteins 
that assemble and bud from the cells as VLPs.  Plaque purification of rBV is not required 
in this system.  The method and confirmation of purification of VLPs in this system is 
similar to the vaccinia expression system.   
Lentivirus-like particles can be administered to rodents or primates as ex vivo, purified 
particles or as DNA plasmids expressing the gene products to form VLPs in vivo.  
Previous studies have been able to elicit mucosal and systemic immune responses using 
VLPs.  Mucosal immunity is often elicited by inoculating particles in saline directly onto 
mucosal surfaces.  Intravenous (i.v.), intraperitoneal (i.p.), intradermal (i.n.), or 
intramuscular (i.m.) immunization of DNA plasmids or purified particles in saline or 
DNA coated onto microparticles and administered by high pressure (gene gun) can elicit 
predominately systemic but also mucosal immune responses.   
 
I.I.3.b. Immunogenicity of virus-like particle vaccines 
 
A major advantage of a VLP approach compared to live-attenuated virus is a VLP 
expresses multiple viral epitopes that stimulate a diverse set of immune responses without 
many of the deleterious effects of a live-attenuated virus. VLPs have the potential for 
activating both the endogenous and exogenous antigen pathways leading to the 
presentation of viral peptides by MHC class I and class II molecules.  These multi-
epitope vaccines are more likely than their single component counterparts to generate a 
broad-based immune response capable of clearing HIV-1 escape mutants.  Moreover, one 
vaccine expressing VLPs may be more cost efficient than co-inoculating multiple single 
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gene vaccines for future phase I clinical trials.  An advantage of VLPs compared to single 
recombinant protein vaccines is the ability of VLPs to bind and enter cells expressing 
appropriate receptors.  Env-mediated entry of the HIV-like particles are able bind to CD4 
and chemokine receptors via gp120 and enter into professional antigen presenting cells 
such as macrophages and dendritic cells (both cell types express CD4 and CCR5).  After 
infection, viral proteins can be processed and presented on MHC class I molecules, 
therefore promoting presentation to T-cells by APCs.  In addition, cell-free VLPs bound 
with antibodies can be taken up by phagocytic cells via Fc receptors, thus increasing 
MHC class II presentation. 
 Antigens expressed in their native conformational form can elicit more effective 
responses compared to proteins in their non-native forms 563.  Many neutralizing 
antibodies directed against HIV are elicited against conformational epitopes only present 
in the native form of Env, and some are only exposed after binding to CD4 during entry 
84, 455, 456, 489, 503, 504, 518, 702.  Many Envgp120 monomeric protein vaccines elicit high titer 
anti-Env antibodies.  However, these antibodies often do not neutralize primary isolates 
of HIV 28, 33, 84, 232, 421, 649, 650, 710.  In contrast, Env presented as a native trimer 
conformation more effectively elicits neutralizing antibodies.  Envgp160, expressed from 
DNA plasmid, undergoes normal processing and glycosylation and is incorporated on the 
surface of the transfected cells.  Soluble Envgp140 engineered to maintain a trimerized 
conformation has also been shown to elicit cross-reactive neutralizing antibodies and 
therefore these results further support the use of native Env structure(s).  VLPs 
expressing native forms of Env have the potential to elicit a strong neutralizing antibody 
response to Env and may lead to enhanced ADCC.  Particle-based vaccines, containing 
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native forms of Env, in addition to other viral antigens have the potential to induce strong 
humoral and cell-mediated responses to multiple viral proteins.  However, particle-based 
vaccine strategies are still in their infancy and future studies need to be conducted to 
determine the optimal vaccination regimen, which includes the form of the antigen, 
delivery system, and the use of adjuvants to induce high titers of neutralizing antibodies 
and strong cell-mediated responses.  
 
I.I.3.c. DNA vaccines expressing virus-like particles 
  
 Multiple studies have demonstrated the effectiveness of lentivirus-like particles 
expressed from a DNA vaccine.  A DNA vaccine expressing a SIV VLP (pIV) was 
constructed to mimic a naturally-occurring attenuated viral strain of SIV (SIVsmB7) 607.  
pIV expresses an SIV VLP that is attenuated due to a deletion in the genome that deletes 
sequences that encode for IN, vif, vpx, and most of vpr (~1.6bp deletion, 5’ end of pol to 
5’ end of vpr).  In addition, the cytomegalovirus immediate-early (CMV-IE) promoter 
was substituted for the 5’ LTR to drive high levels of transcriptional expression of the 
VLP genes.  The ensuing particles were noninfectious (no integration or RT activity) and 
nonpathogenic (no disease from vaccine strain).  Vaccination of New Zealand white 
rabbits with the pIV resulted in enhanced anti-Env antibody titers (1:2048) and robust 
lymphoproliferative responses from isolated PBLs and splenocytes after in vitro 
stimulation with whole virions (SIVsmB7) or SIV Envgp130.   
 Lu et al. also constructed plasmids expressing SIV VLPs using the SIVmac239 
genome 400.  The vaccine, pSIV239.∆pol, generates non-replicating particles.  
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SIV239.∆pol VLP is derived from the live-attenuated strain, SIV∆nef, and it contains the 
gag, vif, vpx, vpr, rev, tat, and env genes.  LTR and pol sequences were deleted by site 
directed mutagenesis/molecular cloning techniques to ensure the vaccine could not revert 
to a pathogenic form.  LTR sequences were removed, a 754bp fragment (nt3571-4325) 
was deleted, and a stop codon was inserted to render the pol gene defective.  The nef gene 
was also defective by introduction of a premature stop codon at the 5’ end of the 3’ LTR.  
DNA vaccines expressing SIV∆pol were inoculated (either by combination of i.v., i.m., 
and gene gun (g.g.) or by g.g only) into rhesus macaques (6 inoculations).  Low levels of 
neutralizing antibodies were elicited; however, high CTL responses directed against Gag 
were detected and persisted for many weeks.  After challenge with a lethal dose of 
SIVmac251 (10 monkey infectious dose), animals had a rapid decline in CD4+ T cells and 
quickly succumb to infection.  Although monkeys vaccinated with DNA expressing 
SIV239.∆pol VLP quickly reduced their viral load compared to unvaccinated animals (6 
vs. 12 weeks), none of the animals were able to clear the infection.  One year post-
challenge, 100% (3/3) of macaques in the g.g. only group and 50% (1/2) of control 
macaques died from AIDS-like illness.  The remaining 5 animals were free from clinical 
signs of disease. VLP vaccines constructed using HIV/SIV protein(s) are attenuated to a 
much higher degree compared to live-attenuated virus vaccines.   Similar to results 
obtained using live-attenuated vaccines (SIV∆nef, SIV∆3X and SIV∆4), these VLPs 
corroborate that there is an inverse relationship between attenuation and efficacy with 
particle-based vaccines.  Vaccination of monkeys with pSIV239.∆pol elicited immune 
responses equal to or slightly lower than the levels observed in monkeys vaccinated with 
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the live-attenuated strains, SIV∆3X and SIV∆4, and these vaccines did not protect the 
animals from live viral challenge. 
 The same group of researchers constructed a noninfectious HIV VLP (pNL4-
3.∆pol) based upon the SIV VLP, SIV239.∆pol, by removing a 1.9kb DNA fragment 
encoding for pol 399.  The 5’ LTR was removed and most of the 3’ LTR sequences were 
deleted without affecting the nef gene.  The CMV-IE promoter replaced the 5’ LTR in 
order to efficiently initiate transcription of the vaccine insert.  BALB/c mice were 
vaccinated (i.v, i.m., or g.g.) with 2µg of DNA.  Antibody responses against Gag were 
persistent and increased with subsequent boosting, whereas Env-specific antibodies were 
transient, rising and falling with each successive inoculation.  Total anti-Env specific 
antibodies were relatively low compared to live-attenuated HIVNL4-3 infection. However, 
sera from VLP vaccinated mice (1:3800) inhibited HIV-1NL4-3 infection of susceptible 
cells in an in vitro neutralization system (50% neutralization).  Thirty-five weeks post-
peak, anti-Env titers declined to undetectable levels.  However, splenocytes restimulated 
with Env V3 loop peptides showed cytolytic activity in the vaccinated mice at this time.  
Overall, the immunogenicity of pNL4-3.∆pol, as well as SIV239.∆pol (SIV equivalent 
VLP), does not elicit the level of anti-HIV immunity compared to the live-attenuated 
parental strains. 
 More recently, Singh et al. have reported protection in macaques from disease, 
but not infection (3/4 monkeys), by immunization of a noninfectious SHIV VLP DNA 
vaccine, p∆rtSHIVKU2 599.  The SHIVKU2 provirus contains the tat, rev, env and vpu genes 
from HIV-1HXB2 and the 5’ and 3’ LTRs, gag, PR, IN, vif, vpx, vpr and nef from 
SIVmac239.  This SHIV VLP DNA vaccine contains all viral genes except RT (removal of 
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amino acids 364-617).  Four rhesus macaques were intradermally immunized with 2 mg 
of p∆rtSHIVKU2 (0, 8 and 18 weeks).  Neutralizing antibodies and low IFN-γ-secreting 
cells (ELISPOT) were detected against SHIVKU2.  Two weeks following the final 
immunization, these four animals and two unvaccinated monkeys were challenged 
rectally with heterologous SHIV89.6P (1 ml of tissue culture medium containing 104 
TCID50 into the rectum twice, one day apart, to ensure exposure).  Viral RNA titers (>106 
copies/ml of plasma) and a loss of CD4+ T cells were detected in the unvaccinated 
animals two weeks following challenge.  These control animals died at weeks 8 and 16 
post challenge.  Although all of the vaccinated animals were infected with SHIV89.6P, the 
average of viral RNA titers were lower (average 104, but ranged from 103-108 copies/ml 
of plasma), which decreased over time in 3/4 of the vaccinated monkeys.  The fourth 
animal remained viremic and died at week 47.  The immunological assays used in this 
study did not predict the degree of replication of the challenge virus in the vaccinated 
animals.   
 Unlike the previous VLP DNA vaccines that contained the majority of viral 
genes, Akahata et. al constructed a single plasmid that expressed Gag and Env from two 
different eukaryotic promoters 9.  This dual promoter expressed HIV-1 Gag from a CMV 
promoter in the first position, while HIV-1 Env was expressed from the Rous sarcoma 
virus (RSV) enhancer promoter in the second position.  The Env160 was a hybrid CCR5-
tropic Env that was modified by deletion of the cleavage site (C), the fusion peptide (F) 
and the interspace between the two heptad repeats (I) to induce strong antibody response 
without weakening the cellular response.  In addition, the V1 and V2 loop regions were 
deleted to expose core conserved determinants (gp145∆CFI∆V1V2).  The final plasmid 
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containing codon-optimized Gag and Env was referred to as pVLPgp145.  This plasmid, 
capable of producing virus-like particles, was compared to the same gag and env genes 
expressed from separate plasmids inoculated together or alone.  VLPs produced from the 
individual plasmids did not contain Env on their surface.  Mice were vaccinated 
intramuscularly with 50 µg of DNA (weeks 0, 3 and 6).  Humoral and cellular responses 
were similar whether the genes were inoculated together (dual promoter plasmid or 
separate plasmids) or alone.  Moreover, a difference in the immunogenicity of Env was 
not observed between the vaccines expressing Env associated with a particle or as a 
individual protein.  Therefore, the data suggested that DNA vaccines expressing HIV-1 
polyproteins (such as Gag and Env) generated immune responses similar to those elicited 
by virus-like particles.   
 A collaborative group of multiple laboratories has analyzed the immunogenicity 
of virus-like particles produced non-infectious, multi-gene DNA priming followed by 
boosting with MVA.  The first group constructed multi-gene VLP DNA vaccines 
expressing Gag and Pol from either BH10 or HXB2 strains of HIV-1 and Env, Tat, Rev 
and Vpu from HIV-1ADA (pJS2 and pJS7, respectively) 603-605.  These vaccines were 
compared to DNA containing codon-optimized consensus B gag.  Macaques were 
intramuscularly primed with 600 µg of DNA and boosted with two intramuscular 
vaccinations with 108 pfu of MVA expressing HIV-1BH10 Gag, PR, RT and a truncated 
form of HIV-1ADA Env.  The priming of anti-Gag cellular responses was similar in 
monkeys vaccinated with codon-optimized or wild-type DNA.  The immune responses 
were enhanced following the first MVA inoculation; however, the second MVA boost 
did enhance the anti-Env antibody titers (40-90 fold) but did not increase CD4+ or CD8+ 
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T cell responses.  Vaccination with MVA only (3 inoculations) reduced the 
immunogenicity 10-100 times lower for cellular responses and 2-4 times lower for 
antibody responses compared to the animals vaccinated with DNA/MVA.  These animals 
were then challenged vaginally with SHIV89.6P 14, 15.  These vaccinated animals were 
infected with the challenge strain but were disease-free for more than 3 years.  Antibodies 
to Env were very low or below the level of detection in monkeys vaccinated with 
DNA/MVA (with Env).  However, monkeys vaccinated with the DNA/MVA without an 
Env component were not able to control viral replication as well as the monkeys 
vaccinated with DNA/MVA with Env 14.  Recently an update on this vaccination study 
was published 606.  A study using peptide pools for Gag and Env demonstrated almost 
complete preservation of the CD8+ T cells response but only 50% conservation of the 
CD4+ T cells response three years post-challenge in DNA/MVA-vaccinated animals. 
 The MVA component was further characterized alone in rodents by the same 
group 701 and was published simultaneously with the DNA/MVA study 605.  MVA/HIV 
48 contains a chimeric HIV-1HXB-2/BH10 gag-PR-RT (point mutations introduced to 
inactivate RT) and HIV-1ADA env (truncation of cytoplasmic tail).  The gag-PR-RT 
sequences were expressed from a vaccinia virus promoter (mH5), while Env was 
expressed from a different vaccinia virus promoter (Psyn II).  Mice were vaccinated by 
i.m. or i.d. with 107 pfu of MVA/HIV 48 or control MVA at weeks 0 and 3.  Guinea pigs 
were immunized at weeks 0, 1, 6 and 7 months with 108 pfu of MVA/HIV 48 by i.m. or 
i.d., and New Zealand white rabbits were immunized (i.m.) with 2.5 X 107 pfu of 
MVA/HIV 48 at weeks 0, 4 and 8.  All three rodents elicited anti-Env antibodies but at 
different levels.  Similar antibody titers were observed in the rabbits and guinea pigs 
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(105-106); however the antibody titers were a log lower in mice vaccinated with 
MVA/HIV 48.  There was not a significant difference in antibody titers in animals 
vaccinated by i.m. or i.d. routes.  In addition, the antibodies elicited by vaccinated rabbits 
were able to neutralize a heterologous HIV-1MN, but neutralization activity did not 
increase after the third inoculation.  Gag-specific CD8+ T cells were also induced by 
vaccination of mice with MVA/HIV 48.  Unfortunately, MVA-specific CD8+ T cells 
were approximately 4-5 times higher than Gag-specific CD8+ T cells in these mice.  
 A similar vaccine approach was characterized and consisted of a multi-gene VLP 
DNA vaccine expressing Gag, PR, RT, Tat, Rev, Vpu and Env from the HIV-1 
recombinant subtype CRF02_AG (pIC2) 173.  Mutations in the PR gene of the VLP DNA 
were introduced to optimize the production of VLPs (pIC25, pIC48 and pIC90).  Particle 
production was increased in these PR-modified VLP DNA vaccines compared to the VLP 
DNA vaccine containing wild-type PR.  These vaccines were further characterized in 
vitro, but immunogenicity data was not reported.   
 
I.I.3.d. Enhancement of immune responses in non-human primates 
 
 Persson et al. used a noninfectious HIV VLP that resembled live virus to elicit 
immune responses in rhesus macaques 508.  The VLP vaccine, V3MN, was constructed 
using gene sequences from the plasmid, pMTHIV, that expresses HIV-1LAI virus.  The V3 
loop of HIV-1LAI was replaced with the V3 loop of HIV-1MN, because HIV-1MN is more 
representative of clade B HIV strains.  In addition, mutations were engineered into 
specific sequences in the genome.  A large region in the pol gene was deleted and 
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resulted in abrogation of RT and IN activity.  In addition, RNA packaging signals were 
deleted in the RNA untranslated leader sequence and gag in order to prevent 
incorporation of genomic RNA into the budding particle. These VLPs were purified and 
vaccinated into rhesus macaques but only elicited low neutralizing antibodies levels 
(HIV-1MN, 1:112-1:1473 and HIV-1IIIB, <1:20-1:24, >90% inhibition).   
 Montefiori et al. focused on generating a stronger neutralizing antibody response 
using a slightly different VLP vaccine approach 454.  The noninfectious VLP vaccine, 
VLPBx08, is comprised of HIV-1LAI Gag and PR with HIV-1Bx08 gp120 fused to a 28-
amino acid fragment of HIV-1LAI gp41.  This vaccine is similar to vCP1452 except the 
gp120 from HIV-1LAI was replaced with the gp120 from HIV-1Bx08.  Macaques were 
immunized with this VLP in one of four ways:  1) as purified VLPs, 2) expressed from 
DNA plasmid, 3) expressed in a canarypox (ALVAC) vector, or 4) as a combination of 
these strategies.  Anti-Gag and anti-PR antibodies were elicited in all vaccinated 
monkeys regardless of how the VLP immunogen was administered.  In addition, low 
neutralizing antibody titers were elicited in animals vaccinated with 1) VLP expressing 
DNA and boosted with purified VLP, 2) VLP expressing DNA and boosted with 
ALVAC-VLP, and 3) purified VLP alone.  Induction of Gag-specific IFN-γ producing T 
cells were elicited by DNA expressing VLPs, whereas purified VLP immunogens or 
VLPs expressed by ALVAC did not. 
 Most previous studies using HIV VLPs have utilized gene sequences from clade 
B HIV-1 strains.  However, in 2001, Buonaguro et al. constructed a VLP using gene 
sequences from the clade A strain of HIV-1 Gagpr55 81.  VLPs were combined with an 
independent vector system that expresses Gagpr55, Envgp120 (HIV-194UG018), Nef, and Pol 
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to construct the noninfectious VLP vaccine, HIV VLPA.  The Env used in this study is 
90% homologous (amino acids in the V3 region) with other African HIV-1 clade-A 
strains.  Particle formation was confirmed by western blot analysis, sucrose gradient 
centrifugation (1.14-1.18g/ml, 10-60%), and standard transmission electron microscopy.  
Several viral genes were combined to efficiently produce a noninfectious VLP with 
multiple targets for the immune response.   
 These VLPs then were used in immunogenicity studies in BALB/c mice 
vaccinated with multi-dose regimens of HIV VLPA without adjuvants 82.  BALB/c mice 
vaccinated (i.p.) with purified VLPs (3 doses/4 inoculations) had both humoral and cell-
mediated immune responses directed against Gag and Env proteins.  Neutralizing 
antibodies prevented infection of target cells by homologous (HIV-194UG018) and 
heterologous (HIV-1IIIB) strains in an in vitro neutralization assay.  In addition, enhanced 
proliferative and CTL activity against Gag and Env were elicited.   
 In a different study, the levels of neutralizing antibodies appear essential for 
clearance of virus from infected monkeys.  Notka et al. constructed SIV Gagpr56 VLPs 
containing the native conformation of Env or VLPs containing env sequences (V3 loop, 
CD4 binding domain, and gp41) that were incorporated into dispensable regions of gag 
(amino acids 445-464) 487.  The latter vaccine does not have Env incorporated into the 
virion surface.  Both humoral and CTL responses were elicited regardless of the 
vaccination strategy used.  In contrast to anti-Gag antibody responses, anti-Env antibody 
titers were not boosted by additional inoculations.  After non-lethal challenge with SHIV-
4 (SIVmac239 Gag, Pol, Vif, Nef and HIV-1HXBc2 Tat, Ref, Vpu, Env) (week 20, 25, 50 
monkey infectious dose (MID50)), all vaccinated animals became infected with the 
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challenge virus.  Monkeys vaccinated with VLPs containing Env in its native 
conformation decreased viral loads (SHIV-4) more quickly than unvaccinated animals.  
However, clearance of virus was directly correlative with the appearance of neutralizing 
antibodies after challenge. 
 
I.I.3.e. Strategies to elicit cell-mediated responses using VLPs 
 
 Various strategies have been employed to optimize the induction of CTL 
responses by HIV VLPs.  One strategy involves the insertion of env gene sequences into 
a gag gene backbone, thereby directing a CTL response not only to epitopes of Gag 
proteins, but also Env.  Schirmbeck et al. purified HIV VLPs (Pr55-gag/V3-3) consisting 
of HIV-1IIIB Gagpr55 with sequences from the V3 loop of HIV-1IIIB Env 571.  Dispensable 
regions within the Gag were replaced with the V3 loop.  In BALB/c mice, a single low-
dose of Pr55-gag/V3-3 VLP (1µg) elicited cell-mediated responses against both Gag and 
Env proteins, while recombinant gp160 (10µg) alone resulted in cytotoxic responses 
similar to unvaccinated animals.  The particles were also inoculated after sodium dodecyl 
sulfate (SDS)-denaturation and gel-purification was performed on Pr55-gag/V3-3.  These 
denatured particles (1µg) were still effective for priming anti-Gag and anti-Env CTL 
responses and were slightly better at eliciting CTL responses than undenatured particles.  
However, the cytotoxicity levels were identical to SDS-denatured recombinant gp160 
(1µg).  Therefore, native particles or denatured monomeric proteins are capable of 
eliciting strong CTL responses against Gag and Env. 
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 In a similar approach, three additional Pr55gag/V3 loop VLPs efficiently elicited 
immune responses to HIV antigens.  Wagner et al. determine the most favorable position 
to insert a sequence from the V3 loop (amino acids 296-332) within the gag gene 
sequence 663.  Also, sequences encoding for the CD4-binding domain in addition to the 
V3 loop (amino acids 419-444) from HIV-1LAI were also inserted into this gag sequence.  
In both cases, V3 loop sequences were inserted to replace amino acids (211-241 and 436-
471) in the gag gene.  Rabbits, immunized (i.m., 3X) with purified VLPs (50µg), had 
strong antibody responses to Env and Gag even though low neutralizing titers were 
elicited.  However, strong MHC I-restricted CTL activity was induced in VLP-vaccinated 
mice.  The addition of adjuvants (incomplete Freud’s adjuvant or aluminum hydroxide) 
to these VLP immunogens almost completely abrogated CTL activity.  Interestingly, the 
position of V3 loop sequences within Gag did not affect the efficacy of these vaccines.    
 Rhesus macaques vaccinated with HIV-1IIIB Gagpr55 with Env incorporated into 
the virion surface (strategy 1) or HIV-1IIIB Gagpr55 particles replacing dispensable regions 
of the gag gene with sequences from the HIV-1IIIB V3 loop or CD4 binding domain 
(strategy 2) did not elicit the levels of CTL responses observed in mice 667.  These VLPs 
were inoculated (i.m.) into rhesus macaques, without adjuvant(s). Antibodies against Gag 
for strategy 1 (1:8,000-1:510,000) and strategy 2 (1:4,000-1:16,000) were elicited 
throughout the study.  Total anti-Env and neutralizing antibodies were only detected in 
animals vaccinated with VLPs (strategy 1) (1:2,000-1:32,000 and 1:32-1:128, >90% 
inhibition, respectively).  Gag- and Env-specific CTL responses were similar in both 
groups.  Four weeks after the last vaccination, macaques were challenged (i.v.) with 
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SHIVIIIB (20 MID50).  All vaccinated animals became infected with the challenge virus in 
spite of anti-Env neutralizing antibody and CTL responses against Gag and Env elicited. 
 In another approach, Paliard et al. used VLPs (HIVIIIB Gag55 and HIV-1SF2 Env) 
to evaluate their ability to induce a strong CTL response without adjuvant(s) in rhesus 
macaques 499.  Monkeys, vaccinated (i.m.) with purified VLPs (200µg, 4 inoculations) 
elicited robust, long-lived Gag-specific cytolytic responses from isolated PBMCs and 
cells in the draining lymph nodes.  These CTLs recognized a wide range of viral epitopes.  
Therefore, this type of HIV VLP has the potential to be combined with immunogens that 
elicit cross-reactive neutralizing antibodies to design an effective therapy against HIV in 
future studies. 
 
I.I.3.f. Modifications in Env to enhance the efficacy of VLPs 
 
 Rovinski et al. constructed a VLP containing the full length, unprocessed HIV-
1gp160 552.  An HIV VLP containing unprocessed gp160 (non-cleaved) was developed to 
compensate for the rapid loss of gp120 from the surface of particles due the weak 
interaction between gp120 and gp41.  The unprocessed gp160 is produced by mutating 
the gp120/gp41 cleavage site of the chimeric HIV-1LAI-MN Envgp160.  Subcutaneous 
inoculation of guinea pigs with these purified particles elicited cross-reactive neutralizing 
antibodies against HIV-1LAI/MN and anti-Env antibodies capable of inhibiting syncytia 
formation and blocking Env-CD4 interactions. 
 Yamshchikov et al. generated a Gagpr56 SIV VLP containing different forms of 
SIV Env using one of two versions of Env; full length gp160 (Envfl) or a truncated form 
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containing the complete Env sequences with a truncated cytoplasmic tail (17 amino 
acids) (Envt) 709.  Interestingly, Envt was transported to the cell surface and incorporated 
into particles more efficiently compared to Envfl.  Co-expression of furin resulted in more 
efficient cleavage of Envgp160 into Envgp120/gp41 and incorporation of Env into viral 
particles.  Assembly of SIV VLPs with Envfl was three to five times higher compared to 
SIV VLPs with Envt.  However, the SIV VLPs containing Envt had more Env molecules 
on the surface of the particles compared to Envfl.  In addition, higher levels of the SIV 
VLPs were observed with processed (cleaved) versus non-processed Gagpr55 proteins 
similar to previous reports 291, 478.  Therefore, the higher levels of Envt incorporation into 
VLPs may be due to the more fusogenic nature of these proteins and therefore 
incorporation increases the host range of the particles.  
 Another study confirmed that truncated forms of Env increase the incorporation 
of Env into virions (SHIV).  Yao et al. used purified VLPs comprised of Gag 
(SIVmac239) and Env (HIVBH10 and HIV89.6) 714.  This study also compared Envfl or Envt.  
There was a 20-50% increase in expression and incorporation of the Envt into the virion.  
Cell surface expression of the Envt was noted to be 8 fold higher than Envfl.  Once more, 
the addition of the cellular protease, furin, enhanced the cleavage of Envfl into 
gp120/gp41.   
 These VLPs containing Envfl and Envt were evaluated in an immunogenicity study 
by the same group 660, 661.  VLPs (Gag, SIVmac239 and Env, HIVBH10 or HIV89.6), with 
similar levels of incorporated Envfl and Envt, elicited similar neutralizing antibody titers 
in mice.  The VLP vaccines containing Envt that were given as DNA induced higher 
levels of anti-Env specific antibodies compared to Envfl.  However, DNA vaccination in 
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combination with VLP boosting resulted in similar patterns of neutralizing antibody titers 
for Envfl and Envt indicating that the immunogenicity of the two forms of Env are similar.  
Therefore, the use of either form of Env would be useful for future development of HIV 
VLP vaccines. 
 HIVIIIB gp120 covalently linked to a transmembrane domain from the Epstein 
Barr virus (gp120tmEBV) has been shown to stabilize the envelope molecule into the virus-
like particle 486.  SIVmac239 Gagpr56 VLPs containing gp120tmEBV proteins induced 
significant anti-SIV antibody titers (whole virus, ELISA), T cell activity (T-cell 
proliferation and CTL assay) in rhesus macaques, regardless if the purified VLPs were 
administered alone or adsorbed to alum as an adjuvant.  Vaccinated monkeys were 
subsequently challenged with a lethal dose of SHIV.  After challenge, there was a sharp 
rise in virus in the blood followed by a rapid decline in viremia compared to naïve 
animals.    
 
I.I.3.g. Adjuvant enhancement of VLP immunogens 
 
 A variety of adjuvants have been used to enhance the immune responses elicited 
by VLPs to stimulate both systemic and mucosal immune responses.  Purified SIV VLPs 
(SIVmac239 Gag with Envfl or Envt) administered into the nares of BALB/c mice resulted 
in enhanced anti-Gag and anti-Env antibodies in the saliva and vaginal secretions but 
only when co-administered with the adjuvant, cholera toxin (CT) 715.  Co-inoculation of 
CT with the SIV VLPs induced significantly higher anti-Env antibody responses, 
including higher IgA titers, compared to vaccination with SIV VLP only.  Furthermore, 
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splenocytes and lymph nodes isolated from SIV VLP/CT vaccinated mice contained cells 
that expressed elevated levels of interferon-gamma (IFN-γ) and interleukin (IL)-4.  
Therefore, effective cell-mediated responses were elicited by mucosal inoculation.   
 In addition, the same group demonstrated DNA plasmids expressing a codon 
optimized Env in conjunction with plasmids expressing SHIV VLPs (SIVmac239 Gag and 
HIV89.6 Env) and purified CT (10µg) protein enhanced immune responses compared to 
Env 713.  Codon optimization is described as the preferential usage of codons by different 
organisms.  Codon optimization entails using a nucleotide gene sequence that uses 
codons most commonly observed in a host cell to thereby increase gene expression.  For 
example, in human cells, tyrosine residues are most often encoded by the codon “TAC”. 
In HIV-1 gene sequences, tyrosines are encoded predominately by the codon “TAT” 18.  
Converting all the codons in HIV-1 genes to the most prominent codons used by human 
genes increases the expression of HIV-1 gene products.  One hypothesis of the enhanced 
protein expression of HIV-1 antigens using codon-optimized gene sequences is 
transcription of codon optimized genes may lead to a greater number of mRNA 
transcripts, which results in higher protein expression.  Alternately, codon optimization 
may enhance protein expression by utilizing the most common and abundant tRNAs in 
human cells.  Codon optimized genes also contain an increased GC content thereby 
removing AT-rich regions (intron-like inhibitory sequences) that decrease the nuclear 
export of mRNAs.  Therefore, a DNA vaccine expressing a viral gene that has been 
codon-optimized or “humanized” expresses more protein in eukaryotic cells compared to 
the non-humanized gene.  DNA expressing HIV-1 gene products can induce both 
humoral and cell-mediated immune responses.  However, after codon optimizing, these 
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same viral genes elicit enhanced humoral and cell-mediated immunity 14, 16.  DNA 
plasmids expressing a codon optimized Env in conjunction with plasmids expressing 
SHIV VLPs (SIVmac239 Gag and HIV89.6 Env) and purified CT (10µg) protein were 
vaccinated into mice and rabbits.  Sera collected from mice immunized with DNA 
expressing codon-optimized genes were able to neutralize heterologous virus 
(SIVmac1A11) and splenocytes isolated from these animals had enhanced cellular immune 
responses.  Mice that received CT in conjunction with DNA expressing VLPs exhibited 
even higher titers of anti-Env and anti-Gag antibodies, T-helper and CTL activity.  After 
vaccination of these DNAs into New Zealand white rabbits, high levels of neutralizing 
antibody against SIVmac251 were elicited in rabbits vaccinated with SIV239mac VLPs 
(SIVmac239 Gag and Env). Fixed SIVmac239 VLPs elicited a neutralization titers against 
SIVmac251 (1:200 at week 16, >90% inhibition).  However, non-fixed SIV VLPs showed 
an average neutralization titer of 1:516 with one rabbit as high as 1:900.  
 The effectiveness of VLPs to induce anti-HIV immune responses can be 
improved by co-inoculating with immunostimulatory cytokines.  Rhesus macaques that 
were primed with DNA (pVecB7) expressing the SIV VLP (SIVsmB7 Gag and Env) were 
co-inoculated with IL-12 and GM-CSF (weeks 0, 13, and 26) 490.  At week 39, monkeys 
were inoculated with purified VLPs with or without IL-12 and subsequently challenged 
(intrarectally) with a lethal challenge of the viral strain SIVsmE660.  Five of six macaques 
survived the challenge, and animals that received SIV VLP DNA and cytokines (IL-
12/GM-CSF as a prime and/or IL-12 as a boost) had lower viral set points than SIV VLP-
DNA vaccinated or unvaccinated monkeys.  In addition, control of viremia correlated 
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with the prevention of disease.  Therefore, co-inoculation of pro-inflammatory cytokines 
with VLP vaccination enhances protection against viral challenge.     
 
I.I.3.h. Human clinical trails using VLPs 
 
 There have only been a few human trials conducted using HIV VLP vaccines.  
The first VLP vaccine (p17/p24:Ty) has been tested in prophylactic Phase I and II trials 
419, 510. This particle does not contain the Env protein. "Ty" is a yeast protein, which 
contains 25% p17 protein and 79% p24 protein (30% of the total mass of vaccine).  Low 
levels of HIV-specific antibodies and cell mediated responses were generated in most of 
the volunteers after three or four immunizations in Phase I and II trials.  In contrast to 
results found in mice immunized with this vaccine, low levels of Gag-specific CTL 
activity was induced in humans so far.  In Phase II trials, vaccines were well tolerated and 
increased CD4 levels in vaccinated individuals appeared promising, but they were not 
statistically significant to controls.  However, long term follow-up demonstrated that this 
vaccine had no effect on HIV disease progression in infected subjects 389. 
 In 1998, Kelleher et al. performed a phase I clinical trial to determine the safety 
and efficacy of a HIV VLP composed of Gagp24 without envelope glycoproteins (VLPp24)  
38,319.  These purified VLPs were administered in combined with zidovudine (ZDV, a 
nucleoside reverse transcriptase inhibitor) in infected, asymptomatic HIV-1 infected 
patients.  Patients were randomly placed into three treatment groups: 1) 200mg of ZDV 
(3x daily) plus inoculation (i.m.) of alum (alum hydroxide) adjuvant once per month, 2) 
200mg of ZDV (3x daily) plus vaccination (i.m.) of VLPp24 (500µg) in alum once per 
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month, and 3) placebo (3x daily) plus vaccination (i.m.) of VLPp24 (500µg) in alum once 
per month.  Viral load, anti-p24 antibody, and T-cell responses (CD4+ and CD8+) were 
similar regardless of the immunization regimen administered.  Although the VLP was 
well-tolerated by patients (no adverse side-effects reported), VLPp24 in alum did not boost 
the anti-HIV immunity in patients on ZDV.  
 A VLP/canarypox virus vaccine was developed that contains Envgp160, Envgp120, 
Gagpr55 and Gagp24 and forms particles 71, 464.  The canarypox vector virus does not 
replicate in human cells, but only transiently infects human cells.  This transient infection 
results in production of a single round of HIV VLPs.  This vaccine is based on a non-
syncytium inducing clade B primary isolate of HIV-1 (Gag, HIVLAI and Env, HIVMN).  
Preliminary findings demonstrate that strong humoral and cellular immune responses 
were elicited in all recipients.  However this vaccine has only been given to HIV-negative 
individuals (i.m.).   
 Few VLP vaccines have been immunized into humans.  Some other Gag VLPs 
that are entering or are in early Phase I trials include Gagp24/p17 VLP plus CTL epitopes 
for clade A 469 or B485.  In the near future, multiple VLP vaccine candidates will be 
entering Phase I or continuing to Phase II human trials.  Preliminary studies of vaccines 
expressing VLPs in humans have revealed positive results and support their inclusion in 
future trials.   
 
I.I.4. Gag Virus-Like Particles Vaccines 
  
 Gagp55  is  the  precursor polyprotein  that  encodes  for  the  main  structural  gene  
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products: MA, CA and NC (see Section I.C.1.a).  In the absence of all other viral proteins 
and RNA, Gagp55 is sufficient for the assembly and formation of virus-like particles 137, 
312, 441, 666, 689.  In numerous rodent and non-human studies, Gagp55 VLPs have elicited 
strong cellular and humoral responses.  Gagp55 VLPs can be purified similar to VLPs 
containing Env described in I.I.3.a.  These systems include: 1) baculovirus 142, 216, 237, 555, 
635, 636, 662, 663, 2) vaccinia virus 246, 659, 665, 3) Vero cells 551 and 4) yeast 559. 
 Priming of the humoral response was demonstrated in rabbits and non-human 
primates 139, 140, 421, 454, 662.  Gagp55 VLPs also induced CTL responses in non-human 
primates 499.  These cellular responses were long-lived and directed against multiple 
epitopes (MA, CA, p7/p6).  Gagp55 in the form of a particle is more immunogenic than 
the same Gagp55 immunogen inoculated as a soluble protein 499.  Various groups have 
analyzed the immunogenicity of Gagp55 as a particle alone 216, 559, 593, carriers of epitopes 
for other viral genes 403, 662, 666 and Gag particles with a variety of Env embedded in the 
particle surface 81, 139, 140, 209, 245, 260, 349, 493, 552, 636, 659.   
 Unlike its soluble counterpart, Gagp55 VLPs contain supplemental components or 
intrinsic properties that contribute to its immunogenicity.  Following Gagp55 VLP 
vaccination, Gag epitopes are processed and presented on MHC I and II molecules, 
therefore enhancing the number and quality of T-helper and CTL responses.  This 
broaden immunity may be due to the particulate nature of the immunogen, presence of 
lipids, and fusogenic antigens (in the case of Gag VLPs with Env).  In addition, APC 
maturation and cytokine production are stimulated by VLP-associated substances derived 
from the expression system (i.e. viral or insect nucleic acid, immunostimulatory 
molecules (baculovirus gp64), cell membranes (yeast, insect), etc.).  Some of these 
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pathogen-associated molecular patterns (PAMPs) may be recognized by the innate 
immune system as “danger signals”.  Recognition of PAMPs results in upregulation of 
costimulatory molecules (B7.1 and B7.2) and cytokines (Il-12 and IL-18), which leads to 
an enhanced and broadened cellular (Th1) and humoral immune response.     
 
I.I.5. Application of VLP vaccines 
 
 Two primary strategies for the production of particle-based lentiviral vaccines 
have been reviewed:  1) replication-competent virus that integrates into the host genome, 
persistently infecting the host (live-attenuated virus) or 2) viral proteins inoculated as ex 
vivo, purified particles or expressed from DNA in vivo to form non-infectious, non-
replicating, non-pathogenic particles (virus-like particles).  Live-attenuated virus is 
effective at eliciting protective immune responses against HIV in non-human primate 
models.  Live-attenuated virus elicits a robust, broad CTL response, as well as high levels 
of cross-reactive neutralizing antibodies.  These vaccines persistently express viral 
antigens and therefore usually require fewer boosts.  In addition, live-attenuated viruses 
contain multiple viral antigens in native conformation(s) that can infect professional 
APCs.  However, live-attenuated virus vaccines for HIV have some significant 
drawbacks that need to be overcome before they can be widely used in patients.  The 
most significant safety issue is the potential of live-attenuated HIV to revert to a 
pathogenic form after inoculation, as well as the possibility to recombine with wild-type 
virus in an infected host.  Another problem with live-attenuated HIV vaccines is the 
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degree of attenuation is either insufficient and therefore the vaccine causes disease or 
these vaccines are overly attenuated as to not elicit protective immune responses.   
 An alternative approach to live-attenuated virus vaccines for HIV is the use of 
virus-like particle vaccines.  These VLPs mimic the virion particle without the concerns 
for safety of live-attenuated viruses.   Some of the advantageous characteristics of VLP 
vaccines include the 1) induction of humoral/cell-mediated and systemic/mucosal 
immune responses, 2) multi-gene composition, 3) expression of native conformation(s) of 
Env, 4) presentation of viral peptides on MHC I and II molecules, and 5) infection of 
APCs.  Nonetheless, additional parameters need to be addressed in order for lentiviral 
VLPs to elicit protective immune responses such as the dose of inoculum and the number 
of immunizations.  In addition, future research needs to focus on overcoming the inverse 
relationship between the degree of attenuation and efficacy of particle-based vaccines.  
The ability of the vaccine to protect the host from infection decreases as the number of 
genes deleted or rendered nonfunctional to attenuate the virus increases.  The use of 
effective adjuvants co-administered with VLPs may assist in these efforts.  There are 
multiple particle-based HIV vaccines in pre-clinical and clinical trials and the future of 
these vaccines appear promising for the induction of anti-HIV immunity. 
 
I.J. Mucosal Vaccination and Immune Response 
 
 Many pathogens gain access to the host through surfaces such as the respiratory, 
gastrointestinal, vaginal and rectal mucosa.  The mucosal immune system is comprised of 
an integrated network of lymphoid cells that interacts with innate host factors to preserve 
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the integrity of the host defense.  HIV can infect Langerhans cells located in the 
pluristratified epithelial layer of the vagina or dendritic cells in the rectal cavity and 
transverse the intact epithelial barrier 100.  These dendritic cells have high expression of 
DC-SIGN which promotes the internalization of the virus 211, 277, 360, 481, 618, 685.  
Consequently, HIV infects a substantial number of CD4+ T cells found in these tissues.  
Eventually, this localized infection rapidly leads to widespread infection of the host.  In 
contrast to the viral load in the blood, treatment with antiviral drugs does not lower the 
viral titer in the rectal mucosa 147.  In addition, Langerhans cells in the epithelium and 
lamina propria in the vagina and rectal mucosa can act as reservoirs of viral infection 46, 
147, 515.  
 Protection against mucosal pathogens is conferred by a combination of antibodies 
(IgG and sIgA) and CTLs 35, 37, 67, 350, 368.  IgG and sIgA block HIV infection of 
susceptible cells in vitro 347.  These anti-HIV antibodies can prevent viral transcytosis 
across a mucosal monolayer 10, 54, neutralize virus infectivity 146, and mediate antibody-
dependent cellular cytotoxicity 53.  Additionally, containment of viral replication by lysis 
of infected cells is achieved primarily by CTLs 424.  The number of antigen-specific 
cytotoxic CD8+ T cells in the lamina propria of the gut is directly proportional to the 
level of protection after mucosal viral challenge 35, 425, 466.  Therefore, augmentation of the 
immune response at the mucosa by mucosally-administered vaccines may induce high 
titer anti-HIV immunity and is more likely to prevent viral infection and the 
establishment of viral reservoirs compared to vaccines inoculated parenterally.   
 HIV-1, similar to many other pathogens, is primarily transmitted at the mucosal 
surface.  Yet, the majority of experimental vaccines against HIV-1 have been inoculated 
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parenterally.  Although an efficient systemic immune response develops, immunity at the 
mucosa after parenteral inoculation is negligible.  In contrast, mucosal immunization can 
induce immune responses at both local and distal mucosal sites as well as systemic 
immunity 100, 128, 372, 376.  HIV vaccines have been inoculated at multiple mucosal sites in 
the form of 1) protein/peptides 36, 374, 445, 615, 2) bacteria 363, 531, 584, 585, 651, 3) DNA 15, 22, 26, 
306, 402, 564, 669, 4) virus 37, 77, 117, 165, 177, 185, 620 and 5) VLPs 331, 373, 390, 451, 647, 715.  In contrast 
to HIV, successful vaccination of animals and humans with VLPs has been achieved with 
viral pathogens such as papillomavirus 590, Norwalk virus 239, hepatitis E virus 385, 482 and 
Sindbis virus 647.     
 
I.K. Cytosine Phosphate Guanosine Oligodeoxynucleotides 
  
Synthetic oligodeoxynucleotides containing unmethylated cytosine-phosphate-
guanosine motifs (CpG ODNs) can be used as an immune adjuvant.  Unmethylated CpG 
motifs are prevalent in bacterial but not in mammalian genomic DNA 186, 219, 708.  The 
relevant sequence motif consists of an unmethylated CpG dinucleotide flanked by two 5’ 
purines and two 3’ pyrimidines 353.  This motif is found approximately 20 times more 
often in bacteria compared to mammalian DNA due to the utilization and methylation 
patterns of CpG dinucleotides in prokaryotes versus eukaryotes 87, 532.  CpG ODNs 
activate host defense mechanisms against a variety of pathogens (viral, allergy, fungal, 
and tumor immunogens), which lead to innate and acquired immune responses in a 
variety of fish, birds and mammals 528.    
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 The recognition of CpG ODNs is through Toll-like receptor (TLR) -9, which 
instigates alterations in cellular redox balance and the induction of cell signaling 
pathways in both rodents and primates 264, 625.  These pathways include the mitogen 
activated protein kinases (MAPKs) and NF-κB, which lead to direct upregulation of 
cytokine/chemokine gene expression 7, 244.  Cells that do not express TLR-9 or TLR-9 
knockout mice are unresponsive to CpG ODNs 7, 17, 244, 625.  TLR-9 is a member of a 
receptor family that mediates responses to PAMPs expressed by a variety of infectious 
pathogens 438.    
 In humans, cells that express TLR-9 include plasmacytoid dendritic cells, 
macrophages and B cells.  Activation of these cells leads to production of pro-
inflammatory (IL-1, IL-6, IL-18, TNF-α) or Th1 cytokines (IFN-γ and IL-12), interferons 
(IFN-α,β) and chemokines 249, 339, 353.  CpG ODNs also induce the polyclonal activation 
of IgM secreting cells (including memory B cells) 43, 353, 717 and the maturation of 
professional APCs 240.  In contrast, mammalian DNA and oligodeoxynucleotides lacking 
unmethylated CpG motifs do not induce cytokine secretion or APC maturation 240, 339.  
Natural killer (NK) cells are activated secondarily, secreting IFN-γ and gaining cytolytic 
activity.  In addition, B cells become more sensitive to activation through their antigen 
receptor.  The expression of costimulatory molecules is enhanced on APCs, which 
improves their ability to activate T-cell responses (IgG2a).     
 Co-vaccination of CpGs with a variety of immunogens has improved the 
immunity to pathogens in various animal challenge models.  Vaccination of CpG ODNs 
with influenza 262, 451, measles 345, hepatitis B 69, 428, tetanus 169 and HIV 714, 715 
immunogens leads to increased antibody responses, CTL activity and IFN-γ secretion.  
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Enhancement of the immune response by CpG motifs has been demonstrated with DNA 
336, 458, 545, 566, 645 and protein vaccines 66, 69, 126, 169, 450.  Ongoing human clinical trials 
indicate that CpG ODNs, administered as adjuvants, are safe, well-tolerated and have 
augmented the vaccine-elicited immune responses 222, 351, 352. 
 CpG ODNs have also been used as mucosal adjuvants.  Immune responses were 
enhanced by co-immunization of CpG ODNs with influenza 450, Hepatitis B 274, 429 and 
HIV immunogens 714, 715.  The immune response induced by co-inoculation with CpG 
ODNs was comparable to vaccination with other adjuvants such as cholera toxin (CT) 
and RANTES 715. 
 
I.L. Blocks in HIV-1 Replication in Rodents 
 
 HIV-1 productively infects and causes disease in humans and chimpanzees but 
not in rodents.  There are multiple species-specific restrictions in HIV-1 replication in 
rodents that are derived from the dependency of the virus on host cellular functions for 
replication.  In particular, HIV-1 does not replicate in murine cell lines in vitro, nor does 
HIV-1 infect laboratory mice (inbred or outbred) 461.    
 There are a number of reasons for the failure of HIV-1 to replicate in murine cells.  
First, there is a block in viral entry.  HIV-1 Env does not readily bind to murine CD4 
(mCD4), mCCR5 nor mCXCR4 39, 330, 364, 406.  Expression of hCD4 with either hCXCR4 
or hCCR5 on murine cells permits HIV-1 to enter these cells, however little or no 
productive replication occurs 47, 207, 417.  Similar results are seen in transgenic mice (hCD4 
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plus hCCR5 or hCXCR4) in vivo following infection with HIV-1 73, 568; cells are infected 
but viremia is not detected. 
 In addition to the block in virus entry in murine cells, there are several post-entry 
blocks in rodent cell lines.  Tat trans-activation is inefficient in murine cells, which 
results in low levels of viral protein expression 12, 206, 259, 480.  The host gene responsible 
for this block is human cyclin T1 (hCycT1), which is a Tat-interacting protein and a 
component of the pTEFb transcription factor complex.  Murine CycT1 (mCycT1) differs 
from its human homolog by several amino acids, but the presence of a tyrosine rather 
than a cysteine at position 261 is responsible for its interaction with Tat 49, 207, 359.  
Expression of hCycT1 in murine cells restores Tat function and along with hCD4 and 
appropriate coreceptor, allows HIV-1 replication to proceed from viral entry through 
proviral gene expression 47, 417.   
 More recently, research has been focused on elucidating the mechanisms 
responsible for the late blocks in HIV-1 replication.  Controversy has surfaced regarding 
a possible defect in the function of Rev in rodent cells.  In some studies, only a small 
reduction was noted in the abundance of unspliced viral mRNAs, which suggested that 
the defect was minor 322, 417.  Whereas, other studies revealed a more profound defect in 
Rev function in several rodent cell types 47, 641. Although the discrepancy of Rev function 
remains unclear, it may be due to differences in cell types rather than species.  The 
reduction in unspliced viral mRNA in certain rodent cells may be due to oversplicing, 
reduced stability of unspliced transcripts or some other mechanism yet to be determined.  
Regardless, the relative amount of unspliced viral mRNAs found in the cytoplasm did not 
correlate with the magnitude of infectious virus production from multiple cell types 47.  
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Therefore, if a defect in Rev exists in certain rodent cell types, it is unlikely to contribute 
significantly to the prevention or decreased production of infectious virus 47, 417.  
However, the contribution of a defective Rev in the failure of HIV to replicate in rodent 
cells is still under investigation. 
 HIV-1, similar to other complex retroviruses, uses the Rev/Response Element 
(RRE) system in conjunction with the Crm-1 dependent pathway for nuclear export of 
unspliced and singly-spliced viral mRNAs.  Analogous to the nuclear export pathway 
mediated by Rev, the constitutive transport element from the Mason-Pfizer monkey virus 
(MPMV CTE) can also facilitate the nuclear export of unspliced and singly-spliced viral 
mRNAs 68, 731.  Simple retroviruses and other RNA and DNA viruses contain CTE or 
CTE-like sequences that interact with cellular proteins to facilitate nuclear export of viral 
mRNAs 258, 692.  These cellular proteins include two nucleocytoplasmic shuttle proteins: 
TAP (NXF1) (mRNA export factor) 238, 309 and the adenosine 5’-triphosphate-dependent 
RNA helicase A 627 and may include others 505.  Addition of one copy of the MPMV CTE 
effectively replaces the Rev/RRE system of HIV and SIV, but with a lower efficiency 68, 
540, 731.  The addition of multiple copies of the MPMV CTE overcomes this restriction and 
is actually more efficient than the Rev/RRE system 693.  These two systems can 
functionally replace one another presumably due to the use of common cellular factors 
(such as Sam68) 533, 534.  In HIV-1, RRE must be present in the mRNA, but the location 
of the RRE within the exon is not important for its function in the Rev/RRE system 86.  
Unlike the Rev/RRE system, the close association of the CTE in relation to the poly A 
sequence is critical for its function in the genomic or the subgenomic context 467, 539.    
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 One of the major obstacles in the development of a rodent model for HIV-1 
infection is a potent block at the stage of virus assembly.  This type of replication block is 
relatively rare for most mammalian retroviruses, which can undergo virion assembly and 
release from a variety of cell types.  For example, HIV-1 VLPs can assemble and release 
from yeast spheroplasts that have had their cell wall removed 559.  The specific 
mechanism of the block in assembly has yet to be elucidated.  Intravesicular Gag 
aggregates are observed by electron microscopy in HIV-infected murine cells 417.  This 
data suggests that Gag may be trapped within intracellular compartments and therefore 
may be responsible for the block in assembly. 
 Controversy also surrounds the non-infectious nature of the particles derived from 
rodent cells.  Some studies have reported particles derived from rodent or human cells 
were equally infectious based on TCID50:p24 ratios 322, 417.  In contrast, another study 
indicated virions produced in rat or mouse cells were largely non-infectious 47.   
 The underlying mechanism responsible for the block in virion assembly and 
release in murine cells has yet to be clarified.  One theory proposed includes the 
mistargeting of Gag, which may result in the accumulation of Gag in intracellular 
vesicles 416.  There are many cellular proteins that play a role in the assembly process of 
HIV in human cells including Tsg101 (vacuolar protein sorting) 653 and HP68 (post-
translational events in immature capsid assembly) 730.  However, inhibiting the function 
of these proteins in human cells resulted in a block in viral egress, but the phenotypes 
were dissimilar to the phenotypes seen in murine cells.  These results suggest the 
involvement of other unknown host factors (cellular protein or a lipid component of the 
plasma membrane).  Further research will need to focus on the mechanism of the block in 
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virion assembly and release in rodent cells.  Most likely, this block in the replication 
cycle is due to a missing host factor rather than some other component of the cell.  Since 
HIV-1 VLPs have been reported to assemble and bud from Saccharomyces spheroplasts, 
this model may be manipulated in the future to identify the missing factor(s) essential for 
HIV-1 egress.        
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II. Chapter 2:  Material and Methods 
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II.A. DNA Plasmids 
 
The lineage of all the plasmids is outlined in Table 2.  Digestion (Section II.A.1), 
ligation (Section II.A.2) bacterial transformation and amplification (Section II.A.3), 
extraction and purification from agarose gels (Section II.A.4), PCR (Section II.A.5), and 
SDM-PCR (Section II.A.6) and sequencing of plasmid DNA (Section II.A.7) were all 
performed as described.  The plasmids were stored at 4°C (short term) or –20°C (long 
term).    
 
II.A.1. Digestion of DNA with Restriction Enzymes 
 
 Plasmid DNA was digested in a 1.5 ml centrifuge tube in the following reaction:  
500 ng (vector plasmids) or 1 µg (insert plasmid) of plasmid DNA, 2 µl of enzyme buffer 
(final concentration, 1X) (Table 2) and 1 µl of each restriction enzyme in a final volume 
of 20 µl.  The samples are placed at 37°C for 1-4 h (1 h for diagnostics, 2-4 h for 
molecular cloning).  The digested DNA was analyzed by agarose gel electrophoresis.  
Digested DNA was mixed with 1X blue sucrose loading dye (Invitrogen Life 
Technologies, Carlsbad, CA, USA) and loaded onto a 1% agarose gel (1% agarose in 
TAE buffer (40mM Tris acetate, 2mM Na2 EDTA (pH 8.0) in distilled water) along with 
a 1kb ladder (Invitrogen Life Technologies, Carlsbad, CA, USA).  The samples were 
electrophoresed (70-80V) for 1-2 h.  Digested DNA was analyzed for fragment size using 
a Transiluminator ultraviolet light (Fisher Scientific, Pittsburgh, PA, USA) and a Photo-
Documentation Camera (Fisher Scientific, Pittsburgh, PA, USA).   
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II.A.2. Ligation of DNA Fragments 
  
 Plasmid DNA was digested and purified as described in Sections II.A.1 and 
II.A.4.  DNA fragments were ligated using the following reaction: vector and insert 
fragments (vector to insert ratios: 1:1, 1:2 and 1:4) were added to 1 µl of 10X T4 DNA 
ligation buffer, 1 µl (1 U/µl) of T4 DNA ligase (Invitrogen Life Technologies, Carlsbad, 
CA, USA) in a total volume of 10 µl of distilled water.  The samples were incubated at 
16° C for 4 h followed by transformation into E. coli XL-gold cells (see Section II.A.3).   
 
II.A.3. DNA Amplification and Purification from Bacteria 
 
Competent cells 
 Bacterial transformation was used to introduce plasmid DNA into competent 
bacterial cells.  The bacterial cells used for transformation, chemically competent XL10-
Gold cells, are derived from XL10-Gold ultracompetent cells (Invitrogen Life 
Technologies, Carlsbad, CA, USA).  XL10-Gold ultracompetent cells (50 µl) were 
thawed on ice for 10 min.  The cells were added to 200 ml of Luria Broth (LB) and 
incubated for 16 h at 37°C (225 rpm).  2.5% of the overnight culture was added to 200 ml 
of fresh LB broth and incubated at 37°C with shaking until the O.D. reading at 550 nm is 
0.3 using a BioMate 3 spectrophotometer (Thermo Spectronics, Rochester, NY, USA).  
LB broth alone was used as the blank.  The bacterial culture was placed into four 50 ml 
conical tubes (U.S.A. Scientific, Ocala, FL, USA) and incubated on ice for 15 min.  The 
cells were pelleted by centrifugation (3,000 rpm for 5 min) at 4°C.  The supernatants 
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were decanted, and each pellet was resuspended in 16 ml of Transformation Buffer #1 
(99.3M RbCl, 48.5M MnCl2, 1M KOAc, 10.2M CaCl2, 15% glycerol, pH 5.8).  The 
samples were mixed thoroughly, and the cells were pelleted by centrifugation (3,000 rpm 
for 5 min) at 4°C.  The supernatants were decanted, and each pellet was resuspended in 4 
ml of Transformation Buffer #2 (0.5M MOPS (pH, 6.8), 19.9M RbCl, 150M CaCl2, 30% 
glycerol) and pooled together.  The sample was mixed thoroughly and placed into 1.5 ml 
centrifuge tubes (200µl each).  The cells were flash-frozen in an ethanol-dry ice bath for 
1 min and stored at -80°C.     
 
Bacterial Transformation and DNA Amplification 
 Plasmid DNA (50-200 ng) was mixed with 20 µl (~1.0 x 106 cells) of chemically 
competent XL10-Gold cells in a 1.5 ml microcentrifuge tube (Fischer Scientific, 
Middletown, VA, USA).  The mixture was incubated on ice for 30 min, and incubated in 
a 420 C water bath for 45 sec.  The mixture was returned to ice for an additional 5 min.  
80 µl of sterile LB (EZmix: enzymatic casein digest 10 g/L, yeast extract 5 g/L, NaCl 5 
g/L, and inert binder 0.6 g/L) (Sigma, St. Louis, MO, USA) was added to the mixture.  
The mixture was incubated at 37° C with shaking at 200 rpm for 1 h.  The entire mixture 
was then transferred onto a pre-warmed, room-temperature, antibiotic agar plate 
(ampicillin or kanamycin) (Sigma, St. Louis, MO, USA) (50 µg/µl).  Sterile glass beads 
(10-12 beads per plate) (Fischer Scientific, Middletown, VA, USA) were added onto the 
plate and used to spread the mixture evenly by shaking the plate back and forth several 
times.  The plate was inverted and incubated in a 37°C incubator for 18 h.  A bacterial 
colony was picked from the plate and used to inoculate 5 ml of sterile LB containing 0.01 
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µg/µl antibiotic (kanamycin or ampicillin).  The culture was incubated at 37°C with 
shaking at 200-250 rpm for 8 h.  1 ml of the culture was then added to 200 ml of LB 
containing 0.01 µg/µl antibiotic.  The culture was then incubated at 37°C with shaking at 
200-250 rpm for 15-18 h. 
 
Bacterial Purification 
 Bacterial cells were harvested by centrifugation at 6,000 rpm for 15 min at 4°C in 
a 250 ml polyclear centrifuge tube (Nalgene, Rochester, NY, USA) using a RC5C 
centrifuge (Sorvall Instruments, Newtown, CT, USA).  The supernatant was decanted and 
the bacterial pellet was resuspended in 4 ml of Qiagen Buffer P1 (50 mM Tris-Cl, pH 8.0, 
10 mM EDTA, and 100 µl/ml RNase A) (Quiagen Inc, Valencia, CA, USA).  The 
bacterial cells were transferred to a 50 ml tube and 4 ml of Qiagen Buffer P2 (200 mM 
NaOH and 1% SDS) was added to lyse the cells.  The solution was mixed by gently 
inverting the tube 4-6 times and incubated at room temperature for no more than 5 min.  
The lysis process was neutralized by adding 6 ml of pre-chilled Qiagen Buffer P3 (3.0 M 
potassium acetate, pH 5.5).  The solution was gently mixed by inverting the tube 4-6 
times and incubated on ice for 20 min.  The samples were centrifuged at 20,000 rpm for 
30 min at 4°C.  The supernatant containing plasmid DNA was transferred into a new 
tube.  The sample was centrifuged at 20,000 rpm for an additional 15 min at 4°C.  A 
Qiagen-tip 100 column was equilibrated by applying 4 ml of Qiagen Buffer QBT 
(750mM NaCl, 50mM MOPS, pH 7.0, 15% isopropanol, 0.15% Triton X-100).  The 
column was allowed to drain by gravity flow.  The supernatant containing the plasmid 
DNA was then applied to the column and allowed to drain by gravity flow.  The column 
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was washed two times with 10 ml of Qiagen Wash Buffer QC (1.0M NaCl, 50mM 
MOPS, pH 7.0, 15% isopropanol).  The plasmid DNA was eluted with 5 ml of Qiagen 
Buffer QF (1.25 M NaCl, 50mM Tris-Cl, pH 8.5, 15% isopropanol) into a new tube.  
Plasmid DNA was precipitated by adding 3.5 ml of room temperature isopropanol to the 
5 ml of eluted DNA.  The sample was immediately mixed and centrifuged at 15,000 rpm 
for 30 min at 4°C.  The supernatant was discarded.  The plasmid DNA pellet was washed 
with 2 ml of 70% ethanol and centrifuged at 15,000 rpm for an additional 10 min.  The 
supernatant was discarded and the pellet was air-dried overnight at room temperature or 1 
h at 37°C.  The plasmid DNA pellet was resuspended in distilled water.  A sample of 
each DNA was diluted 1:200 (5 µl of DNA in 995 µl of distilled water), the concentration 
of DNA was determined using a BioMate 3 spectrophotometer (Thermo Spectronics, 
Rochester, NY, USA).  The optical density (wavelength, 260/280 nm) of the diluted 
DNA sample was measured by the spectrophotometer.  The optical density of non-DNA 
containing distilled water was subtracted from the recorded optical density of the diluted 
DNA to calculate the final optical density.  The concentration of DNA was determined by 
the following: DNA concentration (C, µg/µl) = [A260/ 0.020 (µg/ml)-1] x (1 ml/1000µl). 
 
II.A.4. Extraction and Purification of DNA from Standard Agarose Gels 
 
 Restriction enzyme-digested DNA was extracted and purified from agarose gels.  
After separation of restriction enzyme-digested DNA fragments by electrophoresis, the 
extracted and purified DNA was used for the construction of the various molecular clones 
(Table 2).  The restriction enzyme-digested DNA was removed from the agarose gel (1% 
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agarose in TAE, 40 mM Tris Acetate, 2 mM Na2EDTA (pH 8.0) in distilled water) 
(Cambrex Bio Science Rockland, Inc., Rockland, ME, USA) by physical separation with 
a razor blade and placed in a 1.5 µl microcentrifuge tube and weighed.  DNA fragments 
were separated from the agarose using a QIAquick gel extraction kit (QIAGEN Inc, 
Valencia, CA, USA) according to the manufacturer’s recommended protocol.  Briefly, 
three volumes of Buffer QG (proprietary compound mixture, 50-100% guanidinium 
thiocyanate, pH indicator) were added to one volume of agarose gel.  For example, 300 µl 
of Buffer QG was added to 100 mg of gel.  The microcentrifuge tube was incubated at 
50°C for 10 min or until the agarose was completely dissolved.  The tube was vortexed 
every two to three minutes to help dissolve the gel.  One volume of isopropanol (Sigma, 
St. Louis, MO, USA) was then added to one volume of gel.  The dissolved mixture was 
overlaid into a QIAquick ion-exchange spin column was placed in a collection tube and 
centrifuged for 1 min at 10,000 rpm.  The flow-through was discarded, and the QIAquick 
spin column was placed back in the same collection tube.  The sample was washed with 
750 µl of Buffer PE (proprietary compound mixture, 44.4% ethanol) and centrifuged for 
1 min at 10,000 rpm.  The flow-through was discarded and the QIAquick spin column 
was placed back in the same collection tube.  The QIAquick spin column was centrifuged 
for an additional 1 min at 10,000 rpm and the flow-through was discarded.  The 
QIAquick spin column was placed in a new 1.5 µl microcentrifuge tube.  The DNA was 
eluted by adding 30 µl  of  distilled water  to the center of the QIAquick membrane (25°C  
 for 1 min).  The sample was then centrifuged for 1 min at 10,000 rpm, the spin column 
was then discarded, and the eluted DNA was stored at 4°C.   
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Table 2.  DNA plasmids. 
   
† pTR600 is the base vector unless otherwise noted. 
 
 
Plasmid† Description 
pHIV-1BH10 HIV-1 BH10 provirus (pBC12 vector) 
pHIV-1ADA HIV-1 ADA provirus (pBC12 vector) 
pHIV-189.6 HIV-1 89.6 provirus (pBC12 vector) 
pVLPBH10/wt HIV-1 BH10 VLP: gag, PR, RT, env, vpu, tat, rev-no safety mutations  
pVLPBH10 HIV-1 BH10 VLP:gag, PR, RT, env, vpu, tat, rev + safety mutations   
pVLPADA pVLPBH10 + HIV-1 ADA env, vpu tat, rev + safety mutations 
pVLP89.6 pVLPADA + HIV-1 89.6 env  
pVLPR2 pVLPADA + HIV-1 R2 env 
pVLPJR-FL pVLPADA + HIV-1 JR-FL env 
pVLPcoADA pVLPADA + codon optimized HIV-1 ADA env  
pVLPcoR2 pVLPADA + codon optimized HIV-1 R2 env  
pVLPADA/2xCTE pVLPADA + 2 copies of MPMV-CTE + 200bp nonsense sequence 
pVLPADA/∆RT pVLPADA without RT 
pVLPSHIV/ADA pVLPADA + SIV mac239 gag, PR, RT-no safety mutations 
pVLPSHIV/ADA/∆RT pVLPSHIV/ADA without RT 
pLTR-SEAP HIV-1 5’ LTR + secreted alkaline phosphatase (pBC12 vector) 
pCD4 4 extracellular domains of human CD4 (soluble) 
pcoADAgp120 codon optimized HIV-1 ADA Env gp120 
pcoR2gp120 codon optimized HIV-1 R2 Env gp120 
pGag codon optimized HIV-1 NL4-3 Gag 
pGag∆Myr codon optimized HIV-1 NL4-3 Gag without myristylation site 
pGag-Pol codon optimized HIV-1 NL4-3 Gag-Pol 
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II.A.5. Polymerase Chain Reaction (PCR) 
 
 In vitro polymerase chain reaction was used to amplify gene products.  Plasmid 
DNA (50 ng) with the sequence of interest was added to a microcentrifuge tube with 2 
synthetic oligonucleotide primers (1 µg/µl), ~30 nucleotides in length.  Each reaction 
mixture (Table 3) was placed in a Robocycler® Gradient 96 thermal cycler (Stratagene, 
La Jolla, CA, USA).  A DNA fragment was amplified using a three step reaction cycle 
(Table 3).  The amplified product was cloned into pCR2.1-TOPO plasmid vector using 
the TOPO TA Cloning Kit® (Invitrogen Life Sciences, Carlsbad, CA, USA).  Each 
amplified fragment (2 µl) was incubated in a 1.5 ml centrifuge tube in the following 
conditions:  1 µl of salt solution (1.2 M NaCl, 0.06 M MgCl2), 1 µl of pCR2.1-TOPO 
vector (10 ng/µl plasmid are in: 50% glycerol, 50 mM Tris-HCl, pH 7.4 (25°C), 1 mM 
EDTA, 1 mM DTT, 0.1% Triton-X 100, 100 µg/ml BSA, phenol red), and 2 µl of 
distilled water for 5-20 minutes at 25°C.  2 µl of the ligation reaction was then incubated 
in 50 µl One Shot® TOP10 Competent Cells (E. coli, F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆(ara-leu)7697 galU galK rpsL (StrR) endA1 
nupG)  (Invitrogen Life Sciences, Carlsbad, CA, USA) on ice for 5-30 min.  The samples 
were heat-shocked for 30 sec at 42°C and then returned to 4°C for 2-3 min.  S.O.C. 
medium (2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
10 mM MgSO4, 20 mM glucose) (250 µl) was added to the competent cell mixture.  The  
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Table 3.  Polymerase chain reaction cycling parameters. 
 
 
†Each reaction contains 200 ng of plasmid DNA, 5 µl of 10X reaction buffer (100mM 
Tris-HCl, pH 8.3 (at 42°C) 500mM KCl, 25mM MgCl2, 0.01% gelatin), 50mM of 
dNTP (12.5mM dATP, 12.5mM dCTP, 12.5mM dGTP, 12.5 mM dTTP, neutralized 
at pH 8.0 in water), 1 µg of each oligonucleotide primer, 1 U of Taq DNA 
polymerase (1 U/µl) (Stratagene Cloning System, La Jolla, CA, USA) and distilled 
water added to final volume of 50µl.   
 
 
 
 
 
 
 
Table 4.  Site-directed mutagenesis polymerase chain reaction cycling parameters. 
 
 
 
†Each reaction contains 50 ng of plasmid DNA, 5 µl of 10X reaction buffer (100mM 
Tris-HCl, pH 8.3 (at 42°C) 500mM KCl, 25mM MgCl2, 0.01% gelatin), 50mM of dNTP 
(12.5mM dATP, 12.5mM dCTP, 12.5mM dGTP, 12.5 mM dTTP, neutralized at pH 8.0 
in water), 125 ng of each oligonucleotide primer, 2.5 U of Pfu Turbo Taq DNA 
polymerase (2.5 U/µl) (Stratagene Cloning System, La Jolla, CA, USA) and distilled 
water added to final volume of 50µl.   
Cycles† Temperature (°C) Time 
1 (hot start) 95 1 minute 
 
30 
95 
55 
72 
1 minute 
1 minute 
2 minutes 
Cycles† Temperature (°C) Time 
1 (hot start) 95 1 minute 
 
18 
95 
60 
68 
50 seconds 
50 seconds 
2 minutes x kb of the plasmid 
1 (clean-up) 70 10 minutes 
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mixture was incubated at 37°C for 1 h with shaking (200 rpm).  The samples were spread 
using glass beads onto pre-warmed antibiotic selective agar plates (ampicillin or 
kanamycin), and incubated for 16-18 h in at 37°C.    
 
II.A.6. Site-Directed Mutagenesis Polymerase Chain Reaction 
 
 In vitro site-directed mutagenesis using the QuickChange™ Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) introduced point mutations in DNA 
sequences using synthetic complementary oligonucleotide primers (~30 nucleotides in 
length) containing the desired mutations (Table 4).  The reaction mixture was placed in a 
Robocycler® Gradient 96 thermal cycler (Stratagene, La Jolla, CA, USA).  The plasmids 
were amplified using the cycling parameters described in Table 4.  Then, each reaction 
mixture was digested with Dpn I (2 Units) and incubated at 37°C for 2-4 hours.  XL-10 
Gold competent cells were transformed with a sample of Dpn I-digested DNA following 
the same protocol as described in Section II.A.3.   
 
II.A.7. DNA Sequencing 
 
      DNA plasmids that were modified by site-directed mutagenesis were often 
sequenced to verify the mutation using the dye terminator cycle sequencing method 261, 
284.  A Model 373 DNA Sequencing System (Applied Biosystems, Foster City, CA, USA)  
at the East Carolina University Genomics Core Facility or the 3730 DNA Analyzer 
(Applied Biosystems, Inc., Foster City, CA, USA) at the University of Pittsburgh 
Genomics and Proteonomics Core Laboratories and the BigDye v3.0 chemistry from ABI 
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was used for the sequencing reactions.  A reaction mixture of  double-stranded plasmid 
DNA (750 ng), specific oligonucleotide primers (10µM each), Bigdye (containing excess 
amounts of the four deoxynucleotide triphosphates (dNTP), fluorescence tagged 
dideoxynucleotide triphosphate (ddNTP) terminators, AmpliTaq DNA polymerase, 
magnesium chloride,  and distilled water.  Each ddNTP terminator was tagged with a 
different fluorescent molecule.  The reaction mixtures were electrophoresed in a high 
resolution polyacrylamide gel under denaturing conditions, so the DNA remains single-
stranded.  During electrophoresis, a laser excites the fluorescence tags and a charged-
couple device (CCD) camera detects the signal and sends it to a computer for 
interpretation.  The data were analyzed by DNA Sequencing Analysis software or 
Chromas (Technelysium, Tewantin, Australia).  DNA sequencing results were recorded 
as a text file and as a 4-color histogram.   
 
II.B. Cell Culture 
 
II.B.1. Transfections 
 
Cell Viability 
 The efficient expression of each plasmid was determined by transient transfection 
of plasmid DNA into mammalian cells.  Cell lines were plated at a concentration of 
approximately 5.0 X 105 cells per well in 6-well plates (35 mm2) (Becton Dickinson, 
Piscataway, NJ, USA).  Cell viability was determined by trypan blue exclusion cell 
counting.  Cells were detached from the flask using 3ml of 1X trypsin (0.05% trypsin, 
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0.4% EDTA⋅4Na) (Gibco, Grand Island, NY, USA) for 3-5 min at RT.  The cells were 
triturated with 7 ml of complete Dulbecco’s Modified Eagle Medium (DMEM) 
(cDMEM) [DMEM supplemented to contain 10% heat-inactivated fetal bovine serum 
(FBS) (1 h at 56° C) (Atlanta Biologicals, Atlanta, GA, USA), 4 mM L-glutamine 
(Invitrogen Life Technologies, Carlsbad, CA, USA), and 0.4 mg/L gentamicin (Gibco, 
Grand Island, NY, USA)] and placed in a 50 ml conical tube.  After thorough mixing, 10 
µl of the cell suspension was incubated for 5 min with 10 µl of 0.4% Trypan Blue 
solution (Gibco, Grand Island, NY, USA) and half of the solution was added to each side 
of a hemacytometer (VWR, Bridgeport, NJ, USA).  Within the hemacytometer, the cells 
within the four outer quadrants were counted using a light microscope (100X power) 
(Fryer Company, Inc, Huntley, IL, USA).  Only the non-blue cells were counted and the 
average of the four quadrants was recorded.  The number of viable cells was determined 
with the following equation: # viable cells (cells/ml) = (average number of cells in 4 
quadrants) X dilution factor for size of quadrant (i.e. 10,000) X dilution factor for 
addition of trypan blue.  Each sample was performed in duplicate to accurately determine 
the cell number.  Cell counts within 10% of each other were considered accurate.  The 
total number of cells within the flask was determined by the following equation:  Total 
cells in flask = cells/ml X # ml in flask.  
 
DNA Transfection 
 After the cell count was determined, the cells were seeded (5 X 105 cells/well, 6-
well plate) allowed to acclimate for 24 hours at 37° C plus 5% CO2.  The medium was 
then removed by aspiration, and cells were washed with 1 ml of DMEM (Gibco, Grand 
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Island, NY, USA).  The plates were rocked back and forth to thoroughly wash the cells.  
The wash medium was aspirated, and the cells were replenished with 1 ml of DMEM.  
The cells were then transfected with the DNA listed in Table 2.  DNA plasmid (2 µg) was 
incubated with Lipofectamine™ reagent (2 mg/ml) (Invitrogen Life Technologies, 
Carlsbad, CA, USA) in DMEM at room temperature for 45 min.  Each transfection 
mixture was added to a well of the 6-well plate and incubated at 37° C plus 5% CO2.  
After 18-24 h, the transfection mixture was replaced with 2 ml of cDMEM.  Cells were 
incubated for an additional 48 h at 37° C in a humidified 5% CO2 incubator.  Forty-eight 
hours post-transfection, the supernatant were harvested and placed into 1.5 ml centrifuge 
tube.  The supernatant was clarified by centrifugation (1 min for 10,000 rpm) and 
transferred to a new 1.5 ml centrifuge tube and stored at -80° C.  After the supernatants 
were removed, the cells were washed with 1 ml of phosphate buffered saline (PBS) (137 
mM NaCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 2.7 mM KCl, in distilled water) (Gibco, 
Grand Island, NY, USA).  The plates were rocked back and forth to thoroughly wash the 
cells.  The wash solution was aspirated, and the cells were incubated with either 300 µl of 
distilled water or 1 % Triton-X 100 (Sigma, St. Louis, MO, USA) until the cells 
completely detached from the plate.  The samples were incubated at -80° C for 5-10 min 
and then thawed at room temperature for 5-10 min.  Freeze/thawing was repeated two 
times.   The cell lysate samples were centrifuged (1 min at 10,000 rpm) and the 
supernatants were transferred to a new 1.5 ml centrifuge tube and stored at -80°C. 
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II.B.2. Human Embryonic Kidney (293T) 
 
 The human (Homo sapiens) embryonic kidney (HEK or 293) cell line is adherent.  
293 cells are transformed with adenovirus 5 DNA (39768) and require Biosafety Level 2 
facilities.  293T is a highly transfectable derivative of the 293 cell line (American Type 
Culture Collection, (ATCC), CRL-1573) into which the temperature sensitive gene for 
simian virus 40 (SV40) T-antigen was inserted 234, 586.  The cells were maintained 
according to the American Type Culture Collection (ATCC) recommended growth 
conditions in cDMEM at 37° C in a humidified 5% CO2 incubator.     
  
II.B.3. COS-7 
 
 COS-7 cells are an adherent, kidney fibroblast cell line derived from the African 
green monkey (Cercopithecus aethiops) (ATCC, CRL-1651) 223.  These cells contain SV-
40 viral DNA sequences, which require Biosafety Level 2 facilities.  This line was 
derived from the CV-1 cell line (ATCC, CCL-70) by transformation with an origin 
defective mutant of SV40, which encodes for wild-type T antigen.  The cells were 
maintained according to the ATCC recommended growth conditions in cDMEM at 37° C 
in a humidified 5% CO2 incubator.     
 
II.B.4. NIH/3T3 
 
 The  NIH/3T3  cell   line  was  used  for  in vitro  expression  experiments  for  the  
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plasmids described in Table 2.  NIH/3T3 is an adherent, embryo fibroblast cell line 
derived from the NIH/Swiss mouse (Mus musculus) (ATCC, CRL-1658) 295.  NIH/3T3, a 
continuous cell line of highly contact-inhibited cells was established from NIH Swiss 
mouse embryo cultures similar to the original randomly bred 3T3 (ATCC, CCL-92) and 
the inbred BALB/c 3T3 (ATCC, CCL-163) [Jainchill, 1969 #28].  The established 
NIH/3T3 line was subjected to more than 5 serial cycles of sub-cloning to develop a sub-
clone with morphologic characteristics optimized for transformation assays.  The cells 
were maintained according to the ATCC recommended growth conditions in cDMEM at 
37° C in a humidified 5% CO2 incubator.     
 
II.B.5. BALB/c 10ME HD A.5R.1 (BC10ME) 
 
 BC10ME is an adherent, embryonic fibroblast cell line derived from the BALB/c 
mouse (Mus musculus) 506.  This cell line is derived from BALB/c CL.7 (ATCC TIB-80) 
by transformation with methylcholanthrene epoxide.  BC10MEGag and BC10MEPol were 
produced by stable transfection of BC10ME with HIV-1NL4-3 Gag and Pol DNA 
sequences, respectively 283.  The cells were maintained according to the ATCC 
recommended growth conditions in cDMEM at 37° C in a humidified 5% CO2 incubator.     
 
II.B.6. TZM bl 
 
 TZM bl is an adherent, cervical epithelial cell line derived from the HeLa-
CD4/CCR5 (JC53) human (Homo sapiens) cell line 517, 677, which is susceptible to 
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infection with both R5 and X4 HIV-1 isolates.  It is maximally sensitive to infection by 
including DEAE-dextran in the medium.  Using an HIV-based vector, genes that encode 
the Escherichia coli β-galactosidase (β-gal) and firefly luciferase (LUC) coding 
sequences were introduced into the JC53 cell line.  These cells contain papovavirus, 
which require Biosafety Level 2 facilities.  The cells were maintained according to the 
ATCC recommended growth conditions in cDMEM at 37° C in a humidified 5% CO2 
incubator.     
 
II.C. Protein Expression  
 
II.C.1. Tat Reporter Assay 
  
 Tat protein activity was determined by an in vitro reporter assay 40.  293T cells 
(5.0 X 105/ well, 6 well-plate) were transiently transfected with 1 µg of each VLP vaccine 
and 1 µg of the reporter plasmid, pLTR-SEAP as described in Section II.B.1.  pLTR-
SEAP expresses the secreted alkaline phosphatase (SEAP) gene under the control of the 
HIV-1 promoter located in the HIV-1 5’ LTR.  After 18 h, media was replenished with 
1.5 ml of cDMEM and the cells were incubated an additional 48 h.  Cell supernatants 
were collected and incubated at 65°C for 5 min to inactivate endogenous phosphates.  
The samples were analyzed for SEAP activity using a colorimetric assay.  2X SEAP 
buffer (100 µl) (2 M diethanolamine, 1 mM MgCl2, 20 mM L-homoarginine) was 
incubated with 100 µl of each sample in a 96 well plate for 10 min at 37°C.  20 µl of 
paranitrophenol (PNP) (120 mM) (Sigma, St Louis, MO, USA) was added and incubated 
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for 30 min at 37° C in the dark.  The colorimetric change was measured as the optical 
density (O.D. at 405 nm) by a spectrophotometer (Dynex Technologies, Chantilly, VA, 
USA).  The non-specific SEAP activity was detected in cells transfected with pTR600 
vector and was subtracted from each test sample. 
 
II.C.2. Western Blot 
 
  Mammalian cells were transfected with DNA and samples were collected as 
described in Section II.B.1.  For Western blotting, cell lysate (3.3%, 10 µl) or supernatant 
(1.5%, 30 µl) was diluted (1:2) in sodium dodecyl sulfate (SDS) Laemmli sample buffer 
(1M Tris-Cl pH 6.8, 20% SDS, 3.3 % Glycerol, 0.006 M bromophenol blue and 0.05 M 
beta-mercaptoethanol) (Bio-Rad, Hercules, CA, USA).  The mixture was briefly vortexed 
and then boiled for 4 min.  The sample mixtures and a pre-stained molecular weight 
ladder were loaded onto a 5-10% SDS-polyacrylamide gel (Stacking Gel:  30% 
acrylamide:bis, 10% SDS, 10% ammonium persulfate, 1% TEMED, 0.5 M Tris-HCl pH 
6.8 or Resolving Gel:  1.5 M Tris-HCl, pH 8.8).  The proteins were separated by 
electrophoresis at 100 V for 20 min followed by 175 V for 1 h in running buffer (25 M 
Tris base, 192 M glycine, 0.1% SDS, pH 8.3).  The resolved proteins were transferred 
from the SDS-PAGE to a Immobilon™ nitrocellulose membrane (Millipore, Bedford, 
MA, USA) in transfer buffer (25 mM Tris, 192 mM glycine, and 20% v/v methanol, pH 
8.3) using the transfer apparatus (Mini Trans-Blot, Bio-Rad, Hercules, CA, USA) for 1 h 
at 200 mA.  The nitrocellulose membrane was removed and placed in blocking solution 
(5% dry non-fat milk, 0.05% Tween 20, PBS) overnight at 4° C with gentle rocking.  The 
blocking solution was replaced with polyclonal antiserum (HIV Ig) (NIH ARRRP, 
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Germantown, MD, USA) (1:10,000 in PBS containing 0.05% Tween 20 and 5% non-fat 
dry milk) and gently rocked for 1 h at room temperature.  The nitrocellulose membrane 
was then washed 3 times for 10 min each in 25 ml of PBS supplemented with 0.05% 
Tween 20 (PBS-T) on a shaker at 25° C.  The membrane was then incubated with anti-
human IgG conjugated to horseradish peroxidase (HRP) (Bio-Rad Laboratories, 
Hercules, CA) (1:10,000 in PBS containing 0.05% Tween 20 and 5% non-fat dry milk) 
on a shaker for 1 h.  The membrane was then washed 3 times for 10 min each in 25 ml of 
PBS-T on a shaker at 25° C.  The membrane was washed for 20 min in 25 ml of PBS on 
a shaker at 25° C.  The membrane was then incubated with 1 ml of stable peroxide 
solution and 1 ml of lumino/enhancer solution (Amersham, Buckinghamshire, UK) and 
manually rocked for 3 to 4 min.  The membrane was then briefly dried, wrapped in 
cellophane, and exposed to CL-X Posure™ film (Pierce, Rockford, IL, USA) for 10 sec 
to 5 min.   
 
II.C.3. BCA Protein Assay 
 
 The concentration of protein was determined using a Micro BCA™ Protein Assay 
Reagent Kit (Pierce, Rockford, IL, USA).  A protein standard (2 mg/ml of bovine serum 
albumin (BSA) in a solution of 0.9% saline and 0.05% sodium azide) was used to 
produce a standard curve (Figure 4).  Standard protein concentrations or test samples 
(150 µl) and 150 µl of the working reagent [52% Micro BCA Reagent A (sodium 
carbonate, sodium bicarbonate and sodium tartrate in 0.2N NaOH), 48 % Micro BCA 
Reagent B (4% bicinchoninic acid in water), 2% Micro BCA Reagent C (4% cupric 
sulfate, pentahydrate in water)] were pipetted into the wells of a 96 well plate (Corning,  
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Figure 4.  BSA standard curve for protein quantitation.   
Total protein content was determined for the purified VLP inoculum used for the 
vaccination studies.  The concentration of protein was determined using a Micro BCA™ 
Protein Assay Reagent Kit (Pierce, Rockford, IL, USA).  Bovine serum albumin (BSA) 
was used as the protein (BSA) to produce a standard curve.  Standard protein 
concentrations or test samples were analyzed for a colorimetric change measured as the 
optical density (O.D. at 540nm) by a spectrophotometer.  Tests were performed in 
duplicate at two different dilutions, whereas the standard samples were analyzed in 
triplicate.  The concentration of protein in the test samples was extrapolated using the 
standard curve.         
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Corning, NY, USA).  The plates were covered and placed on a shaker for 1 h at 37°C.  
The samples were analyzed for a colorimetric change measured as the optical density 
(O.D. at  540nm)  by  a  spectrophotometer  (Dynex  Technologies, Chantilly, VA, USA).  
Tests were performed in duplicate at two different dilutions, whereas the standard 
samples were analyzed in triplicate.  The O.D. of each sample was compared to the 
standard curve, and the concentration of the protein was extrapolated from the standard 
curve (Figure 4).         
 
II.C.4. Silver Stain 
 
 The purity of purified proteins or particles were verified by silver staining 215 
using a ProteoSilver Stain Kit (Sigma, St. Louis, MO, USA) and the manufacturer’s 
recommended protocol.  Samples were prepared and electrophoresed as described in 
Sections II.B.1 and II.C.1.  After electrophoresis of the proteins by SDS-PAGE, the gel 
was placed in a clean tray with 100 ml of Fixing Solution (50% ethanol, 10% acetic acid 
in ultrapure water) for 20 min.  The Fixing Solution was decanted, and the gel was 
washed with 100 ml of Ethanol Solution (30% ethanol in ultrapure water) for 10 min.  
The Ethanol Solution was removed, and the gel was washed twice (10 min) with 200 ml 
of ultrapure water (Sigma, St. Louis, MO, USA).  After removal of the water, the gel was 
incubated with 100 ml of Sensitization Solution (1% ProteoSilver Sensitizer in ultrapure 
water).  The Sensitization Solution was removed, and the gel was washed twice (10 min) 
with 200 ml of ultrapure water.  The water was decanted and 100 ml of Silver 
Equilibration Solution was added to the gel for 10 min.  After the Silver Equilibration 
Solution was removed, the gel was washed for 60-90 sec with 200 ml of ultrapure water.  
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The  water  was   decanted and   100  ml  of   Developer  Solution   (5%  of  Proteo Silver 
Developer 1, 0.1% of ProteoSilver Developer 2 in ultrapure water) was added to the tray 
for 3-7 min until the desired staining intensity was observed.  5 ml of the ProteoSilver 
Stop Solution was added to the Developer Solution to stop the reaction (5 min).   
  
II.D. CD4 Binding Assay 
 
 A CD4 binding assay was used to determine whether envelopes (purified gp120 
or on the surface of a particle) expressed from DNA bound the primary receptor, hCD4.  
DNA expressing VLPs or gp120 (5 µg) was transiently transfected into COS cells (1 X 
106 cells per T75 flask (U.S.A. Scientific, Ocala, FL, USA) as described in Section 
II.B.1.  Briefly, DNA plasmid (5 µg) was incubated with 5% lipofectamine (30 µl in 600 
µl of DMEM) for 45 min.  The cells were overlaid with the DNA-lipofectamine mixture 
in DMEM (5 ml) for 16 h.  The cells were replenished with fresh cDMEM (9 ml) and 
incubated for 48 h.  Supernatants were collected and clarified by centrifugation (2,000 
rpm for 5 min).  Then supernatant (9 ml) was incubated with 16 µg of hCD4 (NIH 
ARRRP, Germantown, MD, USA) (4 h at 25°C) and pelleted through 20% sucrose (w/v 
in PBS) (Invitrogen, Carlsbad, CA, USA) (2ml) for 2 h at 100,000 X g (24,000 rpm) 
(SW40Ti rotor) (Kendro Laboratory Products, Newtown, CT, USA).  The pellets were 
analyzed CD4 by Western blot (see Section II.C.2).  hCD4 was detected using mouse 
anti-CD4 (1:3,000) 59.  The primary antibody was detected using goat anti-mouse IgG 
conjugated to horseradish peroxidase (HRP) (1:7,000) (Southern Biotechnology 
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Associates, Birmingham, AL, USA). Detection of the protein-antibody complexes was 
enhanced by chemiluminescence and visualized by autoradiography (see Section II.C.2).  
 
II.E. Particle Purification 
  
 Cells were plated at a concentration of approximately 5-7 X 106 cells per T75 
flasks (U.S.A. Scientific, Ocala, FL, USA).  The cells were allowed to acclimate for 24 h 
at 37° C plus 5% CO2.  The wash medium was aspirated, and the cells were replenished 
with 5 ml of DMEM.  The cells were then transfected with the DNA listed in Table 2.  
DNA plasmid (5 µg) was incubated with Lipofectamine™ reagent (30 mg/ml) (Invitrogen 
Life Technologies, Carlsbad, CA, USA) in DMEM (600 µl) at room temperature for 45 
min.  Each transfection mixture was added to a T75 flask and incubated at 37° C plus 5% 
CO2.  After 18-24 h, the transfection mixture was replaced with 10 ml of cDMEM.  Cells 
were incubated for an additional 48 h at 37° C in a humidified 5% CO2 incubator.  Post-
transfection (48 h), the supernatants were clarified by centrifugation (3,000 rpm for 10 
min) at 4°C and the supernatant (10 ml) was transferred to a 12 ml polyclear 
ultracentrifuge tubes (Kendro Laboratory Products, Ashville, NC, USA) and underlaid 
with 1 ml of 20% glycerol (w/v in PBS) (Sigma, St. Louis, MO, USA).  Each sample was 
balanced with an Explorer Pro analytical scale (Ohaus Inc., Pine Brook, NJ, USA) and 
placed in a pre-chilled TH641 rotor (Kendro Laboratory Products, Ashville, NC, USA).  
The rotor was placed into a Sorvall Discovery 905E ultracentrifuge (4°C) (Kendro 
Laboratory Products, Newtown, CT, USA) and the samples were ultracentrifuged 
(100,000 x g (24,000 rpm) for 2 h) at 4°C.  The supernatants were decanted and the 
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pellets were rinsed one time with sterile PBS.  The pellets were then resuspended in 500 
µl sterile PBS and used for: 1) in vivo immunization or 2) sucrose density gradient 
utltracentrifugation.   
Pellets used for immunization were analyzed for total protein by the Micro BCA 
Protein Assay Kit (Pierce, Rockford, IL, USA) as described in 2.3.3.  In addition, the 
level of non-HIV protein contamination (from the media/cell debris) in each inoculum 
was visualized by a silver-stained SDS-PAGE using the ProteoSilver Silver Stain Kit 
(Sigma, St. Louis, MO, USA) as described in Section II.C.4.  The specificity of each 
inoculum was analyzed in a separate immunoblot that was probed with HIV-Ig as 
described in Section II.C.2.    
 Pellets analyzed for particle formation were resuspended in PBS (500 µL) and 
overlaid onto a 20-60% sucrose gradient (Figure 5).  The sucrose gradient was made by 
adding 1 ml of each fraction (11 steps, 4% increments) starting at the bottom of the tube 
with 60% sucrose (w/v in PBS) and overlaying subsequent fractions (60%-20% of 
sucrose). The glycerol pellet was added to the top of the gradient, and the tubes were 
balanced using an analytical scale.  The tubes were loaded onto the TH641 rotor and 
ultracentrifuged for 17 h at 100,000 x g (24,000 rpm) at 4°C.  Eleven fractions (20-60%, 
1 ml each) were collected (top to bottom) from the gradient and placed into 2.0 ml 
centrifuge tubes (Brinkmann/Eppendorf, Westbury, NY USA).  The proteins were 
precipitated with 1 ml of 20% trichloroacetic acid (TCA) (30 min at 4°C) and centrifuged 
for 20 min at 4°C.   The supernatants were decanted; the protein was resuspended with 
Laemmli sample buffer plus 2 µl of 5N NaOH and subjected to SDS-PAGE and 
immunoblotting as described in Section II.C.2. 
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Figure 5. Schematic of virus-like particle production by sucrose density gradient 
ultracentrifugation.   
Supernatant from COS cells transiently transfected with VLP DNA was concentrated 
through a 20% glycerol cushion, resuspended and then subjected to 20-60% (w/v) 
sucrose density gradient ultracentrifugation (16 h, 100000 x g).  Fractions were collected 
from top to bottom, precipitated with equal volumes of 20% TCA and proteins were 
detected by western blot analysis.  Percent of sucrose fraction is located at the bottom of 
each lane: lane 1, 20%; lane 2, 24%; lane 3, 28%; lane 4, 32%; lane 5, 36%; lane 6, 40%; 
lane 7, 44%; lane 8, 48%; lane 9, 52%, lane 10, 56%, lane 11, 60%.  All samples were 
electrophoresed through a 5-10% polyacrylamide/SDS gel and transferred to a PVDF 
membrane.  Proteins were immunoblotted with HIV-1 Ig and mouse anti-human IgG and 
visualized by enhanced chemiluminescence.  Fractions are indicated where disrupted 
particles, intact particles and particle aggregates sediment in the 20-60% gradient.  
Percentage of sucrose and densities (g/ml) are specified for the different fractions on the 
tube and western blot illustrations. 
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II.F.  BALB/c Mice 
 
II.F.1. Husbandry 
 
 Five to 7 week old BALB/c mice (Harlan Sprague Dawley, Indianapolis, IN, 
USA) were used for vaccination studies.  The mice were housed (5 mice per cage, free 
access to food and water, cages cleaned weekly) in compliance with the U.S. Department 
of Agriculture (USDA) regulations.  Mice were monitored daily for weight loss, 
behavior, and adverse reaction.  Mice were anesthetized based on their weight with 
xylazine (Phoenix Pharmaceutical, Inc, St. Joseph, MO, USA) (20 mg/ml) and ketamine 
(Phoenix Pharmaceutical, Inc, St. Joseph, MO, USA) (100 mg/ml) administered 
subcutaneously (50 mg ketamine and 5 mg xylazine per kilogram of body weight, 
average 20 g) in the abdomen prior to immunization and blood collection.  Mice were 
sacrificed by CO2 (100%) inhalation.    
 
II.F.2. Intramuscular Inoculation 
  
 Female BALB/c (5-7 weeks old) mice were intramuscularly immunized with 
DNA (5 µg), purified protein (10 µg) or purified VLPs (40 µg total protein) alone or co-
inoculated with phosphorothioate CpG oligodeoxynucleotides (CpG ODN, 10 µg each) 
via the hind muscle.  All intramuscular inoculations were performed in a total of 50 µl of 
sterile PBS.  Each CpG ODN (ODN-1:  5'-TCCATGACGTTCCTGACGTT-3', ODN-2:  
5'-TGACTGTGAACGTTCGAGATGA-3') was synthesized and purified by high-
pressure liquid chromatography (Sigma-Genosys, The Woodlands, TX, USA).  The CpG 
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ODNs were resuspended in sterile distilled water (2 µg/µl) and stored at -80°C.  Mice 
were administered VLP vaccines (DNA or purified particles) in sterile PBS +/- CpG 
ODN into the hind leg of each mouse (50 µl total volume) using a 1 ml syringe (Becton 
Dickinson & Co., Franklin Lakes, NJ, USA).   
 
II.F.3. Intranasal Inoculation 
 
 Female BALB/c mice (5–7 weeks old) were immunized with purified protein (10 
µg) or purified VLPs (40 µg total protein) alone or co-inoculated with CpG ODN (10 µg 
each) via the nares.  All intranasal inoculations were performed in a total of 40 µl of 
sterile PBS.  Each CpG ODN (ODN-1:  5'-TCCATGACGTTCCTGACGTT-3', ODN-2:  
5'-TGACTGTGAACGTTCGAGATGA-3') was synthesized and purified by high-
pressure liquid chromatography (Sigma-Genosys, The Woodlands, TX, USA).  The CpG 
ODNs were resuspended in sterile distilled water (2 µg/µl) and stored at -80°C.  Mice 
were administered VLPs in sterile PBS +/- CpG ODN into the nares of each mouse (40 µl 
total volume) using a 100 µl Pipetman.   
 
II.F.4. Blood Collection, Mucosal Washings and Organ Harvesting 
 
 Blood samples were collected by retro-orbital plexus puncture using a heparinized 
capillary tube (Drummond Scientific Company, Broomall, PA, USA) and a 1.5 ml 
centrifuge tube on anesthetized mice and incubated (4° C for 16 h) to allow coagulation 
of the red blood cells.  Serum was separated from the red blood cells by centrifugation 
(5,000 rpm for 10 min).  Collected serum was stored in at -80° C.   
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Three mucosal surfaces were washed to collect antibody elicited by vaccination:  
vagina, lungs, and intestines.  Vaginal lavages were collected on anesthetized mice by 
repeated rinsing of the vagina with 200 µl of sterile PBS using a 200 µl Pipetman.  
Following euthanasia (described in Section II.F.1), lungs were excised using surgical 
scissors (Fischer Scientific, Middletown, VA, USA) and dissected into small pieces using 
a sterile scalpel (Fischer Scientific, Middletown, VA, USA) and placed in sterile PBS 
(200 µl).  The lung matter was centrifuged (12,000 rpm for 5 min).  A section of the 
intestines (1.27 cm) was aseptically removed using surgical scissors and placed in sterile 
PBS (200 µl).  The collected fecal samples were disrupted using a sterile pipette tip, 
vortexed (15 sec), and centrifuged (12,000 rpm for 5 min).  The protein concentration of 
the fecal supernatants was adjusted to a final concentration of 1 mg/ml with sterile PBS 
using the Micro BCA Protein Assay Kit as described in Section II.C.3.  All samples were 
stored in at -80°C. 
 Spleens were removed by making an incision from the rib cage to the tail using a 
sterile scalpel and tweezers.  The spleen was removed using surgical scissors and placed 
in sterile PBS (10 ml volume in a 15 ml conical tube) (U.S.A. Scientific, Ocala, FL, 
USA).  The spleen was then placed on a wire mesh (Fischer Scientific, Middletown, VA, 
USA) over a 60 x 15 mm dish (U.S.A. Scientific, Ocala, FL, USA).  The splenocytes 
were manipulated into a single cell suspension using the rubber stopper end of a 5 ml 
syringe plunger (Becton Dickinson & Co., Franklin Lakes, NJ, USA).  The cell 
suspension was transferred to a new 15 ml conical tube and incubated on ice (5 min) to 
allow larger debris to settle to the bottom of the tube and the cell suspension was then 
transferred to a new 15 ml conical tube.  The cells were centrifuged at 1500 rpm (5 min at 
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4°C) and the supernatants were discarded.  The cells were resuspended in 1 ml of ACK 
solution (0.155M ammonium chloride, 0.1M Na2EDTA, 0.01M potassium bicarbonate in 
distilled water) and incubated on ice (3 min).  PBS (10 ml at 4°C) was added to the tube, 
mixed gently, and centrifuged at 1500 rpm (5 min at 4°C).  The supernatants were 
discarded, and the cells were washed with PBS and centrifuged again.  The cells were 
then resuspended in 2-5 ml of complete Roswell Park Memorial Institute (cRPMI) media 
(RPMI supplemented to contain 10% heat-inactivated FBS (Atlanta Biologicals, Atlanta, 
GA, USA), 4 mM L-glutamine (Invitrogen Life Technologies, Carlsbad, CA, USA) and 
0.4 mg/L, 0.01% penicillin-streptomycin (Gibco, Grand Island, NY, USA)) and used in 
assays described in Section II.H.3 and II.H.4.        
 
II.G. New Zealand White Rabbits 
 
II.G.1. Husbandry 
 
 Five to 7 week old New Zealand white rabbits (Harlan Sprague Dawley, 
Indianapolis, IN, USA) were used for vaccination studies.  The rabbits were housed (1 
rabbit per cage, free access to food and water, cages cleaned weekly) in compliance with 
the U.S. Department of Agriculture (USDA) regulations.  Rabbits were monitored daily 
for weight loss, behavior, and adverse reaction.  Rabbits were anesthetized based on their 
weight with xylazine (Phoenix Pharmaceutical, Inc, St. Joseph, MO, USA) (20 mg/ml) 
and ketamine (Phoenix Pharmaceutical, Inc, St. Joseph, MO, USA) (100 mg/ml) 
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administered subcutaneously (40 mg ketamine and 5 mg xylazine per kilogram of body 
weight, average 2 kg) in the hind leg prior to immunization. 
 
II.G.2. Intramuscular Inoculation 
 
Five to 7 week old New Zealand white rabbits were used for the vaccination 
study.  Each rabbit was anesthetized (see Section II.G.1) and inoculated with 200 µg of 
VLP DNA in 500 µl of sterile PBS intramuscularly with a 20-gauge (Becton Dickinson, 
Piscataway, NJ, USA) needle.  The inoculum was divided in half and inoculated equally 
in both quadricep muscles.   
 
II.G.3. Blood Collection and PBMC Harvesting 
  
 Blood samples were collected at week 20 by ear venipuncture using a 5 ml 
syringe (Becton Dickinson, Piscataway, NJ, USA) and allowed to coagulate.  The whole 
blood was transferred to a 15 ml conical tube (U.S.A. Scientific, Ocala, FL, USA), 
centrifuged at 3,000 rpm (5 min at 4°C).  The sera was removed from the red blood cells 
and stored at -80°C.   
 Peripheral blood mononuclear cells were harvested from vaccinated rabbits.  
Ficoll Paque (Pharmacia Biotech, Wikstroms, Sweden) (3ml) was added to a 15 ml 
conical tube (USA Scientific, Ocala, FL, USA), and blood samples (4ml) were layered on 
top.  Without mixing, the samples were centrifuged (1,000 rpm for 30 min) at 18-20°C.  
The plasma (upper layer) was removed, leaving the lymphocyte layer (buffy coat) at the 
interface.  The lymphocyte layer was then removed and added to a new 15 ml conical 
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tube containing salt solution (0.1% anhydrous D-glucose, 5 X 10-5M CaCl2 X 2H2O, 9.8 
X 10-4M MgCl2 X 6 H2O, 5.4 X 10-3M  KCl, 0.145M TRIS, 0.14M NaCl) (6 ml).  The 
cells were resuspended and centrifuged (3,000 rpm for 10 min) 18-20°C.  The 
supernatant was removed and the cells were washed again with salt solution and 
centrifuged.  The supernatant was removed and the cells were resuspended in cRPMI.  
Cell viability was determined by trypan blue exclusion cell counting (see Section II.B.1). 
 
II.H. Immunological Assays 
 
II.H.1. Enzyme-Linked Immunosorbent Assay (ELISA)  
 
 Sera and mucosal samples were individually collected and tested for antibody 
responses to VLP antigens by ELISA.  Each well of a 96-well plate (Corning, Corning, 
NY, USA) was coated with culture supernatant from cells transfected with DNA 
expressing Envgp120 from genes codon optimized for mammalian cells (pcoADAgp120 or 
pcoR2gp120) (50 ng) or purified Gagp55 protein (100 ng) (NIH ARRRP, Germantown, MD, 
USA) in PBS (total volume, 100 µl) at 4°C.  Plates were blocked (25°C for 2 h) with PBS 
(200 µl) containing Tween 20 (0.05%) and non-fat dry milk (5%).  The blocking buffer 
was removed and 100 µl of serially diluted samples (sera or mucosal washings) was 
added to each well (25° C for 2 h).  Following thorough washing (3X) in PBS-Tween 20 
(0.05%), samples were incubated (25° C for 1 h) with 100 µl of biotinylated goat anti-
mouse IgG (1:5,000) (Southern Biotechnology Associates, Inc., Birmingham, AL) diluted 
in PBS-Tween 20 (0.05%) and nonfat dry milk (5%).  The unbound antibody was 
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removed, and the wells were washed three times.  Strepavidin-HRP (1:7,000) (Southern 
Biotechnology Associates, Inc., Birmingham, AL) was diluted in 100 µl of PBS-Tween 
20 (0.05%) and incubated (25°C for 1 h).  100 µl of TMB substrate (1 TMB tablet per 10 
ml of phosphate-citrate pH 5.0 buffer; 2 µl 30% H202) (Sigma, St Louis, MO, USA) was 
added to each well (25°C for 1 h), and the colorimetric change was measured as the O.D. 
by a spectrophotometer (Dynex Technologies, Chantilly, VA, USA).  Results were 
recorded as the arithmetic mean plus the standard deviation (S.D.) after the value of naïve 
sera was subtracted from the test samples.   
In order to measure the levels of HIV-1 Env-specific IgG subtypes, a modification 
to the above protocol included the use of biotinylated goat anti-mouse IgG1 or IgG2a 
antibodies (Southern Biotechnology Associates, Inc., Birmingham, AL) to detect Env-
antibody complexes (1:5,000) in place of the biotinylated goat anti-mouse IgG. 
 
II.H.2. Neutralization Assay  
 
 In vitro virus neutralization by antisera from vaccinated mice was determined by a 
luciferase reporter infection assay.  TZM bl cells (NIH ARRRP, Germantown, MD, 
USA) were plated (1 X 105 cells/well) in a 96 well plate (Corning, Corning, NY, USA).  
Twenty hours later, purified HIV-1ADA (1300 TCID50) or HIVMN (750 TCID50) (NIH 
ARRRP, Germantown, MD, USA) was incubated with heat-inactivated antisera (1:10) 
(56°C for 1 h) from naïve or vaccinated mice (1 h at 37°C, 5% CO2).  After 1-2 h, the 
virus-sera mixture was added to the 96 well plate containing TZM bl cells in a total 
volume of 100 µl of DEAE dextran (Sigma, St. Louis, MO, USA) (20 µg/ml)  in DMEM.  
The virus-sera mixture was aspirated and the wells were washed twice with cDMEM 
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(200 µl).  The cells were overlaid with cDMEM (200 µl) and incubated at 37°C (5% 
CO2) for 48 h.  Lysates were collected (see Section II.C.2) and assayed for the presence 
of luciferase using the Promega Luciferase Assay System (Promega, Madison, WI, 
USA).  Luciferase reagents were gently thawed at 25°C for 30 min.  The cell lysates were 
briefly vortexed and then centrifuged at 2,000 rpm for 1 min.  The lysates were 
transferred to a new 1.5 ml microcentrifuge tube and placed on ice.  The luciferase 
substrate (2 mg/ml) was added to a new 1.5 ml microcentrifuge tube.  Next, 20 µl of cell 
lysates were added to the substrate microcentrifuge tube and mixed by trituration.  The 
luciferase reaction was measured using a Femtomaster FB12 luminometer (Zylux 
Corporation, Oak Ridge, TN, USA), and the value was recorded as relative light units per 
second (RLU/sec).  The parameters of the instrument were set for a 2 sec delay and a 10 
sec reading time.  Inhibition of virus was assessed by the additional reduction in 
infectivity beyond the background of mock-vaccinated and pre-bleed antisera.  The 
neutralizing capacity of antisera was measured by comparing the reduction in luciferase 
activity per sample to sera from age-matched, mock-vaccinated mice.  Each mouse 
sample was analyzed in duplicate assays on the same day and averaged.  Results are 
given as:  % Inhibition of Infection = [(Experimental – Age-Matched, Mock-Vaccinated) 
÷ Virus Alone] X 100. The arithmetic mean ± the S.D. was determined for each group 
after the appropriate background values were subtracted from the test samples.   
 
II.H.3. Enzyme-Linked Immuno-Spot (ELISPOT) Assay 
 
 Splenocytes   were  isolated  as  described  in  Section  II.F.4.   Cell  viability  was  
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determined by trypan blue exclusion staining (Gibco BRL, Grand Island, NY, USA) (see 
2.2.1).  The number of anti-Gagp24 or anti-Envgp160 murine INF-γ (mINF-γ) secreting 
splenocytes was determined by an enzyme-linked immunospot (ELISPOT) assay kit (R 
& D Systems, Minneapolis, MN, USA).  Pre-coated anti-mIFN-γ plates were incubated 
(25°C for 2 h) with RPMI supplemented with 10% FBS (200 ml) and then were 
incubated with splenocytes (1 X 106/well) isolated from vaccinated mice.  Splenocytes 
were stimulated for 48 h with peptides representing the HIV-1 Gagp24 immunodominant 
epitope (HIV-1 consensus B Gag: GHQAAMQMLKETINE and 
AMQMLKETINEEAAE) 423, 2 µg of purified, soluble Gagp55 or Envgp160 (North 
America consensus sequence: KSIHIGPGRAFYTTG and B-subtype isolate: 
KSIPMGPGKAFYATG) (NIH ARRRP, Germantown MD, USA).  Additional wells of 
splenocytes were stimulated with phorbol 12-myristate 13-acetate (PMA) (50 ng) (Sigma, 
St. Louis, MO, USA) and ionomycin (500 ng) (Sigma, St. Louis, MO, USA) or were 
mock stimulated.  All wells received 10 U/ml of mIL-2 (NIH ARRRP, Germantown, 
MD, USA).  Plates were washed with PBS-Tween (3X) and were incubated (25°C for 
2 h) with biotinylated anti-mIFN-γ (2 µg/ml, mAb XMG1.2) (R & D Systems, 
Minneapolis, MN, USA) at 4°C for 16 h.  The plates were washed and incubated (25°C 
for 2 h) with strepavidin conjugated to alkaline phosphatase (R & D Systems, 
Minneapolis, MN, USA).  Following extensive washing, cytokine/antibody complexes 
were incubated (25°C for 1 h) with stable 5-Bromo-4-chloro-3-indolyl phosphate 
dipotassium nitrotetrazolium blue chloride (BCIP/NBT) chromagen (R & D Systems, 
Minneapolis, MN, USA).  The plates were rinsed with distilled water and air dried (25°C 
for 1-2 h).  Spots were counted by an ImmunoSpot ELISPOT reader (Cellular 
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Technology Ltd., Cleveland, OH, USA).  The number of spots per 1 X106 splenocytes 
was recorded after subtracting the background values (naïve mice stimulated with Gag 
peptides or proteins and unstimulated splenocytes from test samples). 
Results are given as:  Number of spots/1 X106 splenocytes = [(Experimentalprotein/peptide 
stimulated – Experimentalmock stimulated) – (Naïveprotein/peptide stimulated – Naivemock stimulated)].  The 
arithmetic mean ± the S.D. was determined for each group after the appropriate 
background values were subtracted from the test samples.   
 
II.H.4. Cytotoxicity Assay 
 
 The same Gagp24 peptides and Gagp55 protein (NIH ARRRP, Germantown, MD, 
USA) (see Section II.H.3) were used in a cytotoxicity assay (CytoTox 96 Non 
Radioactive Cytotoxicity Assay kit) (Promega, Madison, WI, USA).  A mixture of 
peptides (1 µg of each peptide) and protein (2 µg) was incubated with the splenocytes (1 
X 107 cells/T25 flask) (U.S.A. Scientific, Ocala, FL, USA) at a 45° angle for 7 days 
(37°C, 5% CO2) with 10 U/ml of mIL-2 in cRPMI.  On day 4, fresh cRPMI was added (1 
µg/ml of peptides and protein with 5 U/ml of IL-2 final concentration).  On day 7, 
effector cells (splenocytes) were assayed for cytolytic activity in a non-radioactive CTL 
assay using two BC10ME cell lines stably expressing HIV-1 Gag (relevant protein) or 
Pol (irrelevant protein).  Mouse splenocytes (1 X 105-8 X 106 effector cells) and 
BC10MEGag or Pol (1 X 105 target cells) were incubated in a 96 well plate (Corning, 
Corning, NY, USA) for 5 h at 37°C in 5% CO2.  Cytotoxicity was measured 
quantitatively by the release of lactate dehydrogenase (LDH) from lysed cells using a 
CytoTox 96 Non Radioactive Cytotoxicity Assay kit (Promega, Madison, WI, USA).  
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After 5 h, the samples were centrifuged (3,000 rpm for 10 min), and 100 µl of culture 
supernatant was added to each well of a new 96 well plate.  Cell Titer 96® AQueous One 
Solution Reagent was thawed at 37°C for 10 min and pipetted (20 µl) into each well of 
the 96-well plate containing 100 µl of the test samples and gently mixed.  The plate was 
incubated (37°C, 5% CO2) for 2 h.  The colorimetric change was measured as the O.D. 
(490 nm) by a spectrophotometer (Dynex Technologies, Chantilly, VA, USA).  The 
arithmetic mean plus the S.D. was recorded after the appropriate background values were 
subtracted from the test samples.  The percentage of cytotoxicity was determined by the 
following formula: % Cytotoxicity = [(Experimental - Effector Spontaneous - Target 
Spontaneous) ÷ Target Maximum - Target Spontaneous] X 100.   
  
II.H.5. Western Blot Analysis for Anti-Gag Antibodies 
 
 Sera from rabbits vaccinated with VLP DNA was collected at week 20 (see 
Section II.G.3), and antibody responses were determined by western blot analysis.  
Purified HIV-1SF2 p55 Gag protein (20 ng) (NIH ARRRP, Germantown, MD, USA) was 
loaded per well and electrophoresed through a 5-10% gradient SDS-polyacrylamide gel 
(see Section II.C.2).  Proteins were transferred to a polyvinylidene difloride (PVDF) 
membrane, and serum from immunized rabbits (1:1500) was used as the primary 
antibody.  HIV-1 specific antibodies were detected using goat anti-rabbit IgG conjugated 
to HRP (1:3,000) (Bio-Rad Laboratories, Hercules, CA, USA). The proteins were 
visualized by enhanced chemiluminescence followed by autoradiography (see 2.3.2).   
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II.H.6. Proliferation Assay 
 
 Peripheral blood mononuclear cells (PBMCs) were isolated from immunized 
rabbits 131 (see Section II.G.3).  PBMCs were plated at a concentration of 2 X 105 
cells/well (96-well plate) in 200 µl of cRPMI (Corning, Corning, NY, USA).  PBMCs 
were stimulated with recombinant HIV-1LAI or BAL Envgp120 or Measles F protein (NIH 
ARRRP, Germantown, MD, USA) (10 µg/ml).  Plates were incubated at 37°C in a 5% 
CO2 atmosphere for 72 h and then pulsed with 1 µCi per well of [3H]-thymidine (DuPont 
NEN, Boston, MA, USA) in 50µl of cRPMI.  The cells were then incubated for an 
additional 24 h (37°C in 5% CO2), and the incorporation of [3H]-thymidine was 
determined by harvesting the cells, immobilizing the DNA to glass fiber membranes, and 
counting in a liquid scintillation counter.  Each sample was harvested onto individual 
circular regions of a glass filter paper (Wallac, Turku, Finland) using a Tomtec full-plate 
harvester (Tomtec, Orange, CT, USA).  Scintillation cocktail (Beckman, Columbia, MD, 
USA) (3.6 ml) was added to the filter in a sealed bag and counted with a Wallac 1450 
Microbeta Plus liquid scintillation counter (EG&G Wallac, Milton Keynes, UK). Mean 
liquid scintillation results for triplicate wells were recorded as counts per minute (cpm).  
The arithmetic mean of three samples per group was determined ± the S.D. 
 
II.I. Statistical Analysis 
 
 Sample size calculation for paired t test was determined using the following 
parameters: power = 90, alpha = 0.05 and confidence interval = 90 using the delta-sigma 
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approach using the following equation (assuming 3 fold differences in antibody titer and 
cellular responses and normal population standard deviation=1): n=[2(z1-β+z1-α/2)2]/(δ/σ)2.  
All statistical analysis was done using the Student’s t test and STATA software (STATA 
Corp, College Station, TX, USA). 
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III. Chapter 3:  Specific Aims 
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III.A. Rationale of Research 
 
Overall Design and Rationale 
There are several advantages of a multi-gene virus-like particle DNA vaccine 
approach for HIV-1 compared to individual gene vaccines. This strategy offers a cost-
effective, environmentally stable, easily manipulated alternative to other vaccine 
approaches.  A multi-gene DNA vaccine has the capability of provoking both arms of the 
immune system, inducing neutralizing antibodies against conformational epitopes, and 
expressing multiple viral proteins.     
 
Multi-epitope vaccine in a single component vaccine 
 The VLP vaccine constructs express various HIV-1 proteins.  A diverse group of 
antigens offers multiple epitopes that can be presented to the immune system by an array 
of MHC class I and II molecules.  DNA vaccines elicit both cell-mediated and humoral 
immune responses.  Subsequently, HIV-1 proteins entering the endogenous or exogenous 
antigen pathways will be presented by MHC I or II, respectively.  Multi-epitope vaccines 
are more likely than their single component counterparts to generate a broad-based 
immune response capable of clearing HIV-1 escape mutants.  Lastly, a multi-gene 
vaccine is much more cost effective compared to the equivalent individual genes 
expressed on different plasmids for development and mass production for toxicity, safety 
and immunogenicity in future clinical human trials. 
 
HIV-1 clade B/R5-tropic vaccine 
 The majority of individuals in the United States and northern Europe are infected 
 136
with HIV-1 clade B strains.  The VLP vaccines express proteins derived from clade B 
virus strains.  Within a clade, strains exhibit some antigenic differences but are relatively 
similar.  Therefore if a vaccine proves successful, vaccines can be designed to represent 
other clades such as clade A/C (Africa) and clade E (Thailand).   
 The majority of individuals newly infected contract an R5-tropic strain of HIV-1.  
As these individuals progress in disease, more X4-tropic strains are isolated from these 
patients rather than the original R5-utilizing isolates.  So, Envs from R5-tropic strains 
(ADA, R2, JR-FL) were used to represent the primary isolates that are currently 
circulating in human populations today.  In addition, Env from an R5X4 strain (89.6), 
capable of using either CCR5 or CXCR4 for entry, were also included in this study.    
 
 Vaccines capable of entering antigen presenting cells 
 The production of virus-like particles allows the opportunity of Env-mediated 
entry of the particles into professional antigen presenting cells (APCs) such as 
macrophages and dendritic cells.  Both cell types express CD4 and CCR5, which R5-
tropic HIV strains can use for entry.  The VLP vaccines contain either R5 or R5X4 Envs 
that can bind to APCs.  The VLP can undergo uncoating following Env-mediated entry.  
Therefore, the viral proteins can be processed and presented to the immune system, thus 
enhancing the humoral response to Env.   
  
Virus-like particle immunogen with natural conformation of Env 
 Antigens presented in their native conformation (e.g. particle) elicit more 
effective humoral immune responses compared to individual proteins (soluble Gag or 
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Env).  In addition, many neutralizing antibodies are generated against conformational 
epitopes only present in the native form of the antigen.  The multi-gene vaccine produces 
virus-like particles containing the Env in a trimer/multimeric conformation similar to that 
encountered during a natural infection of HIV-1     
 DNA immunizations by gene gun lead to direct transfection of the professional 
APCs.  Conversely, intramuscular inoculation of vaccine plasmids results in transfection 
of muscle cells or kerotinocytes, which serve as factories of antigens but do act as antigen 
presenting cells.  An immunogen capable of entering APCs will increase the efficiency of 
the vaccine to stimulate both humoral and cell-mediated immunity.  Unlike soluble 
antigen, particulate immunogens can be engulfed by professional APCs and enter the 
cross-presentation pathway thereby enhancing cellular responses in addition to humoral 
responses.   
 
Mucosal vaccination of particulate immunogens 
 HIV-1, similar to many other pathogens, is primarily transmitted at the mucosal 
surface.  Yet, the majority of experimental vaccines against HIV-1 have been inoculated 
parenterally.  Although an efficient systemic response develops, immunity at the mucosa 
after parenteral inoculation is negligible.  In contrast, mucosal immunization can induce 
immune responses at both local and distal mucosal sites as well as systemic immunity.  
An ideal HIV/AIDS vaccine will most likely need to elicit robust immunity against 
multiple viral antigens in both systemic and mucosal immune compartments.  Therefore, 
augmentation of the immune response at the mucosa by mucosally-administered vaccines 
may induce high titer anti-HIV immunity and is more likely to prevent viral infection and 
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the establishment of viral reservoirs compared to vaccines inoculated parenterally.  
Compared to particulate antigens, intranasal vaccination of soluble proteins (in 
the absence of an adjuvant) induces low or undetectable immune responses in rodents and 
primates.  VLPs can be phagocytosed by M cells in the nasal lumen and then directly 
deposited to the NALT via M cell transcytosis, which preferentially drains into cervical 
lymph nodes.  This process induces strong local (NALT) and distant immune responses 
in both peripheral and mucosal immune compartments.  Soluble antigens bypass the 
NALT and are directly fed into superficial lymph nodes by APCs in the nasal lumen 
resulting in a lower local immune response.  Therefore, particulate antigens are better 
mucosal immunogens compared to soluble proteins.   
   
Use of CpG ODNs 
Synthetic oligodeoxynucleotides containing unmethylated CpG motifs are potent 
immune adjuvants, which accelerate and boost antigen-specific immune responses 
following systemic or mucosal vaccination.  CpG ODNs directly stimulate B cells and 
dendritic cells, thereby promoting the production of Th1 and pro-inflammatory cytokines 
and the maturation/activation of professional antigen-presenting cells. Animal challenge 
models establish that protective immunity can be accelerated and magnified by co-
administering CpG DNA with vaccines similar to other adjuvants such as CT or 
RANTES.  
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III.B. Specific Aim I 
 
Goal: To construct and characterize human immunodeficiency virus-like particle 
vaccines and test for efficient protein expression and particle formation. 
 
Hypothesis:  A human immunodeficiency virus multi-gene DNA vaccine will produce 
virus-like particles. 
 
Summary:  In SPECIFIC AIM I, a single vaccine plasmid was constructed to express 
Gag, Pol, Env, Tat, Rev, and Vpu, and this plasmid was examined for protein expression 
and particle formation.  The VLP vaccine constructs were derived from the HIV-1BH10 
provirus.  Safety mutations and deletions were introduced into the VLP DNA to generate 
a vaccine insert that was non-infectious.  The 5’ and 3’ long terminal repeats, integrase, 
vif, vpr and nef were removed to further enhance the safety of the vaccine insert.  
Moreover, mutations were introduced into nucleocapsid, reverse transcriptase, and 
protease to severely restrict viral RNA packaging and to abolish RT, RNase H, and 
protease activity.  The multi-gene vaccine insert was under the transcriptional control of 
the CMV-IE, while the expression of the genes is virally regulated.  Envelopes from 
different Clade B strains of HIV-1 (ADA, R2, 89.6) were cloned into the VLPBH10 Gag-
Pol backbone.  Western blot and functional assays demonstrated efficient protein 
expression.  The expressed VLPs were efficiently released from human cells and were 
similar in density and protein composition to wild-type virions as shown by density 
gradient ultracentrifugation and Western blotting.  These replication-incompetent VLPs 
bound human CD4, and therefore they have the potential to bind and infect susceptible 
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cells in vivo.  In addition, second and third generation VLP vaccines have been generated 
and analyzed for protein expression and particle formation.  These modified VLP 
vaccines include the following: VLP vaccines with codon-optimized env sequences 
(ADA, R2 and JR-FL); VLP vaccines containing two copies of the Mason-Pfizer monkey 
virus constitutive transport element (MPMV CTE); SHIV VLP vaccines expressing SIV 
Gag-PR-RT and HIV Vpu, Env, Rev and Tat; and HIV and SHIV VLP vaccines without 
RT sequences.   
 
Conclusion:  Virally-regulated, multi-gene DNA vaccines express gag, pol, env, tat, rev 
and vpu gene products and produce virus-like particles. 
 
III.C. Specific Aim II 
 
Goal:  To determine the relative immunogenicity of human immunodeficiency virus-like 
particles. 
 
Hypothesis:  Purified virus-like particles administered intranasally will elicit humoral 
and cellular immune responses systemically and mucosally. 
 
Summary:  In Specific Aim II, the goal of this study was to assess the immunogenicity 
of purified VLPs inoculated intranasally alone or co-inoculated with cytosine-phosphate-
guanosine oligodeoxynucleotides (CpG ODNs).  A robust immune response at the 
mucosal surface will be essential in preventing the spread and establishment of the virus 
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within the host.  Mice were inoculated intranasally to induce HIV-specific immune 
response systemically and at distal mucosal sites.  Purified virus-like particles were used 
as the inoculum because of inherent problems associated with expressing virally-
regulated VLP DNA in rodents.  Initially, a minimal response to Env was expected due to 
the low number of Env molecules incorporated in the VLPs.  Consequently, VLPs were 
co-immunized with CpG ODNs to enhance the immune response to Env.  Human 
immunodeficiency virus-like particles were expressed from the DNA plasmids 
constructed and characterized in Specific Aim I.  Each vaccine was expressed using 
sequences encoding gag, pol, (HIV-1BH10), tat, rev, vpu, and env (HIV-1ADA or R2).  Each 
plasmid efficiently induced the secretion of particles from primate cells (COS or 293T); 
however, no particles were secreted from murine cells (NIH 3T3).  Therefore, particles 
were purified from the supernatants of African green monkey cells (COS) and used as 
immunogens.  In this study, BALB/c mice were inoculated intranasally with purified 
human immunodeficiency virus-like particles (day 1 and weeks 3 and 6).  VLPs were 
purified via transient transfection of COS cells followed by ultracentrifugation through 
20% glycerol.  Each VLP elicited specific immunity to HIV-1 antigens in both the 
systemic and mucosal immune compartments.  Anti-Env antibodies were detected in the 
sera, as well as in the washes from harvested lungs, intestines, and vagina from 
immunized mice.  In addition, Env and Gag specific IFN-γ-secreting splenocytes were 
elicited in the mice vaccinated with VLPs.  Co-inoculation of CpG ODNs with VLPs 
significantly enhanced both sets of the immune response.    
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Conclusion:  Systemic and mucosal immune responses to HIV-1 are enhanced by 
intranasal immunization of purified virus-like particles expressed from a virally-regulated 
multi-gene DNA vaccine. 
 
III.D. Specific Aim III 
 
Goal:  To compare the elicitation of immune responses by the same Gag immunogen 
presented to the immune system in different forms. 
 
Hypothesis:  The same immunogen delivered to the immune system in different forms 
will induce a diverse set of immune responses.  Purified Gagp55 VLPs will be more 
immunogenic compared to soluble Gagp55 protein.  DNA expressing VLPs will elicit 
humoral and cellular immune responses, while DNA expressing intracellularly-contained 
VLPs will induce mainly cellular immunity. 
 
Summary:  In SPECIFIC AIM III, the goal of the study was to compare the elicitation of 
immune responses by the same Gag immunogen presented to the immune system in 
different forms.  The gag gene of the human immunodeficiency virus type 1 (HIV-1) 
encodes for viral proteins that self-assemble into viral particles.  The primary Gag gene 
products (capsid, matrix, and nucleocapsid) elicit humoral and cellular immune responses 
during natural infection, and these proteins are crucial immunogens in many HIV/AIDS 
vaccines.  However, the structural form (particulate or free, soluble polypeptides) of these 
proteins may influence the immunity elicited during vaccination.  In this study, mice 
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were inoculated with vaccines expressing HIV-1 Gag gene products in vivo as  1) DNA 
plasmids expressing Gag particles (pGag) or 2) these same proteins retained 
intracellularly (pGag∆Myr).  In a separate experiment the immunity elicited by:  3) Gagp55 
particles (purified in vitro) or 4) soluble Gagp55 proteins administered by intramuscular 
injection was evaluated.  Enhanced cellular responses, but almost no anti-Gag antibodies,   
were elicited with intracellularly-retained Gag proteins.  In contrast, particle secreting 
cells elicited both anti-Gag antibodies and cellular responses.  Mice vaccinated with 
purified Gagp55 pseudovirions elicited robust humoral and cellular immune responses, 
which were significantly higher than the immunity elicited by soluble, non-particulate 
Gagp55 protein.  Overall, particles of Gag effectively elicited the broadest and highest 
titers of anti-Gag immunity.  The structural form of Gag influences the elicited immune 
responses and should be considered in the design of HIV/AIDS vaccines. 
 
Conclusion:  Diverse immune responses are elicited by the same Gag immunogen 
presented to the immune system in different forms.  Purified Gagp55 VLPs are more 
immunogenic compared to soluble Gagp55 protein (humoral and cellular).  DNA 
expressing VLPs elicit humoral and cellular immune responses, while DNA expressing 
intracellularly-contained VLPs induces mainly cellular immunity. 
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IV. Chapter 4:  Specific Aim I 
 
 
Characterization of DNA Vaccines Expressing a Non-Infectious Human 
Immunodeficiency Virus-Like Particle 
 
 
 
 
 
 
 
This chapter was modified with permission from: 
Young, KR, JM Smith, and TM Ross.  
Characterization of a DNA vaccine expressing human  
immunodeficiency virus-like particles.  
Virology, 2004, Oct 1; 327(2): 262-72. 
© Elsevier, Inc. 
 145
IV.A. Introduction 
 
Approximately forty-two million people are infected with the human 
immunodeficiency virus type 1 (HIV-1) 286.  The virus continues to spread to new 
populations adding to the total number of infected individuals.  The use of HAART has 
enhanced both the longevity and quality of life for infected individuals by controlling 
viral replication 270.  Despite the effectiveness of HAART, several drawbacks are 
accompanied with this treatment that limits its worldwide use.  First, HAART does not 
protect patients against initial infection, nor does HAART clear viral infection.  Second, 
treatment is expensive particularly for individuals living in developing nations.  Third, 
there can be severe side effects, and patients on HAART have difficulties adhering to the 
drug regimens.  Therefore, several preventive measures to combat the spread of HIV 
infection have focused on the development of safe, inexpensive, and efficacious vaccines.  
Many of the successful viral vaccines administered to patients, such as vaccines 
developed for the measles or mumps viruses, consist of replication-competent virus that 
has been attenuated in order to prevent disease 157, 304.  The experimental use of live-
attenuated simian immunodeficiency virus (SIV) elicited protective immunity in non-
human primates challenged with SIV or SHIV (a hybrid virus containing the env, tat vpu, 
and rev gene sequences from HIV in a SIV gag-pol backbone) infection 354, 483, 698.  In 
addition, these monkeys had specific cell-mediated and humoral immunity that appeared 
to correlate with protection.  However, reversion of these vaccine strains from attenuated 
to pathogenic forms resulted in uncontrolled replication of the virus, pathogenesis, and 
subsequently death of the vaccinated animals.  These results observed in non-human 
primates may have a direct bearing on the use of live-attenuated HIV for vaccination 
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against infection in humans.  Consequently, this approach is not considered a viable 
vaccine strategy for preventing HIV/AIDS. 
The development of DNA vaccine (genetic vaccine) technology has opened new 
avenues for AIDS vaccine research.  These genetic vaccines consist of eukaryotic 
expression plasmids that are inoculated into target cells of a vaccinated host and 
subsequently translated into protein 152.  DNA plasmids inoculated in vivo, expressing a 
gene insert, elicit protective immunity against a variety of pathogens 152, 542, 543.  Similar 
to live-attenuated virus, DNA vaccines expressing lentiviral antigens elicit both high titer 
antibody and cell-mediated immune responses to HIV/SIV in both rodents and non-
human primates 328, 490.  Therefore, administration of DNA plasmid is an alternative 
strategy to the use of live-attenuated virus.  
 The induction of a broad range of immune responses appears necessary for any 
vaccine strategy against HIV/AIDS 610.  A predominately antibody-mediated immune 
response does not confer protection against HIV infection 420.  Non-human primates 
vaccinated with plasmids expressing HIV or SIV antigens had high-titer, anti-viral 
antibodies but were unable to control viral challenge 468, 675.  In pre-clinical human trials, 
volunteers vaccinated with recombinant Envgp120 or Envgp160 elicited transient, non-
neutralizing anti-Env antibodies that did not result in long-term immune memory 389.  
However, an exclusively cell-mediated immune response against HIV/SIV antigens also 
does not appear to correlate with long-term protective immunity 14.  Vaccine strategies 
that elicit both humoral and cell-mediated immunity appear to be crucial in limiting viral 
replication and protection from live virus infection.  Monkeys primed with DNA 
expressing Gag-Pol and Env, followed by a vector boost of modified vaccinia Ankara 
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(MVA) expressing the same antigens, were able to control viral replication more 
effectively than those animals vaccinated with only Gag-Pol 14.  These results highlight 
the importance of immune responses to Env, as well as to Gag-Pol, in controlling 
immunodeficiency virus challenges.  In the present study, a DNA vaccine was 
constructed to express a virally-regulated human immunodeficiency virus-like particle in 
order to elicit broad-spectrum immune responses to multiple HIV-1 antigens.  These VLP 
were engineered with specific safety mutations and deletions in the genome to prevent 
integration, severely restrict RNA genome packaging, as well as inhibit reverse 
transcriptase and protease activity.   
 
IV.B. Material and Method 
 
DNA plasmids from external sources 
The lineage of all vaccine plasmids is described in Table 5.  The vector plasmid, 
pTR600 62, 235, 446, 634, 720, (Accession number: AF425297) (Harriet Robinson, Emory 
University, Atlanta, GA, USA) uses the cytomegalovirus immediate-early (CMV-IE) 
promoter to efficiently initiate transcription (Figure 6).  Sequences from the bovine 
growth hormone terminator (BGH Poly A Term) were inserted to provide a 
polyadenylation signal.  The vector also contains the Col E1 origin of replication for 
prokaryotic replication, as well as the kanamycin resistance (Kanr) gene for selection in 
antibiotic media.   
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Figure 6.  Schematic of VLP DNA vaccines.   
The plasmid, pTR600, was constructed to contain the cytomegalovirus immediate-early 
promoter (CMV-IE) for initiating transcription of eukaryotic inserts and the bovine 
growth hormone polyadenylation signal (BGH Poly A) for termination of transcription.  
The vector contains the Col E1 origin of replication for prokaryotic replication and the 
kanamycin resistance gene (Kanr) for selection in antibiotic media.  VLP sequences and 
other genes of interest were cloned into the multiple cloning site (MCS).  
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Table 5.  Summary of molecular cloning of vaccine plasmids.  
 
Plasmid Vector 
Parent 
Insert  
Parent 
Restriction 
Endonucleases 
(insert/vector) 
Cloning Verification by 
Restriction Endonuclease 
Digestion 
pVLPADA pVLPBH10 pHIV-1ADA EcoR I-Nhe I 
(3.1 kb/6.5 kb) 
Avr II 
800 bp/4.2 kb/4.5 kb correct 
4.1kb/5.4kb wrong 
pVLP89.6 pVLPADA pHIV-189.6 EcoR I-Bam HI 
(2.7 kb/6.8 kb) 
EcoR I/Nde I 
2.2 kb/7.3 kb correct 
9.5 kb wrong 
pVLPR2 pVLPADA pR2gp160 Xho I-Bam HI 
(2.2 kb/7.3 kb) 
EcoR V 
2.4 kb/7.1 kb correct 
9.5 kb wrong 
pVLPJR-FL pVLPADA pHIV-1JR-FL Xho I-Bam HI 
(2.2 kb/7.3 kb) 
EcoR V 
2.4 kb/7.1 kb correct 
9.5 kb wrong 
pVLPcoADA pVLPADA pcoADAgp160 Eco RI-Bam HI 
(2.7 kb/ 6.8 kb) 
Eag I/Bam HI 
1.3 kb/8.2 kb correct 
9.5 kb wrong 
pVLPcoR2 pVLPADA pcoR2gp120 Xho I-Mlu I 
(1.5 kb/8.0 kb) 
Apa I  
3.7 kb/5.8 kb correct 
9.5 kb wrong 
pVLPADA/2xCTE pVLPADA pCDNA-gp3v-
CTE-CTE 
Nhe I-Sac II 
(550 bp/9.5 kb) 
Nhe I-Sac II 
550 bp/9.5 kb correct 
27 bp/9.5 kb wrong 
pVLPADA/∆RT pVLPADA n/a Eco RI 
(3.6 kb/5.9 kb) 
EcoR I  
7.9 kb correct 
1.7 kb/7.9 kb wrong 
pVLPSHIV/ADA pVLPADA pSIVmac239-3’ Mlu I-Eco RI 
(3.5 kb/6.0 kb) 
Bam HI 
3.8 kb/5.7 kb correct 
9.5 kb wrong 
pVLPSHIV/ADA/∆RT pVLPSHIV/
ADA
n/a Eco RI 
(1.7 kb/7.8 kb) 
EcoR I  
7.9 kb correct 
1.7 kb/7.9 kb wrong 
pCD4 pTR600 sT4DHFR Hind III/Nhe I 
(1.2 kb/3.9 kb) 
Hind III/Nhe I 
1.2 kb/3.9 kb correct 
3.9 kb wrong 
pcoADAgp120 pTR600 pcoADAgp160 Hind III/Bam HI 
(1.4 kb/3.9 kb) 
 
Hind III/Bam HI 
1.4 kb/3.9 kb correct 
3.9 kb wrong 
pcoR2gp120 pTR600 pGAcoR2gp120 Hind III/Bam HI 
(1.4 kb/3.9 kb) 
 
Hind III/Bam HI 
1.4 kb/3.9 kb correct 
3.9 kb wrong 
pGag pTR600 phGag Hind III-Bam HI 
(1.5 kb/3.9 kb) 
Hind III-BamHI  
1.5 kb/3.9 kb correct 
3.9 kb wrong 
pGag-Pol pTR600 phGag-Pol Cla I- Eco RI 
(4.3 kb/3.9 kb) 
Cla I- Eco RI  
4.3 kb/3.9 kb correct 
3.9 kb wrong 
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 The vector plasmid, pBC12 120, (Brian Cullen, Duke University, Durham, NC, 
USA) contains the CMV-IE promoter for efficient initiation of transcription.  Sequences 
from the bovine growth hormone polyadenylation signal were inserted to promote 
termination.  The vector also contains the Col E1 origin of replication for prokaryotic 
replication as well as the ampicillin resistance (Ampr) gene for selection in antibiotic 
media.   
 The following plasmids were generously donated to our laboratory: pHIV-1ADA  
(HIV-1BH10 proviral backbone with HIV-1ADA VERT region in pCB12 vector) 104, 120, 406, 
pHIV-1BH10 (pBluescript II-KS + vector, Stratagene, La Jolla, CA, USA) 275, 530 and 
pHIV-189.6 (pUC19 vector) 48, 112, 153, 326 (National Institutes of AIDS Health Research and 
Reference Reagent Program (NIH ARRRP), Germantown, MD, USA).  Each plasmid 
contains the full length HIV-1 provirus (BH10, ADA/BH10 hybrid and 89.6 isolates, 
respectively) with intact 5’ and 3’ LTRs.   
The reporter plasmid, pBlueScript3-HIV-LTR-SEAP (pLTR-SEAP), expresses 
secreted alkaline phosphatase from the promoter found in the HIV-1 5’ long terminal 
repeat (LTR) (Brian Cullen, Duke University, Durham, NC, USA) 40.  
 
Construction of VLP vaccines 
The construction of the VLP vaccines is outlined in Table 2 and Figure 7.  The 
VLP parental plasmid, pHIV-1BH10, encoded the sequences for the proviral HIV-1 from 
the isolate BH10 (X4) (Accession number: M1564) (pBC12) and was used as a template 
to construct the plasmid, pVLPBH10/wt.  pVLPBH10/wt encodes for the following gene 
sequences: gag and pol (HIV-1BH10 nt 1-3626, VLPADA nt 7-3620)  vpu,  env,  rev and  tat  
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Figure 7.  Schematic representation of DNA vaccine constructs.   
(A) Wild-type, proviral DNA, (B) VLP DNA with regions encoding for the 5’ PCR 
product (HIV-1BH10: p17, p24, p15, PR, RT) and the 3’ PCR product (HIV-1ADA, 89.6, or R2: 
vpu, env, rev, tat), (C) Gag-Pol DNA, (D) Gag DNA.  Restriction sites are based on the 
nucleotide sequence for HIVBH-10. * represent the mutations in NC.    • represents the 
mutations in PR.  X represents the mutations in RT.      
A) 
 
 
 
 
 
B) 
 
 
 
 
 
 
C) 
 
 
 
 
D) 
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(HIV-1BH10 nt 5101-8160, VLPADA nt 3620-6672).  The pVLPBH10 plasmid was 
constructed by first making two subclones encoding for the 5’ end of the VLP gene insert 
and a second subclone encoding for the 3’ end of the VLP gene insert.  Oligonucleotides 
corresponding to the gag-pol sequences were used to amplify a fragment of DNA (5’ 
PCR product) composed of the 5’ untranslated leader sequence (105 nucleotides) and 
gag-pol sequences (start codon of Gag to the stop codon of RT) by PCR (see Section 
II.A.5).  For the 5’ PCR product, a Cla I restriction enzyme site was introduced (HIV-
1BH10 nt 7, VLPADA nt 7) at the 5’ end of the vaccine insert, while EcoR I (HIV-1BH10 nt 
3626, VLPADA nt 3620) and Nhe I sites(HIV-1BH10 nt 8160, VLPADA nt 6672) were added 
at the 3’ end of the 5’ PCR product by PCR.  The following primers were used to amplify 
the 5΄ PCR product (3625 bp):  (sense primer 
5΄-GAGCTCTATCGATGCAGGACTCGGCTTGC-3’ and antisense primer 5΄-
GGCAGGTTTTAATCGCTAGCCTATGCTCTCC-3΄).  The 3’ PCR fragment (3059 bp) 
encoded the vpu, tat, rev, and env gene sequences.  An EcoRI site was introduced into the 
5’ terminus of the 3’ PCR product (HIV-1BH10 nt 5101, VLPADA nt 3620) and an Nhe I 
site was introduced at the 3’ terminus (HIV-1BH10 nt 8160, VLPADA nt 6672), and the 3’ 
PCR product was amplified by the following primers: (sense primer 5΄-
CCCACCTTAAGACGTTGTTGACGACAAATACG-3’ and antisense primer 5΄-
CCACACTACTTTCGGACCGCTAGCCACCC-3΄).  The PCR products were cloned into 
pCR2.1-TOPO (Invitrogen Life Sciences, Carlsbad, CA, USA) (see Section II.A.5).  Both 
the 5’ and 3’ PCR products were cloned into pTR600 using unique restriction enzyme 
sites (5’ PCR product: Cla I and Eco RI and the 3’ PCR product using EcoR I and Nhe I) 
described in Sections II.A.1 and II.A.2.  The gene inserts were verified by digestion with 
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restriction endonucleases (see Section II.A.1 and Table 5).        
pVLPBH10 is derived from the plasmid, pVLPBH10/wt (see Table 2).  Safety 
mutations were introduced in pVLPBH10/wt in the zinc fingers in nucleocapsid (NC) to 
inhibit RNA packaging (C15S, C36S) 449.  In addition, mutations were introduced into the 
pol gene to abrogate RT activity (D185N) 95, inhibit strand transfer (W266T) 368, and to 
inactivate RNase H activity (E478Q) 707.  All mutations were introduced by SDM PCR 
(see Section II.A.6 and Table 6) and verified by DNA sequencing (see Section II.A.7).   
Three additional VLP DNA plasmids were constructed that encoded for various 
env sequences.  The env, tat, vpu and rev sequences were cloned by PCR amplification 
from the DNA from the ADA (Bryan Cullen, Duke University, Durham, NC, USA), 89.6 
(NIH ARRRP, Germantown, MD, USA), R2 (Gerald Quinnan, USA), or JR-FL (Shan 
Lu, University of Massachusetts, Worcester, MA, USA) isolates of HIV-1 and cloned 
into the subclone, pCR2.1-TOPO (Invitrogen Life Sciences, Carlsbad, CA, USA) (see 
Section II.A.5).  Each PCR fragment (2.7 kb, env, tat, vpu and rev sequences) was 
inserted into the VLPBH10 Gag-Pol backbone using unique restriction enzyme sites (see 
Sections II.A.1, II.A.2 and Table 5).  The gene inserts were verified by digestion with 
restriction endonucleases (see Section II.A.1 and Table 5).   
pVLP89.6 was used as a model for the method of molecular cloning (Figure 8).  
VLP89.6 was constructed by restriction endonuclease digestion of parental vector 
(pVLPADA) and insert (pHIV-189.6) DNA.  The parental plasmids, pVLPADA (500 ng) and 
pHIV-189.6 (1 µg), were digested with restriction endonucleases, EcoR I and Bam HI (1 U 
each) for 2 h (see Section II.A.1).  The digested products were resolved on a 1% agarose 
gel by electrophoresis.  The  parental  insert fragment (2.7 kb) was extracted  and purified  
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Table 6.  Primers  used  to  introduce  mutations  to  inactivate  protein  activity  by     
                site-directed mutagenesis polymerase chain reaction.   
 
 
†Location of the first nucleotide in the codon that has been changed in the HIV-1IIIB 
sequence 
 
 
Mutation Nucleotide Sequence (5’-3’)             Location†
C15S  ggttaagagcttcaatagcggcaaagaagggc  
gcccttctttgccgctattgaagctcttaacc 
1285 
C36S gggcagctggaaaagcggaaaggaagg  
ccttcctttccgcttttccagctgccc 
1357 
D185N ccagacatagttatctatcaatacatgaacgattgtatgtagg  
cctacatacaaatcgttcatgtattgatagataactatgtctgg 
2460 
W266T ggggaaattgaataccgcaagtcagatttaccc  
gggtaaatctgacttgcggtattcaatttcccc 
2703 
E478Q ccctaactaacacaacaaatcagaaaactcagttacagc  
gcttgtaactgagttttctgatttgttgtgttagttaggg 
3339 
D25N ggaagctctattaaatacaggagcagatg  
catctgctcctgtatttaatagagcttcc 
1683 
G2A Gag myristylation  
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Figure 8.  Molecular cloning of pVLP89.6.   
(A) Restriction endonuclease digestion of parental vector (pVLPADA) and insert (pHIV-
189.6).  The parental plasmids, pVLPADA (500 ng) and pHIV-189.6 (1 µg), were digested 
with restriction endonucleases, EcoR I and Bam HI for 2 h.  The digested products were 
resolved on a 1% agarose gel by electrophoresis. Lane 1, 1.0 kb ladder; lanes 2, 3, uncut 
pVLPADA; lanes 4, 5, uncut pHIV-189.6; lanes 6, 7, pVLPADA (EcoR I/Bam HI); lanes 8, 9, 
pHIV-189.6 (EcoR I/Bam HI).  (B) Agarose gel extraction and purification of parental 
insert fragment.  The parental insert fragment (2.7 kb) was extracted and purified from 
the agarose gel to be used for ligation reaction.  The parental vector fragments (2.7 kb/6.8 
kb) (10% of total purified fragment) and the purified parental insert fragment (2.7 kb) 
(25% of digestion reaction from (A)) were resolved on a 1% agarose gel by 
electrophoresis.  Lanes 1, 2, pVLPADA (2.7 kb/6.8 kb, vector), lanes 3, 4, pHIV-189.6 (2.7 
kb, insert); lane 4, 1.0 kb ladder.  Arrows indicate the insert (right) and vector (left) 
fragments of interest.  (C) Verification of molecular cloning of pVLP89.6.  The parental 
vector fragments and purified parental insert were ligated, transformed into XL-10 Gold 
cells and plated on antibiotic media.  Plasmid DNA was purified from bacterial cells, 
digested (300ng) with EcoR I/Nde I (2 h) to verify molecular cloning and resolved on a 
1% agarose gel by electrophoresis.  Lane 1, 1.0 kb ladder, lane 2, pVLPADA (EcoR I/Nde 
I); lane 2, pVLP89.6 clone 1 (EcoR I/Nde I); lane 3, pVLP89.6 clone 2 (EcoR I/Nde I).  The 
digested products were analyzed for fragment size (2.2 kb/7.3 kb, correct; 9.5 kb, wrong).  
pVLP89.6 clone 2 is correct and was amplified and purified from bacterial cells for further 
characterization. 
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from the agarose gel and used for the ligation reaction (see Section II.A.4).  The parental 
vector fragments (2.7 kb/6.8 kb) (10% of total purified fragment) and the purified 
parental insert fragment (2.7 kb) (25% of digestion reaction) were resolved on a 1% 
agarose gel by electrophoresis.  The parental vector fragments and purified parental insert 
were ligated, transformed into XL-10 Gold cells and plated on antibiotic media (see 
Section II.A.2 and II.A.3).  Plasmid DNA was purified from bacterial cells, digested 
(300ng) with EcoR I/Nde I (2 h) to verify molecular cloning and resolved on a 1% 
agarose gel by electrophoresis.  The digested products were analyzed for fragment size 
(2.2 kb/7.3 kb, correct; 9.5 kb, incorrect).  The correct clone was amplified and purified 
from bacterial cells for further characterization. 
Two other VLP-expressing DNA plasmids were constructed that contained codon 
optimized env sequences (GENEART, Regensburg, Germany).  pVLPcoADA is derived 
from the plasmid, pVLPADA.  The codon-optimized sequences representing the HIV-1ADA 
env gene (pcoADAgp160) was cloned into the plasmid, pVLPADA, using unique EcoR I 
(HIV-1BH10 nt 3626) and Bam HI (HIV-1BH10 nt 6349) restriction enzyme sites (see 
Section II.A.1 and II.A.2).  The gene insert was verified by digestion with restriction 
endonucleases (see Section II.A.1 and Table 5).        
pVLPcoR2 is derived from the plasmid, pVLPADA.  The codon-optimized env 
sequence from HIV-1R2 (pGAcoR2gp120) was cloned into the plasmid, pVLPADA, using 
unique Xho I (HIV-1BH10 nt 4111, VLPADA nt 4105) and Mlu I (HIV-1BH10 nt 5588, 
VLPADA nt 5582) restriction enzyme sites (see Sections II.A.1 and II.A.2).  The gene 
insert was verified by digestion with restriction endonucleases (see Section II.A.1 and 
Table 5).      
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pVLPADA/2xCTE was derived from the plasmid, pVLPADA.  Two tandem copies of 
the Mason-Pfizer Monkey Virus (MPMV) constitutive transport element (CTE) (2xCTE) 
were cloned by PCR amplification from the plasmid, pCDNA-gp3v-CTE-CTE 611, 614 and 
cloned into pCR2.1-TOPO (sense primer 5’-ctgcgaccgcgggtgggagtggcaccttccagggtc-3’ 
and antisense primer 5’-gcggctgctagccaccataatcgcggccgctcg-3’) (see Section II.A.5).  
The 2xCTE fragment was cloned into pVLPADA using the unique restriction sites, Nhe I 
and Sac II (see Section II.A.1 and II.A.2.  The gene insert was verified by digestion with 
restriction endonucleases (see Section II.A.1 and Table 5).           
pVLPR2/∆RT is derived from the plasmid, pVLPR2.  Introduction of an EcoR I 
restriction enzyme site into pVLP (HIV-1BH10 nt 1937) was performed by SDM PCR 
(sense primer 5’-gagactgtaccagtgaattcaaagccaggaatggatggccc-3’ and antisense primer 5’- 
gggccatccattcctggctttgaattcactggtacagtctc-3’) (see Section II.A.6).  pVLPR2 with an EcoR 
I site (500 ng) was digested with EcoR I (see Section II.A.1) and re-ligated to remove the 
sequences encoding RT (HIV-1BH-10 nt 1937-3626, 1.7 kb fragment) (see Section II.A.2).  
The gene insert was verified by digestion with restriction endonucleases (see Section 
II.A.1 and Table 5).      
 
Construction of SHIV VLP vaccines 
  pVLPSHIV/ADA is derived from the plasmid, pVLPADA.  Introduction of a Mlu I 
restriction enzyme site into pVLPADA (SIVmac239 nt 1313, HIV-1BH-10 nt 135) was 
performed by SDM PCR (sense primer 5’-gcgagagcgtcagtattacgcgtgggagaattagatcg -3’ 
and antisense primer 5’-cgatctaattctcccacgcgtaatactgacgctctcgc-3’) (see Section II.A.6 
and Table 4).  Sequences encoding for gag, PR, and RT from SIVmac239 were cloned by 
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PCR amplification from the plasmid, pSIVmac239-5’, and cloned into pCR2.1-TOPO 
(Invitrogen Life Sciences, Carlsbad, CA, USA) (sense primer 5’-
ctacgtacgcgtgaagaaagcagatg-3’ and antisense primer 5’-
gcgatggaattctaatcatgttcttcttgtgc-3’) (see Section II.A.5).  The gene insert was cloned into 
pVLPADA using the unique restriction sites, Mlu I and Eco RI.  This plasmid contains the 
sequences for gag, PR, RT (SIVmac239) env, vpu, tat and rev (HIV-1ADA).  The gene insert 
was verified by digestion with restriction endonucleases (see Section II.A.1 and Table 5).      
pVLPSHIV/ADA/∆RT is derived from the plasmid, pVLPSHIV/ADA.  An Eco RI 
restriction enzyme site was introduced into pVLPSHIV/ADA (SIVmac239 nt 3131, VLPADA nt 
1929) by SDM PCR (sense primer 5’- gtagagcctgtgaattccgccttaaagccagg -3’ and 
antisense primer 5’- cctggctttaaggcggaattcacaggctctac -3’).  The plasmid was digested 
with Eco RI and religated to remove the sequences encoding RT (HIV-1BH-10 nt 3133-
4822, 1.7 kb fragment).  The gene insert was verified by digestion with restriction 
endonucleases (see Section II.A.1 and Table 5).           
 
Construction of HIV-1 Gag/Gag-Pol vaccines 
pGag and pGag-Pol are derived from the codon optimized sequences encoding 
HIV-1NL4-3 gag (phGag) and gag-pol (phGag-Pol), respectively (generously donated by 
Gary Nabel, NIH, Bethesda, MD, USA) 283.  Sequences encoding for Gagp55 (pHIVBH10, 
nt 112-1644) and Gag-Polp160 (pHIVBH10, nt 112-4552) were molecularly cloned from 
hGag and hGag-Pol into pTR600 using the unique restrictions sites, Hind III/BamH I and 
Hind III/Eco RI, respectively (see Section II.A.1 and II.A.2).  The gene insert was 
verified by digestion with restriction endonucleases (see Section II.A.1 and Table 5).      
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The plasmid, pGag∆Myr, is derived from the plasmid, pGag, and was constructed 
by mutating the myristylation site (second amino acid in MAp17) by SDM PCR (sense 
primer 5’-cgtcgtcgacatggccgcccgcgccagcgtgc-3’ and antisense primer 5’-
gcacgctggcgcgggcggccatgtcgacgacg-3’) (see Section II.A.6).  This mutation resulted in a 
change of the codon from a glycine to an alanine (gga to gca), which was verified by 
DNA sequencing (see Section II.A.7)       
 
Construction of codon-optimized HIV-1 Env 
pcoADAgp120 contains the codon-optimized sequences encoding the soluble 
Envgp120 from HIV-1ADA (HIV-1ADA Env: aa 1-520) 721.  The codon-optimized Envgp120 
gene was cloned by PCR amplification from the plasmid, pcoADAgp160, (generous gift 
from Harriet Robinson, Emory University, Atlanta, GA, USA) and cloned into pCR2.1-
TOPO (Invitrogen Life Sciences, Carlsbad, CA, USA) (sense primer 5’-
gagcgtgctagcctgtgggtgaccgtgtactac-3’ and antisense primer 5’-
cgtgagggatcctgccttggtgggtgctactcc-3’) (see Section II.A.5).  The gene insert was cloned 
into pTR600 using the unique restriction sites, Hind III and BamH I (see Section II.A.1 
and II.A.2.  The gene insert was verified by digestion with restriction endonucleases (see 
Section II.A.1 and Table 5).             
 pcoR2gp120 contains the codon-optimized sequences encoding the soluble Envgp120 
from HIV-1R2 (HIV-1R2 Env: aa 1-520).  The codon-optimized Envgp120 gene was 
molecularly cloned from the plasmid, pGAcoR2gp120, (GENEART, Regensburg, 
Germany) into pTR600 using the unique restriction sites, Hind III and BamH I (see 
Section II.A.1 and II.A.2).  The gene insert was verified by digestion with restriction 
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endonucleases (see Section II.A.1 and Table 5).      
 
 Construction of soluble human CD4 
pCD4 expresses the soluble human CD4 (4 extracellular domains) (aa 1-370) 
using sequences from the full length CD4 gene (sT4DHFR) (Bryan Cullen, Duke 
University, Durham, NC, USA) 105, 136, 406, 407, 432.  Soluble hCD4 was cloned by PCR 
amplification into pCR2.1-TOPO (Invitrogen Life Sciences, Carlsbad, CA, USA) (sense 
primer 5’-gtcagcaagcttatgaaccggggagtcc-3’ and antisense primer 5’-
gctgacgctagcgctacctcctccgcctccatcgatgctacctccgcctccgctacctccgccgcttccgaattcggtggacca
tgtg-3’) (see Section II.A.5).  The gene insert was cloned into pTR600 using unique 
restriction sites, Hind III and Nhe I (see Sections II.A.1 and II.A.2).  The gene insert was 
verified by digestion with restriction endonucleases (see Section II.A.1 and Table 5).      
  
Transfections and expression analysis 
The monkey fibroblast cell line, COS, (5 X 105 cells/transfection) was transfected 
with 2 µg of DNA using 12% lipofectamine according to the manufacturer’s guidelines 
(Life Technologies, Grand Island, NY).  Supernatants (2 ml) were collected and stored at 
–20°C.  Cell lysates were collected in 500 µl of 1% Triton X-100 and stored at –20°C.  
Quantitative antigen capture ELISAs were conducted according to the manufacturer’s 
protocol (Perkin Elmer Life Sciences, Boston, MA).  
For Western hybridization analysis, 3.3% of supernatant and 1.5% of the cell 
lysate was diluted 1:2 in SDS sample buffer (Bio-Rad, Hercules, CA), boiled for 5 min, 
and loaded onto a 10% polyacrylamide/SDS gel.  The resolved proteins were transferred 
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onto a nitrocellulose membrane (Bio-Rad, Hercules, CA) and incubated with a 1:5,000 
dilution of polyclonal human HIV-infected patient antisera (HIV-Ig) in PBS containing 
0.05% Tween 20 and 5% non-fat dry milk.  After extensive washing, bound human 
antibodies were detected using a 1:7,000 dilution of horseradish peroxidase-conjugated 
goat anti-human antiserum and enhanced chemiluminescence (Amersham, 
Buckinghamshire, UK). 
For determination of Tat activity, COS cells (5 X 105) were transiently transfected 
using 12% lipofectamine in DMEM with 1 µg of each VLP DNA and 1 µg of the reporter 
plasmid, pLTR-SEAP 118. After 18 hours, cells were replenished with fresh media (1.5 
ml) and incubated an additional 48 h.  100 µl of collected supernatants were incubated 
with 100ul of SEAP buffer (2M diethanolamine, 1mM MgCl2, 20mM L-homoarginine) 
for 10 min at 37 °C followed by the addition of 20 ul p-nitrophenyl phosphate (120 mM) 
(PNP) (Sigma, St. Louis, MO, USA) for 30 min at 37°C.  Samples were analyzed for 
color change at 405 nm.  Data was recorded as the average of the three independent 
experiments +/- standard deviation. 
 
Virus-like particle formation 
   Supernatant from COS cells, transiently transfected with plasmid expressing Gag, 
Gag-Pol, HIV/SHIV VLP, or infectious virions, were pelleted via ultracentrifugation 
(100,000 x g through 20% glycerol) for 2 h at 4°C.  The pellets were subsequently 
resuspended in PBS and overlaid onto 20-60% sucrose gradients (11 steps, 4% 
increments) and ultracentrifuged for 17 h at 100,000 x g at 4°C.  Eleven fractions (20-
60%, 1ml) were collected top to bottom from the gradient, and the proteins were 
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precipitated with equal volumes of 20% TCA and subjected to SDS-PAGE and 
immunoblotting.  The viral proteins were detected by HIV Ig or SIV Ig via Western 
hybridization.  
 
VLP binding to human CD4 
 Supernatants from COS cells transiently transfected with plasmids expressing 
either pTR600, pVLP, pHIV, or pGag-Pol were incubated at RT for 4 h with supernatants 
from COS cells transiently transfected with a plasmid expressing soluble human CD4 
(sCD4) (9:1 ratio).  The mixture was centrifuged (100,000 x g) and pelleted through 20% 
sucrose.  Each pellet was resuspended in PBS and analyzed by Western hybridization for 
CD4 bound to VLP.  sCD4 was detected by mouse polyclonal anti-CD4 (1:3,000) 
followed by goat anti-mouse IgG conjugated to HRP (1:7,000) (Bio-Rad, Hercules, CA). 
The proteins were enhanced by chemiluminescence and visualized by autoradiography.   
 
Rabbit immunizations 
 Five to 7 week old New Zealand white rabbits were vaccinated (i.m.) at weeks 0, 
6, 12 and 18 with 200 µg of VLP DNA (pVLP89.6) in 500 µl of sterile PBS.  The rabbits 
were housed in compliance with the USDA regulations.  Rabbits were monitored daily 
for weight loss, behavior, and adverse reaction.    
 
Western blot analysis for anti-Gag antibodies 
 Sera from rabbits vaccinated with VLP DNA were collected at week 20, and 
antibody responses were determined by Western blot analysis.  Purified HIV-1SF2 Gagp55 
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protein (20 ng) (NIH ARRRP) was loaded per well and electrophoresed through a 5-10% 
gradient SDS-polyacrylamide gel.  Proteins were transferred to a PVDF membrane, and 
serum from immunized rabbits (1:1500) was used as the primary antibody.  HIV-1 
specific antibodies were detected using goat anti-rabbit IgG conjugated to HRP (1:3,000). 
The proteins were visualized by enhanced chemiluminescence followed by 
autoradiography.   
 
Anti-Env proliferation responses 
 PBMCs were isolated from immunized rabbits 25 weeks following the last 
immunization (week 43) 131.  PBMCs were plated at a concentration of 2 X 105 cells/well 
(96-well plate) in 200 µl of cRPMI.  PBMCs were stimulated with recombinant HIV-1LAI 
or BAL Envgp120 or Measles F protein (NIH ARRRP) (10 µg/ml).  Plates were incubated at 
37°C in a 5% CO2 atmosphere for 72 h and then pulsed with 1 µCi per well of [3H]-
thymidine in 50µl of cRPMI.  The cells were then incubated for an additional 24 h (37°C 
in 5% CO2), and the incorporation of [3H]-thymidine was determined by harvesting the 
cells, immobilizing the DNA to glass fiber membranes, and counting in a liquid 
scintillation counter.  Mean liquid scintillation results for triplicate wells were recorded 
as counts per minute (cpm).  The arithmetic mean of three samples per group was 
determined ± the S.D. 
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IV.C. Results 
 
Construction of plasmids expressing human immunodeficiency virus-like particles 
 In this study, a non-pathogenic, virus-like particle (VLP) was developed to elicit 
broad spectrum immune responses to a variety of HIV-1 antigens.  The proviral plasmid, 
pHIV-1BH-10, which encodes for a CXCR4-utilizing virus, was used as a template to 
construct plasmids expressing VLP.  A deletion was introduced into pHIV-1BH-10, by 
cloning of two PCR products encompassing 1) the regions encoding for gag-pol and 2) 
the vpu, env, rev, and tat genes (Figure7) removing sequences encoding IN, vif, vpr, and 
nef.  In addition, both LTRs were removed.  The final plasmid, pVLPBH10, expresses 
capsid, matrix, nucleocapsid, protease, reverse transcriptase, envelope, Vpu, Tat, and Rev 
from HIV-1BH10.   
 The pVLP89.6 plasmid was constructed by first making two subclones encoding 
for the 5’ end of the VLP gene insert (gag-pol region) and a second subclone encoding 
for the 3’ end of the VLP gene insert (vpu, env, tat, and rev).  Oligonucleotides were used 
to amplify each fragment and then subcloned into the expression vector, pTR600.  The 
two fragments were cloned together into a single VLP gene insert (Figure 7).  Moreover, 
four additional 3’ PCR products were constructed using sequences from clade B viruses.  
Each 3’ PCR product, encoding the env sequences from two R5 HIV-1 isolates, ADA and 
R2 (a kind gift from Gerald Quinnan), was cloned with the 5’ PCR product encoding for 
the gag-pol sequences from HIV-1BH10.  Lastly, safety mutations were introduced in the 
VLP DNA using site-directed mutagenesis to increase the vaccine safety for potential use 
in humans.   These mutations were designed to disable the encapsidation of viral RNA 
(C15S) 395, abrogate RNase H activity (D185N, W266T, E478Q) 95, 368, 448, 707 and 
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inactivate the viral protease (D25N) 25. 
 Additional VLP vaccine constructs were engineered to contain codon optimized 
Env sequence.  pVLPcoADA, pVLPcoJR-FL  and pVLPcoR2 were generated to express Env 
from codon optimized sequences from the ADA, JR-FL and R2 strains of HIV-1, while 
all other proteins were the same as the pVLPADA.  The VLP vaccines were further 
modified to remove the RT gene (pVLPR2/∆RT) or add 2 copies of the MPMV CTE 
(pVLPADA/2xCTE). 
Two SHIV VLP vaccine plasmids were also from made from HIV VLP DNA.  
pVLPSHIV/ADA contains the sequences for gag, PR, RT (SIVmac239), env, vpu, tat, rev 
(SIVmac239).  pVLPSHIV/ADA/∆RT is the same as pVLPSHIV/ADA but does not contain the 
sequence for RT.   
 phGag and phGag-Pol (generously donated by Gary Nabel) express core 
structural and enzymatic proteins from a codon-optimized gene insert 283.  Each of these 
plasmids encodes for the Gag and Pol gene products using an X4 isolate as the pVLP 
(Figure 7).  Both plasmids were used to compare and contrast to the pVLP and pVLPD25N. 
 
In vitro expression and particle formation of HIV VLPs 
 Each VLP expressing plasmid was verified for expression in monkey COS cells 
(Figure 9).  Vaccine plasmids expressing VLP with RT and NC safety mutations, but 
without the protease safety mutations, expressed fully processed Gag and Pol gene 
products that were detected in both the cell lysates and supernatants of transiently 
transfected cells (Figures 9A and B).  Unprocessed Gag-Pol gene products (Gag-Polp160, 
Gagp55, Gagp41) were detected primarily in the cell lysate fraction compared to the 
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supernatant (Figures 9A and B), whereas Gagp24 was detected in both the cell lysates and 
supernatants.  Similar results were observed from cells transfected with phGag-Pol 
(Figures 9E and F).  In contrast, DNA expressing VLPD25N produced incompletely 
processed Gag-Pol gene products (Gag-Polp160, Gagp55, Gagp41) (Figures 9C and D).   
Fully processed Gagp24 or Gagp17 gene products were not detected in supernatants or cell 
lysates from cells transiently transfected with DNA expressing VLP with the PRD25N 
(VLPD25N) mutation.  These results were similar to cells transfected with phGag or 
phGag-PolD25N (Figures 9E and F).  Env was detected in the supernatant of cells (1-2 
ng/ml) transfected with DNA expressing VLP and was not affected by the addition of 
safety mutations.  Therefore, each of the DNA plasmids expressing HIV-like particles 
efficiently expressed all of the structural VLP gene products.   
 Particles were purified from the supernatants of transiently transfected cells by 
ultracentrifugation (20-60% sucrose gradient) and collected fractions were analyzed for 
particle composition and stability.  Supernatants from cells transfected with DNA 
expressing VLP contained particles that banded between 32-40% sucrose (1.14-
1.18g/cm3) (Figure 10).  These virus-like particles banded in a sucrose gradient similar to 
wild-type virions.  Gagp55, Gagp41 and Gagp24 were readily detectable in each of these 
fractions.  All VLPs banded in the same percentage of sucrose regardless of whether they 
were expressed from DNA encoding VLP with or without the NC and RT safety 
mutations.  However, supernatant from cells transfected with DNA expressing VLP with 
the PRD25N mutation had particles without detectable levels of Gagp24.  Similar results 
were  observed from  cells transfected  with phGag-Pol  incorporating  PRD25N.  However,  
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Figure 9.  Expression of vaccine constructs in vitro.   
COS cells were transfected with 2 µg of each vaccine plasmid.  Samples were 
electrophoresis on a 10% SDS-PAGE (2.0% of cell lysate and 1.5% of supernatant).  (A, 
B) VLP with NC and RT safety mutations;  lane 1:  pTR600 vector, lane 2: pVLP89.6, 
lane 3: pVLPADA, and lane 4: pVLPR2.  (C, D)  Gag or Gag-Pol VLP;  lane 1: pGagp55 and 
lane 2: pGag-Polp160.  (E, F) VLP with NC and RT safety Mutations and protease 
mutation; lane 1: pVLPADA, lane 2: pVLPADA(D25N), lane 3: pHIV-1R2, and lane 4: pHIV-
1R2(D25N).  (A, C, E) cell lysates.  (B, D, F) supernatants. 
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Figure 10. Comparison of sedimentation patterns of secreted viral proteins by 
sucrose density-equilibrium gradient analysis.   
Supernatants from COS cells transiently transfected with plasmid DNA were 
concentrated through a 20% glycerol cushion and then subjected to 20-60% sucrose 
density-equilibrium gradient centrifugation.  Fractions were collected (ten 1 ml aliquots) 
from the top of the gradient.  Fractions were examined by western analysis.  Proteins 
were probed with HIV-Ig (1:5000) and mouse anti-human IgG (1:7000) and visualized by 
enhanced chemiluminescence.  (A)  VLPR2, (B) VLPR2(D25N), (C) VLPR2(G48V), (D) HIV-
189.6,  (E) Gagp55, (F) Gag-Polp160. 
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cells transfected with the phGag-Pol plasmid produced particles that contained 
predominantly processed Gag gene products with little higher molecular weight Gag-Pol 
proteins, whereas  cells  transfected  with  phGag DNA  had  unprocessed  gene products.  
Although each DNA plasmid efficiently expressed VLP, the composition of the particles 
differed depending on PR activity.   
 
VLP vaccines containing codon optimized Env sequences 
 VLP DNA vaccines containing codon-optimized env sequences were constructed 
to enhance the expression of Env on the virus-like particles.  In contrast to VLP DNA 
with wild-type env sequences, VLP vaccines containing codon optimized sequences for 
Env demonstrated aberrant protein patterns (Figure 10).  Each VLPcoEnv was transfected 
into COS cells to test for protein expression and Gag processing.  The VLPcoEnv 
constructs had different processing patterns compared to VLPs with wild-type envelopes 
(Figure 9A/B and 10).  All three VLP DNAs with codon optimized env sequences 
expressed viral proteins, but the expression of proteins by pVLPcoJR-FL was significantly 
lower compared to VLP DNA with wild-type envelopes.  The introduction of the codon 
optimized env sequence from HIV-1JR-FL into the VLP DNA resulted in minimal protein 
expression (Figure 10, lane 2).  In contrast, the VLP DNA containing the codon 
optimized env sequence from HIV-1ADA or R2 expressed more viral proteins compared to 
pVLPcoJR-FL but considerably less compared to VLP DNA with wild-type envelopes.  The 
stark difference in protein expression between VLP DNA with wt or codon-optimized 
envelopes was demonstrated by analysis of 10 times the amount of sample for VLP DNA 
with codon-optimized Envs (Figure 10) compared to wt Envs (Figure 9 A and B).  In  
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Figure 11.  Expression of VLP vaccines containing codon-optimized env sequences.  
COS cells were transfected with 2 µg of each vaccine plasmid.  Samples were 
electrophoresis on a 10% SDS polyacrylamide gel.  (A)  Cell lysates (2.0%) and (B) 
supernatants (1.5%) were harvested and analyzed for protein expression.  Lane 1:  
pVLPcoADA, lane 2: pVLPcoJR-FL, and lane 3: pVLPcoR2. 
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addition, the exposure time of the immunoblots to the x-ray film was 15 times longer in 
the VLP DNA with codon-optimized Envs (Figure 10) compared to wt Envs (Figure 9 A 
and B).  In addition to reduced protein expression, Gagp160 was not detected in the cell 
lysates of cells transfected with pVLPcoADA and pVLPcoR2 (Figure 10, lanes 1 and 2). 
Therefore, these codon-optimized plasmids were not further characterized due to their 
aberrant protein expression.   
 
VLP vaccines containing two copies of the MPMV CTE 
 A VLP DNA vaccine containing two copies of the MPMV CTE was constructed 
to increase expression of viral proteins and induce VLP production in murine cells.  Two 
copies of the MPMV-CTE were added to the 3’ end of pVLPADA.  In murine cells (NIH 
3T3), pVLPADA/2xCTE expresses more viral proteins compared to pVLPADA (Figure 11, 
lane 3, 2). Neither of these vaccine constructs produces VLPs in murine cells.     
 
Protein expression of SHIV VLP vaccines 
  VLP DNA vaccines expressing SIV Gag-Pol and HIV-1 Env, Vpu, Tat and Rev 
were constructed to test the immunogenicity of VLPs in a non-human primate 
vaccine/challenge model.  SHIV VLP DNA vaccines were analyzed for expression of 
lentiviral gene products.  Transfection of COS cells with pVLPSHIV/ADA and 
pVLPSHIV/ADA/∆RT resulted in the expression of proteins that were detected in the cell 
lysates and supernatants (Figure 13).  Similar to the protein expression pattern of 
pVLPADA  and pVLPADA/∆RT, multiple Gag gene products were detected (Gag-Polp160, 
Gagp55 Gagp41 and Gagp27).  In  addition, the RT-deficient SHIV  VLP (pVLPSHIV/ADA/∆RT)  
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Figure 12.  Expression of VLP vaccines in murine cells.   
NIH 3T3 cells were transfected with 2 µg of each vaccine plasmid.  Samples were 
electrophoresis on a 10% SDS polyacrylamide gel.  (A)  Cell lysates (4.0%) and (B) 
supernatants (5.0%) were harvested and analyzed for protein expression.  Lane 1:  
pTR600, lane 2: pVLPADA, and lane 3: pVLPADA/2xCTE. 
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Figure 13.  Expression of SHIV VLP vaccine constructs in vitro.   
COS cells were transfected with 2 µg of each vaccine plasmid.  Samples were 
electrophoresis on a 10% SDS-PAGE (A) 5.0% of cell lysate and (B) 5.0% of 
supernatant) were electrophoresed on a 10% SDS polyacrylamide gel and proteins were 
detected by western blot analysis (SIV Ig, 1:10000).  (A) Lane 1:  pTR600 vector; lane 2: 
pVLPR2; lane 3: pVLPR2/∆RT; lane 4, empty; lane 5: pVLPSHIV/ADA; lane 6, 
pVLPSHIV/ADA/∆RT.  (B)  Lane 1:  pTR600 vector; lane 2: pVLPR2; lane 3: pVLPR2/∆RT; 
lane 4, empty; lane 5: pVLPSHIV/ADA; lane 6, empty; lane 7, pVLPSHIV/ADA/∆RT.  SIV and 
HIV proteins are indicated on the left.      
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expressed more proteins compared to SHIV VLP with RT (pVLPSHIV/ADA).  These results 
concur with the protein levels observed with the corresponding HIV VLP vaccines.    
 
Particle formation of HIV and SIV VLP without RT 
 The sequence encoding for RT was removed in the VLP DNA vaccines to 
enhance particle production.  This smaller VLP insert may also be used in a viral vector 
system.  Particles were purified from the supernatants of transiently transfected cells 
(pVLPR2/∆RT, pVLPSHIV/ADA and pVLPSHIV/ADA/∆RT) by ultracentrifugation (20-60% 
sucrose gradient) and collected fractions were analyzed for particle composition and 
stability.  Supernatants from cells transfected with DNA expressing VLPs contained 
particles that banded between 32-40% sucrose (1.14-1.18g/cm3) (Figure 14) similar to 
pVLPR2 (Figure 12A).  Gagp55, Gagp41 and Gagp24/p27 were readily detectable in each of 
these fractions.  Particles produced from pVLPR2/∆RT and pVLPSHIV/ADA/∆RT banded in a 
sucrose gradient similar to wild-type virions (Figure 14), whereas particles were not 
detected for pVLPSHIV/ADA.  Interestingly, the overall amount of Gag gene products was 
higher for pVLPADA/∆RT compared to pVLPADA.  
 
Accessory protein activity 
Rev activity was not measured directly, but was observed as a result of structural 
HIV-1 antigen expression and particle formation.  VLPs secreted into the supernatant of 
transfected cells indicate that Rev actively promoted the cytoplasmic accumulation of 
mRNA transcripts encoding for structural gene products 119.  In addition, DNA 
expressing infectious virions (pHIV-189.6) or VLPs (pVLPADA, R2, or 89.6) had similar levels 
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Figure 14. Sedimentation pattern of secreted viral proteins by sucrose density-
equilibrium gradient analysis of RT-deficient VLPs.   
Supernatants from COS cells transiently transfected with (A) pVLPR2/∆RT or (B) 
pVLPSHIV/ADA/∆RT was concentrated through a 20% glycerol cushion and then subjected to 
20-60% sucrose density-equilibrium gradient centrifugation.  Fractions were collected 
(ten 1 ml aliquots) from the top of the gradient.  Fractions were examined by western 
analysis.  Proteins were detected with (A) HIV-Ig or (B) SIV Ig (1:10000). 
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of Tat activity as observed directly using a SEAP reporter assay 118.  COS cells were 
transfected with DNA expressing infectious virions or VLP plus a reporter plasmid 
containing HIV-1 LTR-SEAP.  The level of Tat activation of the LTR was similar 
regardless of whether Tat was expressed from proviral DNA (pHIVADA) or DNA 
encoding VLPs (Table 7).  Therefore, DNA encoding VLP transcribed mRNA that 
efficiently expressed functional Tat and Rev.   
 
Envelope on the surface of HIV VLP binds the human CD4 molecule 
 VLPs expressed from DNA plasmid bound soluble CD4 (sCD4) (Figure 15).  
VLP secreted into the supernatant of COS cells were incubated with a soluble form of 
human CD4.  Each VLP, with Env89.6, EnvADA, or EnvR2 on the surface, bound sCD4 with 
similar efficiency to wild-type, infectious HIV-1 (Figure 15).  Only VLPs containing 
envelope, and not Gag-only particles, bound sCD4, indicating that the interaction was 
specific to particles incorporating Env.  In addition, cells transfected with a plasmid 
expressing HIV-1 ADA Envgp120 only did not bind to sCD4, because monomeric gp120 
was not able to transverse the 20% glycerol layer during purification.  Interestingly, even 
though EnvR2 on the VLP binds CCR5 independent of CD4, the EnvR2 on the surface of 
the VLP bound CD4 with equal efficiency as CD4-dependent envelopes.   
 
Anti-Gag antibodies elicited to the VLP DNA vaccines 
 The immunogenicity of the DNA expressing VLPs was initially determined in 
rabbits.  New Zealand white rabbits were vaccinated via intramuscular injection with 200 
µg of DNA at day 1 and boosted at weeks 6, 12 and 18.  Sera from the rabbits immunized  
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Table 7.  Induction of Tat activity. 
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Figure 15.  VLP binding to soluble human CD4.   
Culture supernatants from COS cells transfected with plasmid DNA were incubated with 
supernatants from cells expressing sCD4 for 4 h and then pelleted through a 20% sucrose 
cushion followed by western hybridization analysis.  Proteins were probed with rabbit 
polyclonal anti-hCD4 (1:3000).  Antibody bound protein was detected by goat anti-rabbit 
IgG (1:5000) and visualized by enhanced chemiluminescence.  Lane 1: pTR600 vector, 
lane 2: purified sCD4 control, lane 3: pGag-Polp160, lane 4: pVLP89.6, lane 5: pVLPR2, 
lane 6: pVLPADA, and lane 7: pHIV-189.6. 
 
 
 
 
 
 
 179
  
 
 
 
 
Figure 16.  Humoral response to VLP DNA in rabbits.   
Sera samples were collected from rabbits two weeks following the last immunization 
(week 20), and antibody responses were determined by western blot analysis.  Purified 
HIV-1SF2 p55 Gag protein was electrophoresed through a SDS polyacrylamide gel and 
detected by anti-Gag antibodies in HIV-1-infected human (1:3000) or rabbit (1:1500) 
sera samples.  Lane 1, HIV Ig (sera from a patient infected with HIV-1, positive control); 
lane 2, pTR600; lane 3, pVLP89.6 (rabbit #1); lane 4, pVLP89.6 (rabbit #2); lane 5, 
pVLP89.6 (rabbit #3).     
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with the pVLP89.6 elicited antibodies that detected HIV-1 antigens (Figure 16).  The 
antisera from three rabbits vaccinated (#1-3) with the pVLP89.6 construct contained 
antibodies that detected Gagp55 protein by Western blot analysis, whereas vaccination 
with pTR600 did induce antibodies that detected Gagp55.  A similar approach was 
performed using purified Envgp120, however the antibody response to Env was below the 
level of detection.   
 
Anti-Env PBMCs elicited in rabbits vaccinated with VLP DNA 
 HIV-specific proliferation of PBMCs from vaccinated rabbits was performed to 
demonstrate the elicitation of anti-Env responses.  Rabbits were maintained for an 
additional 25 weeks after the last immunization and were assayed for anti-Env T-cell 
responses (Figure 17).  Isolated peripheral blood mononuclear cells from the vaccinated 
rabbits were re-stimulated in vitro with purified Env proteins.  None of the rabbits 
contained T-cells that proliferated in response to re-stimulation with either no antigen 
(mock) or the irrelevant protein (Measles F protein).  In contrast, the rabbits vaccinated 
with pVLP89.6 contained PBMCs that proliferated in response to re-stimulation with both 
HIVLAI and HIV-1Ba-L Envgp120 proteins, whereas, the rabbit that received pTR600 did not 
proliferate in response to the HIV antigens.   
 
IV.D. Discussion 
 
  In this study, molecular clones were constructed to express human 
immunodeficiency virus-like particles as potential vaccine candidates.  The composition  
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Figure 17. HIV-1 Env-specific proliferation of PBMCs in rabbits vaccinated with 
VLP DNA.  
Rabbits were vaccinated with pTR600 or pVLP89.6 (3 rabbits, #1-3) and assayed for anti-
Env T-cell responses at week 43 (25 weeks following the last boost).  PBMCs were 
isolated from rabbits and re-stimulated in vitro with mock protein, irrelevant protein 
(Measles F protein) or HIV-1LAI or BaL Envgp120 and pulsed with [3H]-thymidine (in 
triplicate).  The incorporation of [3H]-thymidine was given are the arithmetic mean ± the 
standard deviation (S.D.) for each rabbit.   
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of the expressed particle has properties that distinguish it from the many VLP for HIV-1 
currently in preclinical trials 71, 319, 389, 464, 719.  In several cases, HIV, as well as SIV, 
proteins were expressed from more than one plasmid, or the expressed particles were 
purified and used as the inoculum 82, 307, 715.  Lentiviral particles, expressed from a single 
DNA plasmid or from MVA and inoculated into non- human primates, elicited a broad 
immune response to the expressed antigens 14, 16.  The virus-like particles expressed from 
plasmids described in this report can be purified and used as an inoculum or the VLP can 
be expressed from DNA plasmid or viral vectors in vivo.  The genome of the VLP 
contains deletions encompassing the IN, vif, vpr, and nef genes, as well as the 5’ and 3’ 
long terminal repeats of HIV-1 (Figure 7).  The VLP was encoded by the HIV-1 gag, pol, 
vpu, env, rev, and tat gene sequences.  The deletion of integrase and each viral LTR 
inhibits the ability of any potential VLP or proviral DNA from inserting into host cell 
chromosomes 188.  The accessory genes (vpr, vif, and nef) have immunomodulatory 
effects on the immune system, which may be deleterious for HIV vaccine development 
and therefore were deleted.  VLP DNA efficiently expressed the structural gene products 
(Figure 9) and secreted particles into the supernatant of transiently transfected cells 
(Figure 12).  The regulatory proteins (Tat and Rev) were efficiently expressed and had 
similar levels of activity as proteins expressed from proviral DNA (Table 1).   
VLP vaccines were constructed that contained a substitution in the region 
encoding for env.  DNA gene segments encoding for env, as well as tat, rev, and vpu, 
were cloned into the VLP DNA backbone (Figure 7).  The env gene segments were 
cloned from one R5X4 (89.6) and two R5 isolates (ADA and R2).  The ADA, along with 
the original 89.6 env genes, were selected for two reasons:  1) each envelope is currently 
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being used by several research groups for HIV vaccine development and therefore would 
be useful for comparison of elicited immune responses, and 2) X4 envelopes, such as the 
Env derived from the HIV-1BH10 or HIV-1IIIB isolates, are more sensitive to neutralizing 
antibody compared to primary R5 isolates 116, 437.  The EnvADA is a particularly difficult 
envelope to neutralize, and therefore vaccine strategies that elicit neutralizing antibodies 
using VLP expressing this envelope may elicit a broader immune response to a diverse 
set of HIV-1 isolates.  EnvR2, cloned from a patient isolate (HNS2), can be neutralized by 
sera from patients infected with HIV-1 from clades A, B, C, D, and F, as well as CRF 524 
and therefore was selected for use as an Env immunogen in the VLP.  Virions 
pseudotyped with the EnvR2 can mediate CD4-independent infection.  In addition, these 
viruses are sensitive to neutralization by a panel of monoclonal antibodies that recognize 
conformational epitopes in envelope 725, 727.  Recently, Dong et al. demonstrated that the 
EnvR2, expressed from a VEE replicon, elicited high titer neutralizing antibodies 151.  
Therefore, the 89.6, ADA, or R2 envelopes, incorporated on the surface of the VLP, each 
has advantages for enhancing the effectiveness of the VLP immunogen. 
Second and third generation VLP vaccines were also constructed.  VLP DNA 
vaccines containing codon-optimized sequences were produced to increase the expression 
of Env on the VLP surface.  However, codon-optimization of env sequences resulted in 
aberrant protein patterns (Figure 10).  The abnormal protein expression is most likely due 
to modification of splicing sites.  Therefore, the VLP vaccines containing codon-
optimized env sequences were not further characterized.  Next, a VLP DNA vaccine 
containing two copies of the MPMV CTE (2X CTE) was constructed to increase 
expression of viral proteins and induce VLP production in murine cells.  Under normal 
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circumstances wild-type HIV-1 or VLP DNA do not produce particles from 
infected/transfected murine cells.  Rabbits vaccinated with the VLP DNA elicited 
minimal responses to HIV antigens.  No anti-Env antibodies and minimal anti-Gag 
antibodies were detected in the sera of pVLP89.6-vaccinated rabbits.  However, Env-
specific proliferation of PBMCs from vaccinated rabbits was detected 25 weeks 
following the last vaccination.  In the vaccinated rabbits, the VLP DNA vaccine 
expressed viral proteins at low levels, but these proteins most likely did not assemble into 
particles.  So, a VLP DNA vaccine containing two copies of the MPMV CTE (2X CTE) 
was constructed to increase expression of viral proteins and induce VLP production in 
rodents/small animals.  The addition of 2X CTE to the HIV VLP resulted in an increase 
in protein expression in murine cells (Figure 11).  However, particles were still not 
detected from cells transfected with the HIV VLP with 2X CTE.  As an alternative, four 
tandem copies of the MPMV CTE may overcome the block in assembly and allow VLPs 
to be produced from murine cells.  This approach is currently under investigation.   
Also, SHIV VLP vaccines have been constructed to examine the immunogenicity and 
induction of protection of non-human primates from viral challenge.  The SHIV VLP 
vaccines express SIVmac239 Gag-PR-RT and Vpu, Env, Rev, and Tat from HIV-1R2.  Viral 
proteins were expressed from cells transfected with SHIV VLP DNA at levels 
comparable to the HIV VLP DNA (Figure 13).  Lastly, HIV and SHIV VLPs were 
constructed that had the sequence encoding for RT removed to enhance particle 
production.  Viral proteins were expressed and particles budded from cells transfected 
with HIV or SHIV VLP without RT (Figure 13 and 14).  These vaccines expressed viral 
proteins and produced particles similar o the VLP vaccine containing RT (Figure 12A).  
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Characterization of these SHIV VLP vaccines is still ongoing.  Unlike the VLP vaccines 
with RT, the RT-deficient VLP insert may be used in a viral vector system.  This 
modification allows the VLP immunogen to become more versatile, therefore allowing 
the VLP vaccine to be immunized in multiple forms or in a combination (DNA, viral 
vector, purified particles).            
One advantage of incorporating viral envelope glycoproteins on the surface of the 
VLP is the presentation of Env in a native conformation.  The inoculation of monomeric 
Envgp120 elicits high titer anti-Env antibody that does not prevent viral entry into 
susceptible cells.  Various approaches to construct soluble trimeric forms of Env that 
more closely mimic the native Envgp160 on the surface of virions have been employed.  
Soluble trimerized Envgp140, unstablized or stabilized with domains (GCN4 or the T4 
bacteriophage fibritin motifs or by disulfide linkers) 1, 51, 60, 563, 578, 710, 711 elicited modest 
levels of enhancement of neutralizing antibody compared to antibody elicited by 
monomeric forms of Env.  However, even though many of these approaches use a 
trimerized Env form, there are still distinct differences between soluble, trimerized Env 
and the structure of the native trimeric form of Env anchored on the surface of the virion.  
Therefore, the expression of Env in the context of a particle may prove advantageous for 
vaccine development. 
The potential of the VLP RNA to recombine with an HIV-1 genome in an 
infected patient could limit the use of this vaccine in humans.  Therefore, a third 
generation of VLP expressing plasmids was constructed that incorporated a variety of 
mutations to increase the safety of these vaccines for potential use in humans.  The VLP 
was modified to prevent 1) the packaging of RNA, 2) reverse transcriptase activity, and 
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3) the proteolytic processing of Gag-Pol polypeptides.  The first set of mutations, 
introduced into the NC coding region, disrupted the two zinc finger motifs 449.  The 
principal function of the NC involves the specific encapsidation of full length, unspliced 
(genomic) RNA into virions.  Introduction of serine residues at position 15 and 36 in the 
NC prevents the binding of zinc and disrupted zinc finger formation in the NC.  Previous 
studies have demonstrated severely restricted packaging of genomic RNA into both 
infectious virus as well as VLP incorporating these NC mutations 9, 173, 449. 
During the process of reverse transcription, the viral RNA is converted into 
proviral DNA in a series of defined steps 3, 193.  RT activity could have been eliminated 
by the deletion of the gene sequences encoding for RT.  However, at least seven epitopes 
in RT are immunogenic and are advantageous for eliciting anti-viral immunity 283.  The 
introduction of recombinant HIV-1 RT elicited high-titer CTL responses.  Therefore, we 
chose to disrupt RT activity without preventing the expression of this protein 173 and thus 
the presentation of RT epitopes to the immune system.   
The final mutation substituted an asparagine for aspartic acid residue at position 
25 in protease.  Previous studies showed that cells transfected with DNA expressing 
lentiviral VLP with a mutation at amino acid 25 in PR expressed a precursor molecule 
with high levels of unprocessed Gag proteins 173, 502, 602.  Nonetheless, this precursor 
molecule can be incorporated into a particle through its interactions with the capsid 
domain of Gag 282.  The viral protease, similar to other aspartyl proteases, such as renin 
and pepsin, contains the conserved asparagine-threonine-glycine sequence (protease 
amino acid positions 25-27) in the active site.  The initial critical step for autoprocessing 
of the Gag-Pol precursor protein is the folding and dimerization of this protein leading to 
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the formation of the active site.  A substitution of an asparagine residue at this position 
prevents this folding and therefore results in loss of enzymatic activity without an effect 
on protein structure, which allows for an accumulation of unprocessed Gagp55 and Gag-
Polp160 in the cell lysate and supernatants (Figure 12).  In addition, live virus particles that 
are expressed from proviral DNA and contain the PRD25N are non-infectious 25.   
VLP incorporating PRD25N had increased production of unprocessed Gag gene 
products (Figure 9E and F) and increased numbers of immature particles (Figure 12).  
The introduction of PRD25N into the VLP has several advantages for vaccine 
development.  VLP with PRD25N reduces the potential for cytotoxicity derived from 
proteolysis of cellular proteins. In addition, co-expression of proviral DNA and DNA 
expressing the PRD25N resulted in a dose-dependent decrease in particle maturation and 
infectivity 25.  Therefore, expression of these VLP vaccines in an infected patient could 
have the additional benefit of reducing the infectivity of the wild type virions.  Particles 
secreted from cells transfected with DNA expressing VLPD25N produced predominately 
unprocessed Gagpr55 and Gagp160 with little processed Gagp24 or Gag p17 (Figure 12).  
Infection with live virus results in virions containing Gag polyproteins that are 
fully processed during maturation post-budding.  These particles are mature and contain a 
dense capsid core with multiple viral proteins within the particle associated with the 
genome RNA.  In addition, human immunodeficiency virus-like particles are immature, 
contain mostly processed Gag gene products and have severely reduced levels of VLP 
RNA packaging 173.  In contrast, VLPD25N is composed of surface envelope on primarily 
unprocessed Gag-Polp160 and Gagp55 (Fig 12B).  Each of these various particles may have 
advantages for eliciting a broad range of immune responses.   
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These VLPs have distinct advantages for vaccine development.  First, the deletion 
of the viral LTR, integrase, vpr, vif, and nef sequences enhances the safety of the vaccine 
and reduces the immunomodulatory effects of the immunogen.  The introduction of 
mutations or deletions in RT and the NC further increases the safety of this vaccine by 
reducing the infectivity of these particles.  Most live or live-attenuated viruses contain 
viral RNA and are therefore replication-competent with the ability to produce 
pathogenesis in vaccinated hosts.  The lack of particle-encapsidated RNA and the 
inability of the vaccine insert to integrate into host chromosomes are advantages of this 
VLP vaccine.  A second advantage of this VLP is the gene products can be expressed 
from a single DNA plasmid.  The ability to characterize one DNA plasmid expressing the 
entire VLP reduces the potential regulatory and safety concerns associated with testing 
multiple DNA plasmids for prospective use in humans.  Third, VLPD25N produces 
particles with predominately unprocessed, higher molecular weight Gag gene products 
that may elicit higher levels of anti-HIV CTL responses compared to particles with fully 
processed Gag gene products.  Recently, it was demonstrated that splenocytes from mice 
vaccinated with particles composed of Gagp55 lysed a higher number of target cells 
presenting Gag peptides compared to cells from mice vaccinated with particles composed 
of Gag-Polp160 283.  Fourth, the inactivation of the viral protease may lead to markedly 
reduced shedding of gp120 250.  CD4 binding to Env increases shedding of Envgp120 from 
viral particles, and Envgp120 may also be shed from the VLP during the purification 
process 435.  Thus, VLPD25N has the added advantage of retaining Env and thereby 
increasing anti-Env immune responses.  Lastly, the VLPs described in this report have 
the added advantage of presenting Env epitopes to the immune system and therefore 
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eliciting both a broad spectrum antibody and cell-mediated immune response. 
An effective vaccine against HIV/AIDS will most likely need to elicit high levels 
of cross-reactive neutralizing antibodies in combination with a robust cell-mediated 
response against multiple viral antigens to protect from disease in an infected host.  One 
approach to achieve these goals is the development of a human immunodeficiency virus-
like particle.  In general, these particle-based strategies present multiple viral proteins in 
the conformation similar to the live virus without the safety issues associate with 
replication-competent virions.  Current virus-like particle vaccines are similar in nature to 
live-attenuated viruses, expressing both structural and enzymatic proteins.  The virus-like 
particle vaccine described in this study does not produce a productive infection or 
integrate into host chromosomes.  The non-replicative nature of this type of vaccine 
prohibits the particles from reverting or recombining with wild-type vRNA to produce to 
a pathogenic form.  The incorporation of additional safety mutations enhances the value 
of these vaccines for use in humans. 
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V.A. Introduction 
  
 Human immunodeficiency virus type 1 (HIV-1), similar to many other pathogens, 
is primarily transmitted at the mucosal surface.  Yet, the majority of experimental 
vaccines against HIV-1 have been inoculated parenterally.  Although an efficient 
systemic response develops, immunity at the mucosa after parenteral inoculation is 
negligible.  In contrast, mucosal immunization can induce immune responses at both 
local and distal mucosal sites as well as systemic immunity (For reviews see references 
100, 128, 372, 376).  An ideal HIV/AIDS vaccine will most likely need to elicit robust 
immunity against multiple viral antigens in both systemic and mucosal immune 
compartments 610.  
 The mucosal immune system is comprised of an integrated network of lymphoid 
cells that interacts with innate host factors to preserve the integrity of the host defense.  
HIV can infect Langerhans cells located in the pluristratified epithelial layer of the vagina 
or dendritic cells in the rectal cavity and transverse the intact epithelial barrier 100.  These 
dendritic cells have high expression of DC-SIGN which promotes the internalization of 
the virus 211, 277, 360, 481, 618, 685.  Consequently, HIV infects a substantial number of CD4+ 
T cells found in these tissues.  Eventually, this localized infection rapidly leads to 
widespread infection of the host.  In contrast to the viral load in the blood, treatment with 
antiviral drugs does not lower the viral titer in the rectal mucosa 147.  In addition, 
Langerhans cells in the epithelium and lamina propria in the vagina and rectal mucosa 
can act as reservoirs of viral infection 46, 147, 515.  
 Protection against mucosal pathogens is conferred by a combination of antibodies 
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(IgG and sIgA) and CTLs 35, 37, 67, 350, 368.  IgG and sIgA block HIV infection of 
susceptible cells 347.  These anti-HIV antibodies can prevent viral transcytosis across a 
mucosal monolayer 10, 54, neutralize virus infectivity 146, and mediate antibody-dependent 
cellular cytotoxicity 53.  Additionally, containment of viral replication by lysis of infected 
cells is achieved primarily by CTLs 424.  The number of antigen-specific cytotoxic CD8+ 
T cells in the lamina propria of the gut is directly proportional to the level of protection 
after mucosal viral challenge 35, 425, 466.  Therefore, augmentation of the immune response 
at the mucosa by mucosally-administered vaccines induces high titer anti-HIV immunity 
and is more likely to prevent viral infection and the establishment of viral reservoirs 
compared to vaccines inoculated parenterally.  
 A particle-based immunogen, such as a non-infectious virus-like particle (VLP), 
is a promising candidate for a safe and effective mucosal vaccine against HIV-1 13, 14, 16, 
76, 82, 151, 173, 399, 603, 712, 713, 715, 720.  VLPs or pseudovirions can be defined as self-
assembling, non-replicating, non-pathogenic, genomeless particles that are similar in size 
and conformation to intact infectious virions.  There are multiple combinations of viral 
proteins that may be used to generate VLPs, however, they must contain Gag gene 
products in order to undergo the assembly and budding process.  Envgp160 may also be 
processed and incorporated as trimeric spikes protruding from the surface of the particle.  
The VLP used in this study is expressed from a multi-gene DNA vaccine.  Unlike many 
other VLPs currently being used in AIDS vaccine research 44, 76, 82, 92, 283, 341, 376, 379, 471, 640, 
672-674, 712, 715, our multi-gene VLP DNA plasmid expresses Gag, Pol, Env, Vpu, Tat, and 
Rev gene products intracellularly and secretes VLPs extracellularly from a single gene 
insert 720.  
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 The multi-gene VLP vaccine approach described in this study has several 
advantages compared to live-attenuated virus or single gene vaccines.  These VLPs:  1) 
do not integrate into host genomes 720, 2) express multiple viral epitopes that have the 
potential to stimulate a diverse set of immune responses, 3) have point mutations 
introduced into the VLP genome to abrogate reverse transcriptase and RNase H activity 
395, 449, as well as to restrict viral RNA packaging 25, 368, 707, and 4) have the potential to 
bind and enter cells expressing appropriate receptors such as macrophages and dendritic 
cells.  In addition, cell-free VLPs bound with antibodies can be phagocytized by 
macrophages and dendritic cells via Fc receptors, thus enhancing MHC class II 
presentation of viral antigens.   
 In this study, mice were intranasally vaccinated with purified VLPs alone or co-
inoculated with CpG ODNs.  Anti-Env antibodies were detected in both the sera and 
mucosa.  In addition, anti-Env and anti-Gag splenocytes were induced in vaccinated 
mice.  Mice co-vaccinated with VLPs plus CpG ODNs had significantly enhanced 
cellular and humoral responses to HIV antigens.  In conclusion, systemic and mucosal 
immune responses to HIV-1 are enhanced by intranasal immunization of purified virus-
like particles expressed from a virally-regulated multi-gene DNA vaccine.      
 
V.B. Material and Methods 
 
DNA Plasmids 
The plasmids, pVLPADA and pVLPR2, express VLPs and have been previously 
characterized 720.  Briefly, each VLP is expressed from sequences including:   HIV-1BH10 
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gag-pol (pHIVBH10 nt 112-3626) and HIV-1ADA or R2 vpu, env, rev, tat (pHIVBH10 nt 5101-
8159).  Both the 5’ and 3’ LTRs have been deleted along with the sequences encoding for 
IN, Vpu, Vif, and Nef.  Mutations were introduced into the gag and pol genes to inhibit 
reverse transcriptase activity, RNase H activity, strand transfer, and to restrict viral RNA 
packaging 720.  Each VLP is efficiently secreted from primate cells.  The plasmid, 
pVLP2xCTE, is derived from pVLPADA.  Two copies of MPMV CTE and 200bp of 
nonsense sequence was molecularly cloned into pVLPADA using unique restriction sites, 
NheI and SacII. 
 
Transfections and expression analysis 
Monkey (COS) or murine (NIH 3T3) fibroblastic cell lines (5 X 105 
cells/transfection), were transfected with DNA (2 µg) using lipofectamine (12%) 
according to the manufacturer’s guidelines (Life Technologies, Grand Island, NY, USA).  
Supernatants (2 ml) and cell lysates (300 µl dH2O) were collected and stored at -20°C.  
For Western blot analysis, samples were diluted 1:2 in SDS sample buffer (Bio-Rad, 
Hercules, CA, USA), boiled (5 min), and loaded onto a 10% polyacrylamide/SDS gel.  
The resolved proteins were transferred onto a PVDF membrane (Bio-Rad, Hercules, CA, 
USA) and incubated with polyclonal human HIV-infected patient antisera (HIV-Ig) 
(1:10,000 in PBS containing 0.05% Tween 20 and 5% non-fat dry milk).  After extensive 
washing, bound human antibodies were detected with horseradish peroxidase-conjugated 
goat anti-human antiserum (1:10,000 in PBS containing 0.05% Tween 20 and 5% non-fat 
dry milk) and enhanced by chemiluminescence (Amersham, Buckinghamshire, UK). 
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Purification of virus-like particles.   
 Supernatant from COS cells, transiently transfected with VLP-expressing DNA, 
were pelleted (2 h at 4°C) via ultracentrifugation (100,000 x g through 20% glycerol, 
weight per volume).  The pellets were subsequently resuspended and used for 1) in vivo 
inoculation or 2) sucrose gradient utltracentrifugation.  Pellets used for immunization 
were resuspended in sterile PBS.  Total protein concentration was determined by the 
Micro BCA Protein Assay Kit (Pierce, Rockford, IL, USA).  In addition, the level of non-
HIV protein contamination (from the media/cells) in each inoculum was visualized by a 
silver-stained SDS-PAGE using the ProteoSilver Silver Stain Kit (Sigma, St. Louis, MO, 
USA).  The specificity of each inoculum was analyzed in a separate immunoblot with 
HIV Ig as described earlier.    
Pellets were analyzed for particle formation by resuspending the material in PBS 
and overlaid onto 20-60% sucrose gradients (11 steps, 4% increments) and 
ultracentrifuged (17 h at 100,000 x g at 4°C).  Eleven fractions (20-60% sucrose, 1 ml, 
weight per volume in PBS) were collected (top to bottom) from the gradient, and the 
proteins were precipitated with equal volumes of 20% TCA and subjected to SDS-PAGE 
and immunoblotting.  The viral proteins were detected by HIV Ig via western blot and 
visualized by enhanced chemiluminescence.  In addition, the purity of each VLP 
preparation in each inoculum was visualized by a silver-stained polyacrylamide SDS gel. 
 
Immunization of mice 
Female BALB/c mice (5–7 weeks old) were immunized at weeks 0, 3, and 6 with 
purified VLPs (40 µg total protein) alone or co-inoculated with phosphorothioate CpG
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oligodeoxynucleotides (CpG ODNs, 10 µg each) via the nares.  Each CpG ODN (ODN-
1:  5'-TCCATGACGTTCCTGACGTT-3', ODN-2:  5'-
TGACTGTGAACGTTCGAGATGA-3') 203, 274, 307, 308, 428, 451 was synthesized and 
purified by high-pressure liquid chromatography (Sigma-Genosys, The Woodlands, TX, 
USA).  The CpG ODNs were resuspended in sterile dH2O (2µg/ul) and stored at -80°C.  
Mice were administered VLPs in sterile PBS +/- CpG ODNs into the nares of each mouse 
(40 µl total volume).  Supernatants from primate cells transiently transfected with the 
vector, pTR600, were ultracentrifuged through 20% glycerol.  The pellet was 
resuspended in sterile PBS +/- CpG ODNs and inoculated into the naïve mice (equivalent 
volume compared to mice given a VLP inoculum).  Mice were housed in compliance 
with U.S.D.A. regulations and were monitored daily for weight loss, behavior, and 
adverse reaction.  Mice were partially anesthetized with xylazine (20 mg/ml) and 
ketamine (100 mg/ml) administered subcutaneously in the abdomen prior to 
immunization. 
 
Collection of samples 
Blood samples were collected by retro-orbital plexus puncture on day 1 and 
weeks 5 and 8 post-immunization on anesthetized mice.  Sera samples were collected by 
centrifugation (5,000 rpm, 10 mins) and stored at -80°C.  Collected sera were stored in a -
20°C freezer.  Mucosal washings were collected at week 9 post-immunization.  Vaginal 
lavages were collected by repeated rinsing of the vagina (200 µl) with sterile PBS.  The 
lungs were excised and cut into small pieces using a sterile scalpel in sterile PBS (200 
µl).  The lung tissue pieces were centrifuged (12,000 rpm, 5 min), and supernatants were 
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collected.  A section of the intestines (1.3 cm) was aseptically removed and placed in 
sterile PBS (200 µl).  The collected fecal samples were disrupted using a sterile pipette 
tip, vortexed (15 sec), centrifuged (12,000 rpm for 5 min), and the product supernatants 
were collected.  The protein concentration of the fecal supernatants was adjusted to a 
final concentration of 1 mg/ml with sterile PBS.  All samples were stored at -80°C. 
 
Antibody responses to VLP immunizations   
Serum and mucosal samples were individually collected and tested for antibody 
responses to Env by ELISA.  Supernatants collected from 293T cells transiently 
transfected with a plasmid that expressed Envgp120 from either HIV-1ADA (pcoEnvADA) or 
HIV-1R2 (pcoEnvR2).  Each well of a 96-well plate was coated with culture supernatant 
(50 ng Envgp120 per well) (4°C for 16 hr).  Plates were blocked (25°C for 2 hr) with PBS 
containing Tween 20 (0.05%) and nonfat dry milk (5%) and then incubated with serial 
dilutions of each sample (sera or mucosal washings) (25°C for 2 hr).  Following thorough 
washing in PBS-Tween 20 (0.05%), samples were incubated (25°C for 1 hr) with 
biotinylated goat anti-mouse IgG (1:5,000) diluted in PBS-Tween 20 (0.05%) and nonfat 
dry milk (5%).  The unbound antibody was removed, and the wells were washed.  
Strepavidin-HRP (1:7,000) was diluted in PBS-Tween 20 (0.05%) and incubated (25°C 
for 1 hr).  Samples were incubated with TMB substrate (1 hr), and the colorimetric 
change was measured as the O.D. (450nm) by a spectrophotometer (Dynex Technologies, 
Chantilly, VA, USA).  The O.D. value of naïve sera and sera from mice vaccinated with 
virus-like particles composed of only Gag gene products (no Env) was subtracted from 
the samples using antisera from vaccinated mice.  Results were recorded as the arithmetic 
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mean ± the S.D.  The endpoint titer was expressed as the inverse of the dilution of the 
well that was equal to the well that did not receive serum sample.   In order to measure 
the level of HIV-1 Env-specific IgG subtypes, biotinylated goat anti-mouse IgG1 or IgG2a 
(1:5,000) antibodies were used to detect Env-antibody complexes.  Results are given as 
the ratio of the endpoint titers of IgG2a to IgG1.   
Antisera from vaccinated mice were tested for the ability to neutralize virus 
infection in vitro using TZM-Bl cells indicator cells 452.  These cells express human CD4 
(hCD4), human CCR5 (hCCR5) and human CXCR4 (hCXCR4) and a luciferase reporter 
driven by the HIV-1 LTR. TZM-Bl cells were cultured in cDMEM.  Infectivity was 
determined using serial dilutions of antisera with cells in complete, non-selective media 
in the presence of DEAE dextran (20 µg/ml) (25°C for 1hr).  Cells were harvested in lysis 
buffer (25mM Tris phosphate, pH=7.8, 2mM DTT, 2mM 1-2-diaminocyclohexane-N, N, 
N', N'-tetraacetic acid, 10% glycerol, 1% Triton X-100) (48 h) and then clarified by 
centrifugation.  The lysates were mixed with luciferase substrate (2 mg/ml) (20µl each).   
Virus neutralization by mouse antisera was determined in triplicate by measuring the 
RLUs using a Femtomaster FB12 Luminometer (Zylux, Maryville, TN).  Neutralization 
by naïve sera and sera from mice vaccinated with virus-like particles composed of only 
Gag gene products (no Env) was subtracted from the RLU from assays using antisera 
from vaccinated mice.   
 
 Cell-mediated immune responses to VLP antigens 
Spleens were harvested from vaccinated mice at week 9, and splenocytes were 
isolated.  Splenocytes were depleted of erythrocytes by treatment with ammonium 
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chloride (0.1 M, pH 7.4).  Following thorough washing with PBS, cells were resuspended 
in RPMI medium with 10% fetal bovine serum (cRPMI).  Cell viability was determined 
by trypan blue exclusion staining.  The number of anti-Gagp24 or anti-Envgp160 specific 
murine INF-γ (mINF-γ) secreting splenocytes was determined by ELISPOT assay (R & D 
Systems, Minneapolis, MN, USA).  Briefly, pre-coated anti-mIFN-γ plates were 
incubated (25°C for 2 hr) with cRPMI (200 µl) and then were incubated with splenocytes 
(1 X 106/well) isolated from vaccinated mice.  Splenocytes were stimulated (48 hrs) with 
peptides representing the HIV-1 Gagp24 (HIV-1 consensus B Gag: 
GHQAAMQMLKETINE and AMQMLKETINEEAAE) or Envgp160 (NA consensus: 
KSIHIGPGRAFYTTG and B-subtype isolate: KSIPMGPGKAFYATG).  Additional 
wells of splenocytes were stimulated with PMA (50 ng)/ionomycin (500 ng) or were 
mock stimulated.  In addition, IL-2 was added to all wells (10 units/ml).  Plates were 
washed with PBS-Tween (3X) and were incubated (25°C for 2 hr) with biotinylated anti-
mIFN-γ and incubated (4°C for 16 h).  The plates were washed and incubated (25°C for 
2 hr) with strepavidin conjugated to alkaline phosphatase.  Following extensive washing, 
cytokine/antibody complexes were incubated (25°C for 1 hr) with stable BCIP/NBT 
chromagen.  The plates were rinsed with dH2O and air dried (25°C for 2 hr).  Spots were 
counted by an ImmunoSpot reader (Cellular Technology, Cleveland, OH, USA).  
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V.C. Results 
 
Construction of vaccine plasmids 
 Each VLP vaccine plasmid has been constructed and characterized in Chapter IV  
720.  Briefly, each plasmid encodes for the Gag and Pol gene products using sequences 
from HIV-1BH10 and Env, Vpu, Tat, and Rev from sequences isolated from two strains, 
HIV-1ADA or HIV-1R2 (Figure 7).  Sequences encoding IN, Vif, Vpr, and Nef were 
deleted, as well as sequences representing the LTRs.  Lastly, safety mutations were 
introduced in the VLP genome to abrogate the encapsidation of viral RNA 395 and RNase 
H and RT activity 95, 368, 448, 707. 
 
In vitro expression and particle purification of virus-like particles 
Expression of virus-like particles from each DNA plasmid was verified in primate 
(COS) or rodent (NIH 3T3) cell lines (Figure 18A).  Gag and Pol gene products were 
detected in both the supernatant and cell lysates from transiently transfected primate 
cells.  Murine cells transfected with VLP expressing DNA had Gag and Pol gene 
products in the cell lysate fraction, but no HIV-1 proteins were detected in the cytoplasm 
consistent with expected block in HIV-1 assembly in murine cells.  Particles were 
purified from the supernatants of transiently transfected COS cells by ultracentrifugation 
(20-60% sucrose gradient), and collected fractions were analyzed for particle 
composition and stability.  VLPs banded in sucrose fractions (32-40% sucrose, 1.14-
1.18g/cm3) (Figure 18B), in the same fractions as previously described for wild-type 
virions 145, 671.   
 201
 
 
Figure 18.  Expression of viral proteins in primate and rodent cells.   
(A)  Protein expression of VLP DNA.  COS and NIH 3T3 cells were transfected with 2ug 
of each vaccine plasmid and protein expression was analyzed by western blot analysis.  
Lanes 1, 3, 5, and 7: pVLPADA and lanes 2, 4, 6, and 8: pVLPR2.  Lanes 1-4: 3.3% cell 
lysates and lanes 5-8: 1.5% of supernatants.  (COS, monkey fibroblasts and 3T3, NIH 
3T3 murine fibroblasts; LYS, cell lysate and SUP, supernatant)  (B) Virus-like particle 
production by sucrose density gradient ultracentrifugation.  Supernatants from COS cells 
transiently transfected with VLPR2 DNA were concentrated through a 20% glycerol 
cushion and then subjected to 20-60% (w/v) sucrose density gradient-equilibrium 
gradient ultracentrifugation.  Fractions were collected from top to bottom, precipitated 
with 10% TCA, and proteins were detected by western blot analysis.  Percent of sucrose 
fraction is located at the top of each lane.   
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Effectiveness of particle purification process 
 Samples from each step during the purification process were analyzed for the non-
HIV proteins (Figure 19).  Samples from different time points were electrophoresed on a 
10% SDS polyacrylamide gel and silver stained.  Supernatants from COS cells 
transfected with pTR600 contained an enormous amount of non-HIV protein following 
the clarification process (centrifugation and 0.22 µm filter) (0.1% of sample) (lane 3).  
After supernatants were concentrated through a 20% glycerol cushion, there was a 
precipitous drop in non-HIV proteins detected (>99% non-HIV proteins in supernatant 
did not transverse the 20% glycerol) (100% of sample) (lane 4 verses lane 3).  After the 
samples were subjected to 20-60% sucrose density-equilibrium gradient 
ultracentrifugation, non-HIV proteins were below the level of detection (100% of 
fractions 32-44%) (lane 5).      
 
Elicitation of anti-Env antibody responses 
Mice (BALB/c) were vaccinated intranasally with purified VLPs (20 µg of total 
protein per nare) alone or co-immunized with CpG ODNs (10 µg) at day one and weeks 3 
and 6.  Mice vaccinated with VLP plus CpG ODNs elicited higher serum titers (> 1 log) 
of anti-Env antibodies than mice vaccinated with VLP alone (Figure 20A), which 
continued to rise following the third inoculation (week 8).  Mice vaccinated with VLP 
plus CpG ODNs had statistically higher anti-Env titers (1:10,000-50,000) than mice 
vaccinated with VLP only (1:900-4,500) (Figure 20B).  Additional mice were vaccinated 
with 10 µg of purified, soluble HIV-1ADA trimers (+/- 10 µg CpG ODNs) as a positive 
control, and the anti-Env endpoint titers were 1:1920 and 1:696320, respectively.  There  
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Figure 19.  Effectiveness of the particle purification process.   
COS cells (T75 flask) were transfected with TR600 (5 µg).  Supernatant (10 ml cDMEM) 
was concentrated through a 20% glycerol cushion and then subjected to 20-60% sucrose 
density-equilibrium gradient centrifugation.  Fractions were collected (ten 1 ml aliquots) 
from the top of the gradient.  Samples from different timepoints during the purification 
process were electrophoresed on a 10% SDS polyacrylamide gel and silver stained.  Lane 
1:  protein marker; lane 2, empty; lane 3, 0.1% of supernatant from cells transfected with 
pTR600; lane 4: 100% of 20% glycerol pellet; lane 5, 100% of 32-44% sucrose fractions. 
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Figure 20.  Anti-Env antibodies elicited by VLP-vaccinated mice.   
(A) Time course of total serum IgG specific to Env for pooled serum samples.  Mice 
were mock vaccinated or with VLPs alone +/- CpG ODNs.  Serum samples were 
collected prior to immunization (week 0) and two weeks after each vaccination (weeks 2, 
5, and 8).  Anti-Env antibodies were detected by ELISA.  (B)  Total serum IgG for 
individual mice two weeks after final boost.  (C)  IgG isotypes were detected two weeks 
after final boost.  Results are given as a ratio of endpoint titers of IgG2a to IgG1.  
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(A) Time course of total serum IgG specific to Env for pooled serum samples.  Mice 
were mock vaccinated or with VLPs alone +/- CpG ODNs.  Serum samples were 
collected prior to immunization (week 0) and two weeks after each vaccination (weeks 2, 
5, and 8).  Anti-Env antibodies were detected by ELISA.  (B)  Total serum IgG for 
individual mice two weeks after final boost.  (C)  IgG isotypes were detected two weeks 
after final boost.  Results are given as a ratio of endpoint titers of IgG2a to IgG1.  
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was no rise in non-specific antibodies in naïve mice or mice vaccinated with CpG ODNs 
only.   The class of immunoglobulin elicited in the vaccinated animals differed depending 
if the mice were vaccinated with VLPs alone or co-inoculated with CpG ODNs (Figure 
20C).  Mice vaccinated with VLP plus CpG ODNs had higher IgG2a titers compared to 
IgG1, indicating a T helper type 1 immune response.  Whereas, mice vaccinated with 
VLPs only had similar IgG1 and IgG2a titers, indicating a mixed T helper immune 
response.  In contrast, the mice vaccinated with purified, soluble HIV-1ADA trimers had 
higher titers of IgG1 compared to IgG2a.  Interestingly, a Th2 response was also observed 
in mice vaccinated with purified, soluble HIV-1ADA trimers plus CpG ODNs.
Anti-Env antibodies were also detected in mucosal immune compartments.  The 
lung tissue of mice vaccinated with VLP had anti-Env antibodies, which were 
independent of CpG ODN co-inoculation (Table 8).  The anti-Env titers ranged between 
1:102-1:103 in the lungs of mice vaccinated with VLP only and 1:103-1:104 in the lungs of 
mice vaccinated with VLP plus CpG ODNs.  Also, anti-Env antibodies were detected in 
distal mucosal tissues, such as the intestine and the vagina, albeit at lower titers compared 
to the titers detected in the lungs (Table 8).  Lastly, mucosal anti-Env antibodies were 
detected in the lungs, vagina and intestine of mice vaccinated with purified, soluble HIV-
1ADA trimers alone (1:348, 1:24 and 1:24, respectively) or co-inoculated with CpG ODNs 
(1:16826, 1:496 and 1:56, respectively). 
 Sera were examined for the ability to neutralize virus infection in vitro 452.  Mice 
vaccinated with VLPR2 (+/- CpG ODNs) or HIV-1ADA Env trimers (+ CpG ODNs) were 
able to neutralize HIV-1MN infection (Table 9).  Antisera from mice vaccinated with 
VLPR2 +/-  CpG ODNs  (62% and 55%, respectively)  or  HIV-1ADA Env trimer plus CpG  
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Table 8.  Anti-Env antibodies elicited by VLP and Env trimers in mucosal tissues†. 
 
 
Vaccine group Lungs† Vagina Intestine 
VLPADA 683 ± 347 8 ± 0 8 ± 4 
VLPADA + CpG 3678 ± 410 34 ± 10 56 ± 18 
VLPR2 274 ± 63 8 ± 0 8 ± 4 
VLPR2 + CpG 1784 ± 256 28 ± 10 40 ± 9 
TrimerADA 658 ± 356 14 ± 4 27 ± 8 
TrimerADA + CpG 54877 ± 23229 1170 ± 376 82 ± 42 
 
†Results from mucosal samples from naïve mice were normalized to zero and the results 
from the immunized mice were given as the fold increase over naïve samples.   
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Table 9.  Neutralization  of HIV-1MN  by  anti-Env antibodies elicited  by  vaccinated  
                mice. 
 
      
Percentage of virus neutralization†
Vaccine group 
1:20∗ 1:40 1:80 1:160 
VLPADA 19 3 45 19 
VLPADA + CpG 22 30 26 26 
VLPR2 37 23 62 41 
VLPR2 + CpG 25 14 55 30 
EnvADA trimer 12 0 0 0 
EnvADA trimer + CpG 46 43 49 47 
 
†Results from individual sera samples from naïve mice were normalized to zero 
neutralization.  ∗The percentage of virus neutralization was determined multiple dilutions 
(1:20, 1:40, 1:80 and 1:160).  Sera from vaccine groups exhibiting >50% virus 
neutralization are shaded.      
 209
 
 
Figure 21.  HIV-1 Gag and Env peptide-specific T-cell response after immunization 
of mice with VLPs.   
BALB/c mice were immunized intranasally with VLPs +/- CpG ODNs or mock 
vaccinated.  Two weeks after the final boost, splenocytes were prepared and stimulated 
with (A) HIV-1 Envgp120(V3 loop) or (B) Gagp24 peptides.  HIV-specific IFN-γ production 
was detected by an ELISPOT assay.  As a negative control, cells from naïve mice 
produced none or less than 7 spots per 1 million splenocytes.  The number of background 
spots was subtracted from the number of spots in the sample wells (<5 spots per 1 million 
splenocytes).  Error bars, SEs for 5 mice in a group.  The statistical significance of the 
difference between groups was calculated by Student’s t test. 
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ODNs (49%) neutralized >50% of HIV-1MN (1:80 dilution).  In contrast, the mice 
vaccinated with VLPADA (+/- CpG ODNs) or HIV-1ADA Env trimers alone did not elicit 
neutralizing antibodies at the examined dilution of sera. 
 
Cellular immune response elicited by VLPs 
 Mice vaccinated with VLP plus CpG ODNs elicited higher numbers of INF-γ  
secreting cells compared to mice vaccinated with VLP only (Figure 21).  Splenocytes 
collected from mice vaccinated with VLP plus CpG ODNs had a higher number of 
cytokine secreting cells following stimulation with a set of MHC class I restricted (V3 
loop)  peptides  compared  to   mice  vaccinated  with  VLP   alone  (Figure  21A).   Mice 
vaccinated with purified, soluble HIV-1ADA trimers alone or co-vaccinated with CpG also 
elicited splenocytes secreting IFN-γ following stimulation with the same V3 loop 
peptides (13 and 101 spots/106 splenocytes, respectively).  In comparison, splenocytes 
stimulated with the peptides specific for Gagp24 collected from mice vaccinated with VLP 
plus CpG ODNs had 3 times the number of INF-γ  secreting cells as mice vaccinated with 
VLP alone (Figure 21B).  Naïve, age-matched mice, as well as unstimulated splenocytes 
from mice vaccinated with VLP +/- CpG, had few INF-γ secreting splenocytes (0-7 
spots) following in vitro re-stimulation with either set of peptides. 
 
V.D. Discussion 
 
In   this   study,   mice    were    inoculated   intranasally   with    purified    human  
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immunodeficiency virus-like particles.  VLPs were purified via transient 
transfection of COS cells followed by ultracentrifugation through 20% glycerol (Figure 
19).  Each VLP elicited specific immunity to HIV-1 antigens in both the systemic and 
mucosal immune compartments.  Anti-Env antibodies were detected in the sera (Figures 
20A and B), as well as in the washes from harvested lungs, intestines, and vagina from 
immunized mice (Table 8).  In addition, Env and Gag specific IFN-γ-secreting 
splenocytes were elicited in the mice vaccinated with VLPs (Figure 21).  Co-inoculation 
of CpG ODNs with VLPs significantly enhanced both sets of the immune response.  
Additional mice were intranasally vaccinated with a high dose of purified, soluble HIV-
1ADA trimers (+/-) as a positive control.  These mice elicited strong humoral and cellular 
responses when co-immunized with CpG ODNs, but minimal responses were detected in 
mice vaccinated with purified, soluble HIV-1ADA trimers alone.  In contrast to the VLP-
vaccinated mice, the main IgG isotype detected in the mice immunized with purified, 
soluble HIV-1ADA trimers was IgG1 regardless if CpG ODNs were co-inoculated.         
Virus-like particles, or pseudovirions, can be defined as self-assembling, non-
replicating, non-pathogenic, genomeless particles that are similar in size and 
conformation to intact virions.  These immunogens can be administered as purified 
particles or as DNA plasmids expressing the viral proteins to form VLPs in vivo (for 
reviews, see references 149, 719).  Several experimental vaccines for HIV/AIDS use a 
multi-gene strategy to elicit immunity, however, these vaccines do not produce VLPs 
with Env embedded in the particle membrane 326-328, 383, 384, 468.  Many of the lentiviral-
like particles currently under investigation utilize the recombinant vaccinia virus (VV) or 
baculovirus (BV) systems for particle purification 81, 82, 210, 245, 487, 666, 667, 714.  Cellular and 
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humoral immune responses have been elicited using lentiviral VLPs produced from cells 
infected with rVV or rBV expressing SIV or HIV gag and env genes or cell lines stably 
expressing both genes 307, 308, 715.  However, these purification systems have limitations, 
which may limit their use.  Some of the advantageous characteristics of the HIV-1 multi-
gene VLP vaccine used in this study are the VLP:  1) induces both of humoral/cellular 
and systemic/mucosal immune responses, 2) is expressed from a virally regulated gene 
insert, 3) is a single plasmid composed of multiple gene products with native 
conformation(s) of surface envelope 563, 4) can transduce antigen presenting cells, 5) can 
be processed by these APCs for presentation of viral peptides on both class I and II MHC 
molecules, 6) glycosylation by primate rather than insect cells and 7) has increased safety 
due to the lack of replication competence.   
Each VLP was expressed from a single gene insert that contained gag, pol, env, 
vpu, tat and rev gene sequences 720.  In addition, each VLP is non-infectious due to the 
deletion of the sequences encoding IN, Nef, Vpr, and Vif and the LTRs (Figure 7) and 
720).  Several mutations were introduced into the VLP genomic DNA to abrogate reverse 
transcriptase and RNase H activities and to restrict RNA packaging to increase the safety 
of these immunogens for potential use in humans.  Each VLP expressing DNA was 
transfected into both primate and mouse cell lines (Figure 19a), however, only primate 
cells secreted particles from cells.  Several reports have indicated that HIV-1 is unable to 
replicate in rodent cells, due to blocks in entry and fusion, integration, gene expression, 
nuclear transport, viral budding, and maturation (For review, see reference 648).  Not 
surprisingly, murine cells transfected with DNA plasmid expressing the VLP gene insert 
had little or no gene products in the lysate fraction and no particles were detected in the 
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supernatants of transfected cells (Figure 19b).  We introduced two tandem copies of the 
MPMV CTE 611, 613, 614 to the 3’ end of the VLP insert (VLP2xCTE).  Nuclear export and 
subsequent protein expression was enhanced in murine cells transfected with VLP2xCTE.  
However, no particles were detected in the supernatant indicating that the VLPs were still 
blocked from budding.   Therefore, a DNA vaccination strategy using these VLP 
expressing plasmids was not an option for in vivo particle secretion in mice.   
VLPs were purified from supernatants of monkey cells transiently transfected 
with VLP expressing DNA and used to vaccinate mice via intranasal inoculation for the 
elicitation of immune responses.  Anti-Env antibody titers rose after each vaccination.  
These anti-Env antibodies were elicited by envelope on the surface of the VLP, since free 
Env was filtered out during the purification process.  Free proteins, with a density of less 
than 1.081 g/ml, will not penetrate 20% glycerol purification during ultracentrifugation 
720, therefore, only Env, retained on the surface of the VLP, stimulated anti-Env 
immunity.  Even though envelope was detected on the surface of the purified VLP at very 
low levels (10 ng/ml) by ELISA, anti-Env antibodies were elicited by envelope on the 
surface of the VLP in vaccinated mice.  The elicited antibodies were specific for 
envelope, not against cellular monkey proteins embedded in the VLP membrane, since 
sera from mice vaccinated with Gag only particles (no envelope) elicited low levels of 
antibodies that cross-reacted with Env. 
Recent studies have indicated that uncleaved Gag gene products retain Env on the 
surface of a particle more efficiently than fully processed Gag molecules 250, 705, similar to 
these VLPs.  An uncleaved Gag particle core may enhance Env retention by providing 
conformational constraints on the ectodomain of the HIV-1 envelope glycoprotein, 
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leading to enhanced envelope stability 704.  In addition, these finding are supported by the 
detection of envelope on the surface of VLPs by electron microscopy using anti-Env 
immunogold staining of VLPs derived using similar expression systems 173, 174, 603.  In 
order to develop VLPs as a vaccine platform for Env presentation, the use of an immature 
particle cores to avoid Env loss may be advantageous.  In addition, the combination of 
enhanced stability with a highly immunogenic envelope that elicits broadly cross-
reactive, multi-clade immunity to native Env epitopes would advance AIDS vaccine 
development.   
The env gene segments were cloned from two R5 isolates (ADA and R2) into the 
VLPBH10 genome for their unique neutralization properties.  CXCR4 utilizing envelopes, 
such as the EnvBH10, are more easily shed from the particle surface and are more sensitive 
to neutralizing antibody compared to primary R5 isolates 116, 437 and therefore, they have 
not proven effective immunogens for AIDS vaccine development.  The EnvADA is a 
particularly difficult envelope to neutralize and therefore, vaccine strategies that elicit 
neutralizing antibodies using VLP expressing this envelope may elicit a broader immune 
response to a diverse set of HIV-1 isolates.  Only mice vaccinated with VLPR2 had 
neutralization titers (50% inhibition at a 1:80 dilution).  EnvR2 is a CD4-independent 
envelope that efficiently elicits neutralizing antibodies 151, 721.  However, the analysis of 
the neutralizing capacity of the elicited antibodies was compromised due to the well-
documented, non-specific neutralization components in mouse antisera 452, which 
affected our ability to measure the neutralization at lower dilutions.  Future studies using 
these VLPs in rabbits or non-human primates should yield more definitive results.   
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In addition to the induction of antibodies in the peripheral immune system, anti-
Env antibodies were detected in mucosal tissues (Table 8).  Not surprisingly, the lungs 
had the highest antibody titers compared to mucosal sites further from the inoculation 
site.  The NALT contains all the immunocompetent cells required to generate an effective 
immune response.  Immune responses in the NALT are connected to the common 
mucosal immune system through inductive distal sites such as the lamina propria of the 
intestinal tract or urogenital tissues for the generation of both antibody and T cell 
responses 128.  However a high variability was noted in the total sIgA, which was not 
observed in the mucosal anti-Env IgG titers.   
Compared to particulate antigens, such as VLPs, intranasal vaccination of soluble 
proteins, in the absence of an adjuvant, induces low or undetectable immune responses in 
rodents and primates 274, 430, 460, 637.  In this study, intranasal immunization of VLPs 
induced both systemic and mucosal immunity (Figures 20 and Table 8)  Soluble antigens 
can penetrate the nasal epithelium and directly interact with dendritic cells, macrophages 
and lymphocytes and then they are transferred to posterior lymph nodes 632.  In contrast, 
in this study, VLPs were most likely phagocytosed by microfold epithelial cells (M cells) 
in the nasal lumen and then directly deposited to the NALT (nasal associated lymphoid 
tissue) via M cell transcytosis 697, which preferentially drains into cervical lymph nodes.  
This process induces strong local (NALT) and distant immune responses in both 
peripheral and mucosal immune compartments 601.  Soluble antigens bypass the NALT 
and are directly fed into superficial lymph nodes by antigen presenting cells in the nasal 
lumen resulting in a lower local immune response 601.  Therefore, VLP immunogens 
directly interact with the mucosal immune system to elicit high titer immunity.   
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Both humoral and cellular immune responses were enhanced in mice vaccinated 
with VLPs plus CpG ODNs.  Splenocytes collected from mice vaccinated with purified 
VLPs had robust anti-Env and anti-Gag responses (Figure 21), which were increased 2-3 
fold in mice co-administered with CpG ODNs.  The numbers of splenocytes reacting to 
Env or Gag peptides were significant, especially since only 2 overlapping peptides were 
used for each antigen.  Overall, mice vaccinated with VLPs elicited cellular responses 
against Gag and Env, which were enhance by the co-immunization of CpG ODNs. 
For most protein or particle immunizations, adjuvants are necessary in order to 
elicit robust immune responses 350.  Several compounds have been used in rodent and 
non-human primate studies to enhance the mucosal immunity, such as cholera toxin B 
(CT) and Escherichia coli heat-labile enterotoxin (LT) 21, 158, 159, 197 637, QS21 320, 565, 
monophophoryl lipid A (MPL) 241, 242, 646, and CpG ODNs 334, 335, 337, 338, 350, 431, as well as 
cytokines, such as GM-CSF and RANTES 65, 307, 388, 490, 715.  In this study, CpG ODNs 
were used to boost the immunogenicity elicited by intranasal administration of VLPs 
because they: 1) are potent inducers of both humoral and cellular mucosal immune 
responses 255, 2) have reduced toxicity compared to CT or LT 271, 676, and 3) induce both 
mucosal and systemic immune responses 350. These adjuvants are derived from bacterial 
DNA containing unmethylated cytosine-phosphate-guanosine motifs, which are usually 
inoculated in the form of synthetic oligonucleotides (CpG ODNs).  DNA sequences 
containing one or more CpG motifs are endocytosed and activate the toll-like receptor, 
type 9 (TLR9), which are found on human B cells and plasmacytoid dendritic cells 244, 264, 
625.  VLP plus CpG ODN vaccinated mice had a T helper type 1 response compared to 
mice vaccinated with VLPs only, as indicated by a higher IgG2a:IgG1 ratio (Figure 20c).  
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Most likely, mice vaccinated with VLPs plus CpG ODNs had heightened B cell 
activation 249, 339, 353 resulting in increased antigen presentation and antibody production, 
as well as increased T cell activation, antigen presentation by B cells and plasmacytoid 
dendritic cells 240 and enhanced lytic activity by INF-γ secreting NK cells 230, 378, 550.  
Therefore, even though VLPs alone were immunostimulatory, the addition of the CpG 
ODN adjuvant enhanced both humoral and cellular responses, which should be 
considered for future primate experiments. 
In summary, VLPs, derived from a virally-regulated, multi-gene plasmid DNA, 
elicit immune responses to HIV-1 antigens in both the peripheral and mucosal immune 
compartments.  These VLP immunogens can be expressed in vivo from a single plasmid 
or from viral/bacterial vectors or administered as purified particles.  The elicitation of 
immune responses at the mucosa is a goal of AIDS vaccine development, because the 
vast majority of HIV-1 transmission is through sexual contact.  Exposure of the vagina or 
rectal tissue to HIV-1 infected seminal fluid effectively transmits the virus, and the 
induction of urogenital mucosal immunity against HIV-1 could enhance protection.  
Intranasal inoculation of VLPs to induce urogenital tract mucosal immune responses is an 
attractive and practical approach for administration of an AIDS vaccine.  
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VI. Chapter 6:  Specific Aim III 
 
 
HIV-1 Gag Particles Elicit Broader Immunity Compared to  
Soluble, Non-Particulate or Intracellularly-Confined Gag Proteins 
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 VI.A. Introduction 
  
Gag gene products, assisted by cellular machinery and host proteins, are the driving force 
behind viral assembly into particles.  HIV-1 gag encodes for the major structural viral proteins: 
capsid (CA, p24), matrix (MA, p17), and nucleocapsid (NC, p7) (Figure 22).  Similar to all 
lentiviruses, HIV-1 gag and pol are expressed from full-length, unspliced mRNA, which also 
serves as genome for nascent virions.  Both unspliced and singly spliced viral mRNAs are 
transported from the nucleus to the cytoplasm by the virally encoded protein, Rev 409, 411, 412, 723.  
Rev recognizes an element in the viral RNA, RRE, which facilitates the efficient transport of 
incompletely spliced mRNAs 184, 608.  However, optimizing gag or pol genes to express the 
codons most often found in primate cells (codon optimization) circumvents the Rev-dependent 
nuclear export of these mRNAs 138.   
Gag is expressed as a 55 kDa precursor (Gagp55) and is cleaved by the viral protease (PR) 
to produce distinct Gag gene products (MA, CA, p2, NC, p1, and p6Gag) (Figure 22).   Pol is 
synthesized as part of the large ~160 kDa polypeptide (Gag-Polp160) by a ribosomal frame slip (-
1 in the gag reading frame) at the gag-pol junction, which occurs 5-10% of the time during 
protein synthesis 293.  The Gag-Polp160 molecule is cleaved to produce protease (PR), reverse 
transcriptase (RT), and integrase (IN), as well as the Gag gene products.  Translation of 
unspliced mRNAs results in the formation of both Gagp55 and Gag-Polp160 at a 20 to 1 ratio, 
which is critical for particle formation and infectivity 293, 313, 502, 587.  Gagp55 can self-assemble and 
form VLPs, however, Gag-Polp160 cannot form a virus-like particle alone, but can be 
incorporated into particles through interactions with CA domains in Gagp55 97, 154, 156, 314, 315, 536.
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Figure 22.  Schematic representation of the major features of Gagp55.   
The schematic represents the Gagp55 gene sequence.  The major Gag gene products are linearly 
represented; matrix (MA), capsid (CA), nucleocapsid (NC) and p6 (N-terminus, top and C-
terminus, bottom).  The two spacer domains, p1 and p2, are located in between NC/p6 and 
CA/NC, respectively.  The major homology region (MHR) and basic domain are indicated along 
with the membrane-binding (M), Gag-Gag interaction (I) and late (L) domains.  The arrow 
denotes the myristylation site, which was mutated (glycine to alanine, gga to gca) by site directed 
mutagenesis PCR. 
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  Assembly pathways differ between cell types with viral particles budding from the plasma 
membrane in T lymphocytes, while viral assembly occurs in intracellular vesicles in 
macrophages 75, 194, 229, 294, 497.  Regardless of the location of assembly, Gagp55 produces 
multimers by binding to one another at the major homology region (MHR) found in CA, and 
post-translational myristylation of the N-terminus of Gagp55 targets the polyprotein aggregates to 
the membrane.  Gag attaches to the membrane via the myristic acid moiety and is secured by a 
stretch of basic amino acids in MA 491, 492, 496, 722, 728, 729.  Following assembly, the budding of 
immature Gag particles resemble electron-dense, donut-shaped cores, containing uncleaved 
Gagp55 polyproteins 245, 666.   
 Although the correlates of protections are unclear, the main structural proteins encoded 
by gag are major targets of the immune response 139, 662, 663.  Most current HIV/AIDS vaccine 
clinical trials incorporate a Gag component into the vaccine design (for reviews please see 610, 
719).  Gag gene products have been expressed in vivo from viral vectors, DNA plasmid, or live-
attenuated virus 127, 225, 287, 379-381, 397, 512, 544, 594.  In addition, whole-inactivated virions, virus-like 
particles, or soluble Gag gene products have been administered by parenteral and mucosal 
inoculation 141, 509, 662, 719.  Gag proteins, as components of these vaccine strategies, elicit strong 
humoral and cellular immune responses.   
Particle-based vaccine approaches for HIV-1 are particularly attractive strategy because 
particulate antigens have a longer half life than soluble antigens.  In addition, viral particles enter 
different antigen presentation pathways and trigger “danger signals” to stimulate a more robust 
immune response.  Particles administrated mucosally transverse microfold epithelial cells (M 
cells) and enter the associated lymphoid tissue 697.  The associated lymphoid tissues 
preferentially drain into the regional lymph nodes and this process induces strong local and 
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 systemic immune responses 601.  In contrast, soluble antigens remain at the inoculation site or 
bypass the associated lymphoid tissues and directly enter the superficial lymph nodes 632.  
Particulate antigens that enter and interact with this highly concentrated area of immune cells 
may lead to an early and more robust immune response compared to soluble antigens that bypass 
this region.  However, the modality, dose or route of inoculation, immunogens co-inoculated 
with Gag proteins, use of adjuvants, or prior exposure to the pathogen or vaccine appears to 
influence the effectiveness of immunization 4, 141, 260, 454, 499, 552, 555, 559, 635, 659, 663.  In addition, the 
structural form of the Gag gene products may influence the effectiveness of the elicited anti-Gag 
immunity in order to protect a host from disease.   
 Therefore, the goal of this study was to compare the elicitation of immune responses by 
the same Gag immunogens presented to the immune system in different structural forms.  Mice 
were inoculated with vaccines expressing HIV-1 Gag gene products in vivo as DNA expressing 
Gag particles or proteins retained intracellularly.  In addition, the immunity elicited by purified 
Gagp55 particles (virus-like particles) in mice was compared to denatured, soluble Gagp55 
proteins.   
 
VI.B. Material and Methods 
 
DNA Plasmids   
 The vaccine plasmid, pTR600, has been previously described 62, 224, 446, 634, 720.  Briefly, 
the vector was constructed to contain the CMV-IE for initiating transcription of eukaryotic 
inserts and the BGH poly A for termination of transcription.  The vector contains the Col E1 
origin of replication for prokaryotic replication and the kanamycin resistance gene (kanr) for 
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 selection in antibiotic media.  
The previously described plasmid, pGag, expresses Gagp55 VLPs composed of 
unprocessed Gagp55 polyprotein (isolate HIV-1NL4-3) from codon-optimized DNA sequences 283, 
720.  In this study, virus-like particles produced in vitro were purified from COS cells transfected 
with the pGag.  The plasmid, pGag∆Myr, was constructed by mutating the myristylation site 
(second amino acid in MAp17) by site-directed mutagenesis PCR (Quick Change XL Kit, 
Stratagene, Cedar Creek, TX).  This mutation resulted in a change of the codon from a glycine to 
an alanine (gga to gca), which was verified by DNA sequencing.  The plasmids were amplified 
in Escherichia coli strain-DH5α, purified using anion-exchange resin columns (Qiagen, 
Valencia, CA) and stored at –20°C in dH20.  Plasmids were verified by appropriate restriction 
enzyme digestion and gel electrophoresis.  Purity of DNA preparations was determined by 
optical density reading at 260nm and 280nm.   
 
Expression of DNA plasmids 
 Monkey (COS) or murine (NIH 3T3) fibroblastic cell lines were transfected (5 X 105 
cells/transfection) with DNA (2 µg) using lipofectamine (12%) according to the manufacturer’s 
guidelines (Life Technologies, Grand Island, NY, USA).  Supernatants (2 ml) and cell lysates 
(300 µl dH2O) were collected and stored at -20°C.  For western blot analysis, samples were 
diluted 1:2 in SDS sample buffer (Bio-Rad, Hercules, CA, USA), boiled (5 min), and loaded 
onto a 10% polyacrylamide/SDS gel.  The resolved proteins were transferred onto a PVDF 
membrane (Bio-Rad, Hercules, CA, USA) and incubated with polyclonal human HIV-infected 
patient antisera (HIV Ig) (1:10,000 in PBS containing 0.05% Tween 20 and 5% non-fat dry 
milk).  After extensive washing, bound human antibodies were detected with horseradish 
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 peroxidase-conjugated goat anti-human IgG antiserum (1:10,000 in PBS containing 0.05% 
Tween 20 and 5% non-fat dry milk) and enhanced by chemiluminescence (Amersham, 
Buckinghamshire, UK). 
 
Purification of Gagp55 virus-like particles  
 Supernatants from COS cells, transiently transfected with pGag or pGag∆Myr, were 
pelleted (2 h at 4°C) via ultracentrifugation (100,000 x g through 20% glycerol, v/v).  The 
particles were subsequently resuspended and used for 1) in vivo inoculation or 2) sucrose 
gradient utltracentrifugation.  Gagp55 particles used for immunization were resuspended in sterile 
PBS.  Total protein concentration was determined by the Micro BCA Protein Assay Kit (Pierce, 
Rockford, IL, USA).  In addition, the level of non-HIV protein contamination (from the 
media/cells) in each inoculum was visualized by a silver-stained SDS-PAG using the 
ProteoSilver Silver Stain Kit (Sigma, St. Louis, MO, USA).  The specificity of each inoculum 
was analyzed in a separate immunoblot that was probed with HIV Ig as described earlier.    
Pellets were analyzed for particle content by ultracentrifugation through 20-60% sucrose 
gradients (11 steps, 4% increments) (17 h at 100,000 x g at 4°C).  Eleven fractions (20-60% 
sucrose, 1 ml, weight per volume in PBS) were collected (top to bottom) from the gradient, and 
the proteins were precipitated with equal volumes of 20% TCA and subjected to SDS-PAGE and 
immunoblotting.  The viral proteins were detected by HIV Ig via western hybridization and 
visualized by enhanced chemiluminescence.  In addition, the purity of each VLP preparation in 
each inoculum was visualized by a silver-stained polyacrylamide SDS gel . 
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 Mouse immunizations 
 Female BALB/c mice (5–7 weeks old) were immunized (days 1, 21, and 42) with one of 
two DNA immunogens, pGag and pGag∆Myr (5 µg), or soluble Gagp55 protein (10 µg) purified 
from yeast lysates (50mM sodium phosphate, 0.4 M NaCl, 6M Urea, ph 7.9, AIDS Reagent and 
Reference Program), or primate cell-derived Gagp55 virus-like particles (40 µg total protein) via 
intramuscular immunization.  The amount of Gagp55 virus-like particles used for immunization 
was normalized to the amount of VLPs expressed from pGag and the same amount of soluble 
Gagp55 as determined by ELISA.  Soluble Gagp55 protein and Gagp55 VLPs were co-inoculated 
with phosphorothioate CpG oligodeoxynucleotides (CpG ODNs, 10 µg each).  Each CpG ODN 
(ODN-1:  5'-TCCATGACGTTCCTGACGTT-3', ODN-2:  5'-
TGACTGTGAACGTTCGAGATGA-3') 203, 274, 307, 428, 451 was synthesized and purified by high-
pressure liquid chromatography (Sigma-Genosys, The Woodlands, TX, USA).  The CpG ODNs 
were resuspended in sterile water (2 µg/µl) and stored at -80°C.  All animal groups were 
intramuscularly administered (1X) with the respective vaccine in sterile PBS into the left 
quadriceps muscle (50 µl total volume).    
Mock DNA vaccinated (pTR600 vector) or CpG ODN inoculated mice served as 
negative controls.  For mock VLP, supernatants from primate cells transiently transfected with 
the vector, pTR600, were ultracentrifuged through 20% glycerol.  The pellet was resuspended in 
sterile  PBS  plus  CpG  ODNs  and  inoculated  into  the  naïve mice  (equivalent volume 
compared to mice given a VLP inoculum).  Mice were anesthetized with xylazine (20 mg/ml) 
and ketamine (100 mg/ml) administered subcutaneously in the abdomen prior to immunization 
and blood collection.  Mice were housed in compliance with U.S.D.A. regulations and were 
monitored daily for weight loss, behavior, and adverse reaction.   
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 Antibody responses to Gag proteins 
Blood samples were collected by retro-orbital plexus puncture (days 1, 35, and 56 post-
immunization) on anesthetized mice.  Sera samples were separated from red blood cells by 
centrifugation (5,000 rpm, 10 min) and stored at -80°C.  Sera were tested for antibodies to Gagp55 
by ELISA.  Each well of a 96-well plate was coated with 100 ng of purified Gagp55 (NIH 
ARRRP) (4°C for 16 hr).  Plates were blocked (25°C for 2 hr) with PBS containing Tween 20 
(0.05%) and nonfat dry milk (5%), and serial dilutions of each sample were incubated (25°C for 
2 hr).  Following thorough washing in PBS-Tween 20 (0.05%), samples were incubated (25°C 
for 1 hr) with biotinylated goat anti-mouse IgG (1:5,000) diluted in PBS-Tween 20 (0.05%) and 
nonfat dry milk (5%).  The unbound antibody was removed, and the wells were washed.  
Strepavidin-HRP (1:7,000) was diluted in PBS-Tween 20 (0.05%) and incubated (25°C for 1 hr).  
Samples were incubated with TMB substrate (1 hr), and the colorimetric change was measured 
as the optical density (O.D., 405nm) by a spectrophotometer (Dynex Technologies, Chantilly, 
VA, USA).  The value of naïve sera was subtracted from the test samples. 
ELISPOT assay 
Isolated spleens (week 8) were minced using a rubber stopper and mesh gauze using 
sterile PBS to generate a single cell suspension.  Splenocytes were depleted of erythrocytes by 
treatment with ammonium chloride (0.1 M, pH 7.4).  Following thorough washing with PBS, 
cells were resuspended in RPMI medium with 10% fetal bovine serum (cRPMI).  Cell viability 
was determined by trypan blue exclusion staining.  The number of anti-Gag specific murine INF-
γ (mINF-γ) secreting splenocytes was determined using an ELISPOT assay kit (R & D Systems, 
Minneapolis, MN, USA).  Briefly, pre-coated anti-mIFN-γ plates were incubated (25°C for 2 hr) 
with cRPMI (200 µl) and then were incubated with splenocytes (106/well) isolated from 
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 vaccinated mice.  Splenocytes were stimulated (48 h) with 2 overlapping peptides representing 
an immunodominant CTL epitope for HIV-1 Gagp24 (HIV-1 consensus B Gag: 
GHQAAMQMLKETINE and AMQMLKETINEEAAE) or purified Gagp55 purified protein (1 
µg/well of each peptide or 2 µg protein).  Additional wells of splenocytes were stimulated with 
PMA (50 ng)/ionomycin (500 ng) or were mock stimulated.  In addition, IL-2 was added to all 
wells (10 units/ml).  Plates were washed with PBS-Tween (3X) and incubated (25°C for 2 h) 
with biotinylated anti-mIFN-γ and incubated (4°C for 16 h).  The plates were washed and 
incubated (25°C for 2 h) with strepavidin conjugated to alkaline phosphatase.  Following 
extensive washing, cytokine/antibody complexes were incubated (25°C for 1 h) with stable 
BCIP/NBT chromagen.  The plates were rinsed with sterile water and air dried (25°C for 2 h).  
Spots were counted by an ImmunoSpot ELISPOT reader (Cellular Technology Ltd., Cleveland, 
OH, USA).  Results are given as the number of spots per 106 splenocytes after subtracting the 
background values (naïve mice stimulated with Gag peptides or proteins and unstimulated 
splenocytes from test samples).   
 
Cytotoxicity assay 
 At week 8, splenocytes were harvested and sensitized with the same immunodominant 
CTL peptides and Gagp55 protein (2 µg/ml) as described for the ELISPOT assay.  This mixture 
was incubated with the splenocytes for 7 days (37°C, 5% CO2) with 10 units/ml murine IL-2 in 
cRPMI.  At day 4, additional media was added to the samples (Final concentrations: 1µg/ml of 
peptides and protein, 5 units/ml of IL-2).  One week later, effector cells were assayed for 
cytolytic activity in a non-radioactive CTL assay using two BC10ME cell lines stably expressing 
HIV-1 Gag or Pol.  These stably transfected cell lines have been shown to be more sensitive as 
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 target cells compared to peptide-pulsed BC10ME cells in a previous CTL assays 283.  Mouse 
splenocytes (10,000-800,000 effector cells) and BC10MEGag or Pol cells (10,000 target cells) were 
incubated for 5 h (ET ratio = 1:1-1:80).  Cytotoxicity was measured quantitatively by the release 
of LDH from lysed cells using a CytoTox 96 Non Radioactive Cytotoxicity Assay kit according 
to the manufacturer’s protocol (Promega, Madison, WI).  This non-radioactive cytotoxicity assay 
demonstrates similar results compared to 51Cr release assays 132, 342.  Results are given as:  % 
Cytotoxicity = [(Experimental - Effector Spontaneous - Target Spontaneous) ÷ (Target 
Maximum - Target Spontaneous)] X 100.   
 
VI.C. Results 
 
Characterization of Gagp55 immunogens 
 Four Gag immunogens were designed to examine the elicitation of immune responses by 
the same antigen presented to the immune system in different forms.  Two DNA vaccines 
containing the same gene sequences were constructed to express Gagp55 proteins in vivo.  The 
previously described plasmid, pGag 720, expressed Gagp55 VLPs composed of Gagp55 polyprotein 
from HIV-1NL4-3 gag sequences (Figure 22), which have been optimized for expression in 
mammalian cells.  The plasmid, pGag∆Myr, was constructed from pGag.  The myristylation site 
located at the second amino acid (glycine) in the matrix gene (Gagp17) was mutated to an alanine, 
which disrupts the stable association of viral proteins with the membrane components during the 
assembly process and therefore prevents the formation of particles 354, 492, 496, 722, 728, 729.  Two 
additional  Gag immunogens were compared for the elicitation  of  anti-Gagp55 immunity.   These  
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Figure 23.  Expression of Gag proteins in primate and rodent cells.   
(A)  Protein expression of vaccine plasmids.  NIH 3T3 (murine) cells were transfected with 1 µg 
of each vaccine plasmid and protein expression was verified by western blot analysis.  Lanes 1, 
3: pGag and lanes 2, 4: pGag∆Myr.  Lanes 1, 2: 2% cell lysates and lanes 3, 4: 1% of supernatants 
of NIH 3T3 cells.  (B) Sucrose density gradient ultracentrifugation of VLPs.  Supernatants from 
COS cells transiently transfected with pGag were concentrated through a 20% glycerol cushion 
and then subjected to 20-60% (w/v) sucrose density gradient ultracentrifugation.  Fractions were 
collected from top to bottom, precipitated with 20% TCA and proteins were detected by western 
blot analysis.  Percentage of each sucrose fraction is indicated at the bottom of each lane.  
Arrows indicate bands of Gag gene products (Gagp55 and Gagp41). 
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 Gagp55 VLPs were purified from cell culture transfected with pGag to match the same Gagp55 
gene insert expressed in vivo.  Lastly, soluble Gagp55 protein was purified from yeast transfected 
with DNA expressing Gagp55. 
 
Expression and purification of Gagp55 virus-like particles   
Gag proteins (Gagp55 and Gagp41) were detected in both the supernatant and cell lysate 
fractions from murine cells (NIH 3T3) transiently transfected with pGag (Figure 23A).  In 
contrast, murine cells transfected with pGag∆Myr had a higher concentration of Gag gene products 
in the cell lysate fraction compared to pGag, with no detectable proteins in the cell supernatants 
(Figure 23A).  Gagp55 particles were purified from supernatants of COS cells (Figure 23B) 
transfected with pGag by ultracentrifugation (20-60% sucrose gradient) and collected fractions 
were analyzed for particle composition and stability by SDS-PAGE/Western blot.  Gagp55 VLPs 
banded in sucrose fractions (36-44% sucrose) (Figure 23B) similar to other lentiviral particles 145, 
671.   
  
Intracellularly retained Gag proteins elicited higher titers of cellular immunity 
Mice were immunized with pGag and pGag∆Myr (5 µg) at days 1, 21, and 42 (i.m.) and 
both humoral and cellular responses were evaluated.  Mice vaccinated with pGag elicited anti-
Gagp55 antibodies (IgG) in the sera (~1:1240 endpoint dilution titer) compared to low levels of 
IgG detected in mice inoculated pGag∆Myr (<1:120) (Figure 24A).  In contrast, splenocytes 
isolated from mice vaccinated with both vaccines secreted moderate levels of INF-γ following in 
vitro stimulation with 2 overlapping peptides representing an immunodominant CTL epitope for 
HIV-1 Gagp24   (Figure 24B)  or  soluble Gagp55 protein  (Figure 24C).  Interestingly, splenocytes  
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Figure 24.  Immunogenicity of Gag vaccine plasmids.   
Mice were vaccinated with the DNA vaccines, pGag or pGag∆Myr.  Collected sera or isolated 
splenocytes were assayed for anti-Gag immunity (week 8).  (A)  Anti-Gagp55 antibodies were 
detected by ELISA, and the results are presented as the average endpoint titer.  (B, C)  HIV-
specific IFN-γ producing splenocytes were detected by ELISPOT.  Two weeks after the final 
boost, splenocytes were stimulated with (B) two HIV-1 Gagp24 peptides (1 µg each, overlapping 
an immunodominant epitope) (C) or purified Gagp55 soluble protein (2 µg).  Cells from vector-
vaccinated mice produced fewer than 10 spots per 1 X 106 million splenocytes.  Each bar 
represents the average titer of 5 mice per group plus the standard deviation minus the number of 
background spots.  (D) Cytotoxic T-cell activity from isolated splenocytes is presented plus the 
standard deviation.  The average percentage of cytolysis for each effector (splenocytes) to target 
(BC10-ME) cell ratio is shown (four independent samples, 5 mice per group).  The statistical 
significance of the difference between groups was calculated by the Student’s t test (** 
p<0.01;***p<0.001 **** p<0.0001). 
233 
  
 
Figure 24.  Immunogenicity of Gag vaccine plasmids.   
Mice were vaccinated with the DNA vaccines, pGag or pGag∆Myr.  Collected sera or isolated 
splenocytes were assayed for anti-Gag immunity (week 8).  (A)  Anti-Gagp55 antibodies were 
detected by ELISA, and the results are presented as the average endpoint titer.  (B, C)  HIV-
specific IFN-γ producing splenocytes were detected by ELISPOT.  Two weeks after the final 
boost, splenocytes were stimulated with (B) two HIV-1 Gagp24 peptides (1 µg each, overlapping 
an immunodominant epitope) (C) or purified Gagp55 soluble protein (2 µg).  Cells from vector-
vaccinated mice produced fewer than 10 spots per 1 X 106 million splenocytes.  Each bar 
represents the average titer of 5 mice per group plus the standard deviation minus the number of 
background spots.  (D) Cytotoxic T-cell activity from isolated splenocytes is presented plus the 
standard deviation.  The average percentage of cytolysis for each effector (splenocytes) to target 
(BC10-ME) cell ratio is shown (four independent samples, 5 mice per group).  The statistical 
significance of the difference between groups was calculated by the Student’s t test (** 
p<0.01;***p<0.001 **** p<0.0001).  
234 
 Purified Gagp55 VLPs efficiently elicited both humoral and cellular immunity 
from mice vaccinated with pGag∆Myr had a statistically higher number of spot forming colonies 
was elicited in mice immunized with pGag∆Myr compared to pGag (Figure 24C).  In addition, the 
splenocytes from mice vaccinated with pGag∆Myr had significantly higher levels of cytotoxic 
activity compared to mice inoculated with pGag as measured by a nonradioactive CTL assay 
(Figure 24D).  Therefore, DNA immunization of pGag (resulting in expression of Gagp55 VLPs) 
elicited higher titer anti-Gagp55 antibodies, whereas, intracellular containment of Gag proteins via 
DNA immunization of pGag∆Myr enhanced cellular immunity. 
BALB/c mice were vaccinated with purified soluble Gagp55 protein (10 µg) or tissue 
culture purified Gagp55 virus-like particles (40 µg of total protein) plus CpG ODNs (10 µg) at 
days 1, 21 and 42 (i.m.) and both humoral and cellular responses were evaluated.  Antibodies in 
mice immunized with both soluble Gagp55 protein and Gagp55 VLPs were detected as early as two 
weeks following the first vaccination and continued to rise following the third vaccination.  
Although mice vaccinated with soluble Gagp55 protein purified from yeast induced anti-Gag 
antibodies (1:18,000), mice immunized with purified Gagp55 VLPs had approximately 1 log 
higher titer of anti-Gag antibodies at week 8 (1:245,000) (Figure 25A).  Similarly, mice 
vaccinated with soluble Gagp55 protein and Gagp55 VLPs elicited IFN-γ secreting splenocytes; 
however mice vaccinated with Gagp55 VLPs induced four times more INF-γ secreting 
splenocytes compared to mice immunized with soluble Gagp55 protein (Figures 25B and C).  In 
addition, splenocytes from mice vaccinated with Gagp55 VLPs purified from primate cells lysed a 
significantly higher number of target cells compared to splenocytes isolated from mice 
inoculated with soluble Gagp55 protein (Figure 25D).  Therefore, Gagp55 particles induced higher 
titers of humoral and cellular immune responses compared to soluble Gagp55 protein. 
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Figure 25.  Immunogenicity of Gag protein vaccines.   
Mice were vaccinated with purified, soluble Gagp55 or purified virus-like particles (VLP) co-
immunized with CpG ODNs.  Collected sera or isolated splenocytes were assayed for anti-Gag 
immunity (week 8).  (A)  Anti-Gagp55 antibodies were detected by ELISA, and the results are 
presented as the average endpoint titer.  (B, C)  HIV-specific IFN-γ producing splenocytes were 
detected by ELISPOT.  Two weeks after the final boost, splenocytes were stimulated with (B) 
two HIV-1 Gagp24 peptides (1 µg each, overlapping an immunodominant epitope) (C) or purified 
Gagp55 soluble protein (2 µg).  Cells from vector-vaccinated mice produced fewer than 10 spots 
per 1 X 106 million splenocytes.  Each bar represents the average titer of 5 mice per group plus 
the standard deviation minus the number of background spots.  (D) Cytotoxic T-cell activity 
from isolated splenocytes is presented plus the standard deviation.  The average percentage of 
cytolysis for each effector (splenocytes) to target (BC10-ME) cell ratio is shown (four 
independent samples, 5 mice per group).  The statistical significance of the difference between 
groups was calculated by the Student’s t test (* p<0.5; ** p<0.01; *** p<0.001; **** p<0.0001).  
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 VI.D. Discussion  
  
 Gag gene products are key components within most AIDS vaccines for the elicitation of 
protective immunity 225, 287, 301, 303, 421, 471, 594, 635, 664, 665, 712.   Gag-specific T cell  responses  (CD4+ 
and CD8+)  correlate  with  improved  control  of  viral  replication 205, 290, 547.  In particular, anti-
Gag CD8+ cytotoxic T cells initially control viral replication and subsequently reduce viral loads 
during natural infection 55, 332, 343, 462.  These CTL responses may also prevent the establishment 
of persistent infection 462, 554.  Lastly, Gag is  a particularly attractive vaccine target due to cross-
clade sequence conservation 164, 690.   
 In this study, mice were inoculated with four different HIV-1 Gag vaccines to compare 
the elicitation of immune responses by the same Gag immunogen presented to the immune 
system in different forms.  Specifically, the type of immunity elicited by in vivo produced Gag 
proteins (pGag; secreted as particles) was compared to intracellularly retained multimers of Gag 
(pGagp55).  In a separate set of experiments, Gag virus-like particles or soluble, non-particulate 
Gag proteins were inoculated intramuscularly to analyze the elicited immunity.  Mice vaccinated 
with DNA expressing Gagp55 VLPs (pGag) or purified Gagp55 VLPs elicited both anti-Gag 
antibodies and cellular immune responses (Figures 24 and 25).  In contrast, mice vaccinated with 
DNA expressing Gagp55 with a mutated myristylation site (pGag∆Myr) elicited cellular immunity 
and cytotoxic activity, but had almost undetectable titers of anti-Gag antibodies (Figure 24).  
Mice vaccinated with soluble, non-particulate proteins had primarily humoral immune responses.   
 Myristylation is a key component in the particle assembly process.  Gagp55 undergoes 
post-translational myristylation at the N-terminus of matrix, which allows the Gag complex to 
attach to the cell membrane via the myristic acid moiety 491, 492, 496, 722, 728, 729.  Disruption of the 
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 myristylation site (Figure 22) resulted in an accumulation of Gag proteins in the cytoplasm 
(Figure 23A).  The higher concentration of proteins within the cytoplasm most likely increases 
proteosomal degradation of these polypeptides into the endogenous antigen pathway, resulting in 
the loading of Gag peptides on MHC class I molecules.  Since, few Gag gene products were 
secreted from transfected cells, little anti-Gag antibodies were detected (Figure 23) similar to the 
immunity elicited by intracellularly retained Gag proteins using: 1) the addition of degradation 
signals (encephalomyocarditis virus (EMCV) 3C PR or ubiquitin), 2) mutation of the Gag-Pol 
frameshift site, 3) mutation of the major homology region in CAp24, or 4) mutation of the 
myristylation site in MAp17 166, 325, 413, 600, 666, 684, 732.  However, in contrast, other reports have 
indicated no difference between immune response elicited by particle-forming and particle-
defective vaccines 695, which may be attributed to multiple factors in different model systems 
(dose, animal model, inoculation regimen, or immunological assays used for analysis). 
In contrast, Gagp55 VLPs elicited robust immune responses, which were significantly 
higher than the immunity elicited in mice vaccinated with soluble, non-particulate Gagp55 protein 
(Figure 25).  Antigen processing pathways differ for particulate antigens compared to soluble, 
non-particulate antigens.  Professional APCs engulf and present viral peptides by a variety of 
mechanisms depending on the structural form of the antigens 473, 523, 526.  These APCs process 
viral particles for MHC class I presentation more efficiently than soluble proteins leading to 
higher titer immune responses 344.  Particulate antigens, through the process of cross-presentation 
34, 226, 279, 280, 356, 513, 525, 596, can induce an effective cell-mediated immune response in addition to a 
strong antibody responses.  Regardless if the antigen was a soluble protein or particle, Gag 
antigens injected intramuscularly induced high titer anti-Gag antibodies (Figure 25A).  However, 
these two Gag immunogens elicited marked differences in the anti-Gag splenocyte responses (as 
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 indicated by secretion of IFN-γ) and cytolytic activity (Figure 24 and 25).  Gagp55 VLPs elicited 
robust cytotoxic activity, whereas minimal cytolytic activity was detected in mice vaccinated 
with non-particulate, soluble Gagp55.  Not surprisingly, splenocytes isolated from all mice and 
stimulated with soluble Gagp55 protein had higher numbers of IFN-γ-secreting cells compared to 
the same cells stimulated with peptides, because the protein contains many Gag epitopes 
compared to the single Gagp24 epitope for the 2 overlapping peptides (Figure 25).  In general, 
Gagp55 proteins stimulated both CD4+ and CD8+ cells, whereas the two overlapping MHC class 
I-restricted peptides (representing an immunodominant CTL epitope for HIV-1 Gagp24) used in 
this study stimulated primarily CD8+ T cells in vitro 423.  As indicated by antibody titer, 
splenocyte responses, and cytolytic activity, particles composed of HIV-1 Gag gene products 
elicited a broader immunity than non-particulate, soluble Gagp55 or intracellular Gagp55 
multimers. 
 Gag gene products of HIV-1 were used to study the effect of different structural forms of 
the same antigen on the elicitation of immune responses.  In this report, Gag antigens elicited 
different types of anti-Gag immunity depending if these proteins were components of a virus-like 
particle, soluble proteins, or intracellular multimers.  Overall, the expression of Gag gene 
products in any HIV/AIDS vaccine may elicit potentially different and more effective protective 
immunity depending on the structure of the proteins, the cellular compartment the antigens are 
located, and the antigen processing pathways used for presentation of these proteins to the 
immune system. 
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 Overall, the virally-regulated, multi-gene VLP appears to be a promising vaccine 
candidate for HIV-1 although further research must determine the optimal inoculation regimen in 
non-human primates.  The optimal vaccination regimen will include priming with a minimum of 
two inoculations of VLP DNA followed by two particle immunizations.  Priming with DNA will 
ensure that all of the gene products will be expressed in vivo, which will result in a broadened 
humoral and cellular immune response.  The vaccine will be inoculated by gene gun (DNA) and 
at the mucosa (purified particle) to enhance both mucosal and systemic immunity.  Direct 
transfection of professional APCs, such as dendritic cells, by gene gun inoculation will increase 
the expression of viral proteins and VLPs in vivo.  In addition, gene gun inoculation induces both 
systemic and mucosal immunity.  In contrast, mucosal vaccination of DNA requires a high dose 
of DNA and results in a lower immune response compared to gene gun inoculation.  
Intramuscular inoculation may induce a strong systemic response but minimal mucosal response, 
which would be beneficial for a HIV vaccine.  A minimum of two inoculation of DNA will be 
necessary to induce strong, amnestic immune responses to the viral proteins (in particular 
cellular responses) that are not incorporated into the virus-like particles (Tat, Rev and Vpu).  
Boosting with purified VLPs is necessary to enhance the neutralizing antibody response to Env.   
 Many of the current vaccines in the HIV Vaccine Trials Network (HVTN) express 
multiple viral proteins/epitopes similar to the virally-regulated, multi-gene VLP vaccine.  The 
virally-regulated, multi-gene VLP vaccine has several advantages over these other vaccine 
strategies.  The multi-gene, single vaccine insert is more attractive, because it allows expression 
of multiple proteins from a single component.  The inclusion of such a number of genes in one 
insert is only possible due to its virally-regulated nature.  Viral transcription is initiated using a 
single CMV promoter for efficient transcription of the VLP DNA.  Numerous gene products are 
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 produced through RNA splicing and nucleocytoplasmic transport of viral mRNAs observed in 
wild-type infection with HIV-1.  Viral regulation through splicing results in a similar ratio of 
proteins observed during natural infection and prevents aberrant protein expression that may 
impair particle assembly or budding.    The other multi-gene vaccines do not express Gag and 
Env from the same cell.  Therefore, the VLPs produce will not incorporate Env into the viral 
membrane.  A soluble Env immunogen (monomers or trimers) could also induce higher anti-Env 
antibodies, but these antibodies will not be as immunologically relevant compared to antibodies 
induced by the native form of Env on the surface of a particle.  Unlike soluble proteins, Env 
incorporated into a VLP will induce neutralizing antibodies to the native structure of Env, which 
include conformational epitopes only found in the membrane-bound, trimeric form.  Soluble Env 
induces much lower levels of neutralizing antibodies compared to infection with live virus even 
though the overall antibody titer to Env is similar. Vaccination of proteins presented to the 
immune system in a particulate form will activate more potent humoral and cellular responses 
that are rapidly restimulated upon antigen encounter especially when co-inoculated with CpG 
ODNs compared to soluble proteins.  Vaccination with non-particulate antigens, such as the 
immunogens currently in the HVTN, induced a transient immune response that did not protect 
against infection.  This difference in immune responses is most likely due to antigen uptake, 
processing and presentation.  There are a few HIV vaccines entering human phase I trials that 
produce VLPs that contain Env.  However, these VLPs are produced in vitro and can only be 
inoculated as purified particles.  Moreover, these vaccines only express Gag and Env thus 
limiting the breadth of the ensuing immune response.  Previously, vaccines expressing only Gag 
and Env have not protected the host from disease.  The efficacy of the vaccine will be enhanced 
by including numerous viral gene products in the next generation of HIV vaccines.  Humoral and 
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 cellular immunity against the nonstructural proteins will be advantageous since these proteins are 
the first to be produced during natural infection.  Therefore, immunity to these accessory proteins 
will result in the destruction of infected cells that have yet to bud infection virions thereby 
drastically reducing viral load.  Unlike all of the vaccines currently in human trials, the virally-
regulated, multi-gene VLP vaccine incorporates multiple viral proteins in their native 
conformation but with the versatility of single gene vaccines.  
 A protein/particle boost will be required to effectively enhance the neutralizing 
antibodies to Env.  However, the purification of particles will need to be improved before 
entering human trials.  The purification of VLPs from virally-regulated multi-gene DNA (and 
other systems) is expensive and time-consuming, and the particles produced only contain Gag 
and Env gene products.  Currently, the VLPs are purified from transient transfection of virally-
regulated, multi-gene plasmid DNA into mammalian cells in vitro.  One way to increase the level 
of particle production is by generating stable cell lines that contain the VLP DNA.  There are 
other purification systems, but these approaches have multiple issues including anti-cellular 
immunity, non-human glycosylation of Env and lower particle yield.  Particles produced by any 
of the purification processes may induce anti-self immunity due to cellular proteins that are 
incorporated into the VLP during the purification process.  The immunity to cellular proteins 
should be reduced in a primate system, because cell lines from the same species can be used for 
in vitro purification unlike the rodent system which uses a monkey cell line for particle 
purification.  However, a protein/particle component will need to be included to enhance 
antibodies to Env based on other studies.  The co-inoculation of CpG ODNs with VLPs will 
greatly enhance the immunity to HIV.   
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  The first study that should be completed in non-human primates is to compare the virally-
regulated, multi-gene VLP vaccine to codon-optimized single genes that do (gag and env 
expressed from same cell) or do not form particles (gag and env expressed from different cells) 
using the same viral protein sequences and inoculation regimen (DNA-DNA-VLP-VLP).  The 
vaccine inoculums will have to be given at equal concentrations and also normalized for protein 
expression in vitro to compensate for the lower protein expression observed with the virally-
regulated VLP DNA.  Immune function (ability to kill infected cells or prevent infection of 
susceptible cells) rather than total response (non-neutralizing antibody or secretion of cytokines) 
will resolve which vaccine is the best and will be determined based on several criteria: induction 
of broad humoral and cellular responses (number of epitopes not level of activation), 
neutralization capacity of antibodies (systemic and mucosal), cytotoxic capability of CTLs 
(systemic and mucosal), and most importantly, protection against viral challenge.  If none of the 
vaccines induce protection in the non-human primates, the efficacy of the vaccines will be 
determined by immune functions previously stated in addition to viral load, setpoint, CD4 count 
and disease progression.  Although protection from infection is the ultimate goal of vaccination, 
it may be beneficial to characterize the immune response elicited that may protect from disease 
or prolong the asymptomatic stage of infection.  Many of the immune parameters that are 
currently being used to measure the immune response elicited against HIV may not correlate 
with protection.  However, a vaccine expressing multiple proteins may elicit immunity that will 
control viral replication by eliminating infected cells prior to budding of infectious virions.  This 
analysis of the immune response will determine whether the current strategies in humans and 
non-human primates are ideal or alternative strategies should be considered.  A more 
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 comprehensive evaluation of the immune response will be completed to characterize the 
correlates of protection if the VLPs prove to be efficacious in nonhuman primates.   
 Further research in non-human primates will be needed to enhance particle production 
(stable cell lines, inactivation of PR and deletion of pol) and minimize the contribution of 
cellular immunity (species-specific cell lines).  Also in non-human primates, methods to enhance 
broadly cross-reactive neutralizing antibodies to Env by sequence/structure modifications 
(de/hyper-glycosylation, variable loop deletions, truncation, multi-strain/clade or consensus 
sequences) will also need to be examined.  Multiple generations of the VLP vaccine will need to 
be tested in vitro and in a rodent/small animal system.  However, only a small number of these 
vaccines will proceed to nonhuman primate immunogenicity studies based on their ability to 
induce the killing of infected cells and prevent HIV from infecting susceptible cells.  Once the 
optimal vaccine candidate and regimen is determined in non-human primates, safety and 
immunogenicity of the VLP vaccine can be tested in a Phase I human trial. 
 Assuming success in non-human primates, the virally-regulated, multi-gene VLP vaccine 
should induce both humoral and cellular responses to a variety of viral proteins in humans.  Both 
humoral and cellular immunity should be elicited using a combinatorial vaccine regimen (two 
DNA, two purified VLPs) (Figure 29).  This immune response should include broadly cross-
reactive neutralizing antibodies and cellular immunity to multiple viral proteins.  Once the 
vaccinated individual becomes infected with HIV-1 (HIV infection of unvaccinated individuals, 
see Figure 3), strong amnestic (memory) humoral and cellular responses will be induced at the 
mucosa and systemic levels.  APCs (dendritic cells and macrophages) will produce the proteins 
in vivo, and particles will bud from the transfected cells following VLP DNA immunization.  
These cells will become activated and recruit other immune cells.  Systemic and mucosal 
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 immune responses will be elicited against multiple viral proteins following two DNA 
vaccinations and will be greatly enhanced following two immunizations with purified VLPs.  
The purified VLPs/CpG ODNs will be inoculated in the nasal passage, enter the NALT and 
restimulate HIV-specific immune cells induced by priming with DNA.  The presence of CpG 
ODNs will activate dendritic cells, macrophages and B cells.  NK and T cells will also be 
activated indirectly.  The highly concentrated area of cells will undergo clonal expansion and 
result in a very robust local immune response.  These activated, HIV-specific immune cells will 
then migrate to the lymph system and disperse throughout the body.  Neutralizing and opsinizing 
antibodies will prevent further infection of susceptible cells, while infected cells will be 
destroyed by ADCC and CTLs.  A drop in the number of CD4+ T cells will not seen due to the 
increase in vaccine-induced, HIV-specific CD4+ T cells and controlled level of replication.  A 
rapid but potent amnestic response will control or clear the virus from the body before the virus 
can establish a persistence infection.  Viral escape mutants will be less likely to arise shortly 
after infection because the immune response elicited by the VLP vaccine will encompass many 
different  epitopes in multiple viral proteins.  Viral replication will be rapidly controlled (by 
destruction of infected cells before virion release and neutralizing antibodies) and will lead to a 
very low viral setpoint or the virus will be cleared.  There are two possible outcomes following 
infection:  1) The immune system will clear the virus, and the patient will remain 
symptom/disease free (sterilizing immunity).  2) The immune system will control but not clear 
the virus (very low viral set point), and the patient will remain infected but will have a very slow 
disease progression similar to a LTNP or will eventually die from a non-HIV cause.  If the 
individual   remains  infected,  the generation  of  viral  escape  mutants  will   be  similar  to  that  
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Figure 26.  Immune response in VLP-vaccinated individuals infected with HIV.     
(A) Initially, an individual is vaccinated with the VLP vaccine.  Anti-HIV cellular and humoral 
immune responses are elicited following multiple vaccinations (two DNA and two purified 
particle inoculums) at mucosal and systemic compartments.  (B) Following vaccination, the 
elicited immunity HIV decreases to background levels.  The patient is then infected with HIV-1, 
and amnestic humoral and cellular responses are recalled to control the initial viremia.  CTLs and 
ADCC will remove infected cells, while neutralizing and opsinizing antibodies remove cell-free 
virus.  The multi-faceted immune response clears the virus from the body or decreases viral loads 
to undetectable levels.  Following the clearance or containment of the virus, the patient will be 
virus-free or will be infected, but asymptomatic.  Even in the case of persistent infection, the 
patient will remain asymptomatic/disease free for many years similar to that of LTNPs. 
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 observed in LTNPs because the viral setpoint in the vaccinated individuals will be very low or 
undetectable.       
 In contrast to the immune response elicited to the virally-regulated, multi-gene VLP 
vaccine, immunization with single gene vaccines that generate VLPs +/- Env will not protect the 
individual from disease.  Single gene vaccines expressing VLPs containing Gag only and Env as 
a soluble protein (separately) will not induce anti-Env antibodies capable of neutralizing the 
virus once the individual becomes infected.  Cellular responses may be diminished following the 
Gag only particle inoculations, because the particle will not be able to enter susceptible cells in 
an Env-mediated manner.  Each gene will be inoculated as separate plasmids, which will 
increase the cost and complexity of vaccine production.  Single gene vaccine strategies compose 
the majority of the vaccines currently in non-human primate or human trials and have not elicited 
protection from infection.  The virally-regulated, multi-gene vaccine has numerous 
characteristics that set it apart from these other vaccine strategies.  The virally-regulated nature 
allows the VLP vaccine to contain numerous viral proteins expressed similar to natural infection 
(order and quantity of protein expression and native conformation).  More specifically, the only 
target of neutralizing antibodies, Env, will be in the native conformation similar to that of wild-
type virus.  This may result in antibodies that are more immunologically relevant, which are 
directed at conformation-dependent epitopes.  VLPs containing Env are advantageous, because 
they can penetrate restricted immune compartments that soluble proteins cannot enter such as the 
associated lymphoid tissue through M-like cells.  Particulate antigens include both humoral and 
cellular immune responses and have intrinsic properties that activate APCs and promote 
maturation/long-term immunity. 
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  Other VLP vaccines that produce VLPs containing Gag and Env from codon-optimized 
genes have numerous issues.  First and foremost, this vaccination approach only contains Gag 
and Env, so the likelihood of viral escape mutants dramatically increases with this type of 
vaccine.  This vaccine will have to be used in conjunction with other vaccine strategies to 
include other viral proteins to increase the breadth of the immune response.  Also, this vaccine 
approach does not have the versatility of single genes that do not produce particles containing 
Env or the virally-regulated, multi-gene VLP vaccine.  Lastly, this particle production system 
overexpresses Gag and Env.  The Env incorporated into the VLP will be more unstable due to an 
abnormally enhanced number of Env molecules on the surface of the particle, and many of these 
trimers will be composed of uncleaved Envgp160.  Overexpression of Env has been shown to be 
detrimental for particle production and Env incorporation using VLP production by stable cell 
lines expressing codon optimized HIV-1 Gagp55 and Envgp160.  In either case, the antibodies 
produced to these artificial Env trimers will not neutralize virus containing the native form of 
Env seen during natural infection. 
 There are many different categories of individuals that will need to be vaccinated against 
HIV: individuals that are uninfected or infected with HIV-1, elderly, infants and 
immunocompromised.  Although it will work more efficiently as a prophylactic vaccine, the 
VLP vaccine can be used as a therapeutic treatment for infected individuals or in 
immunocompromised patients (elderly, infants, individuals with cancer and transplant recipients, 
etc.).  However, different vaccination regimens could be employed to induce the optimal immune 
response in these individuals (i.e. higher concentration of inoculum, additional inoculations, 
combination of other adjuvants, etc.).  In HIV-infected individuals, the VLP vaccine will 
minimize the level of viral replication and prolong the asymptomatic phase.  One aspect of the 
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 VLP vaccine that may help with the majority of these individuals is the CD4-independent 
elicitation of immune responses by co-vaccination of CpG ODNs.  After the virally-regulated 
VLP vaccine has been demonstrated to induce protective responses in healthy individuals, more 
research will have to focus on the induction of protective immunity in the other groups.  Most 
likely, the individuals will require multiple immunizations throughout their life to maintain 
effective immunity.  Unlike vaccination with a live-attenuated virus, the use of multiple 
inoculations over the lifetime of the host is common among vaccines that do not persist in the 
host (i.e. DNA and protein subunit vaccines).  It is highly unlikely that a single (or even two) 
dose vaccine regimen will elicit protective immunity for the lifetime of the host especially 
considering the mutation rate of the virus for any vaccine/regimen to HIV-1.  That is why the 
proposed vaccine includes two DNA inoculations followed by two particle vaccinations.  
Protective immunity elicited by a vaccine today may not protect against the HIV strains 
circulating in the human population in twenty years.  However, the VLP vaccine can be modified 
to meet the ever-changing face of HIV similar to the influenza vaccine.  The viral sequences 
from most prevalent strains circulating in the population at the time can be engineered into the 
VLP vaccine with relative ease.  In conclusion, the virally-regulated multi-gene VLP vaccine is a 
novel strategy that will induce broadly, cross-reactive immunity to several proteins, and in 
particular humoral responses to native, immunologically relevant epitopes in Env, that should 
protect individuals from infection with HIV-1.    
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